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Abstract 
 
Increased glucose levels are associated with increased risk of vascular disease. 
The risk is elevated 2-4 fold in type 2 diabetes and there is a positive 
relationship between glucose (or HbA1c) levels and vascular disease in the 
general population. We tested the hypothesis that there is a glycaemia-
mediated impairment of reverse cholesterol transport (RCT) by studying an 
early key step, notably the expression and activity of the ATP binding cassette 
transporter-A1 (ABCA1). This protein exports cellular cholesterol to 
apolipoprotein A1 (ApoA-I), thereby forming nascent HDL. In this thesis, it is 
shown that ABCA1 gene expression in leukocytes in men is reduced in Type 2 
diabetes and correlates negatively with circulating HbA1c levels and fasting 
glucose. This confirms our earlier findings in healthy men. An independent 
relationship between glycaemia and leukocyte ABCG1 gene expression was not 
seen. ABCA1 protein concentrations in blood leukocytes were reduced in 
patients with diabetes. ApoA-I-mediated cholesterol efflux in cultured fibroblasts 
taken from subjects was studied as a measure of ABCA1 function. This 
negatively associated with fasting glucose at the time of sampling as well as 
adiposity. Cellular cholesterol removal was reduced in subjects with diabetes 
compared with controls. There was a positive relationship between both ABCA1 
function and leukocyte protein concentration with circulating HDL cholesterol. 
These relationships were independent of expression of liver X receptor-α 
(LXRα) and peroxisome proliferator-activated receptor-γ (PPARγ). These data 
imply a persistent glycaemia-mediated suppression of an early step in RCT 
which may contribute to the excess vascular disease observed in such patients. 
It further proposes impaired cholesterol efflux may contribute to the low 
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circulating HDL cholesterol which is commonly seen in patients with impaired 
glucose regulation.
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ABBREVIATIONS 
 
ACAT  acyl-coenzyme A:cholesterol acyltransferase 
ABC  Adenosine triphosphate binding cassette transporter  
ATP  Adenosine triphosphate 
ABCA1 ATP Binding Cassette Transporter A1 
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CRP  C reactive protein 
DMSO Dimethylsulfoxide        
DMEM Dulbecco's Modified Eagle Medium 
DMEM/F12 Phenol-red-free Dulbecco’s modified Eagle medium  
ER  Endoplasmic reticulum 
EL  Endothelial lipase 
ELISA  enzyme linked immunosorbent assay  
EDTA  Ethylenediaminetetraacetic acid 
FPG  Fasting plasma glucose 
FACS  Fluorescent activated cell sorting 
FBS  Foetal bovine serum 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
GOI  Gene of interest 
GTPase  Guanosine triphosphatase   
HDL-C High density lipoprotein cholesterol 
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HL  Hepatic lipase 
HUVEC Human Umbilical Vein Endothelial Cells 
ICAM  Inter-cellular adhesion molecule 
IGH  Impaired glucose homeostasis 
IMT   Intima-media thickness 
KO  Knock out 
LpA  lipoprotein A 
LCAT  Lecithin-cholesterol acyl transferase 
LSC  Liquid scintillation counting 
LXRα  Liver X Receptor alpha 
LDL-C  Low density lipoprotein cholesterol 
MM  Master Mix 
mRNA Messenger RNA 
MS  Metabolic syndrome 
MI  Myocardial infarction 
NO  Nitric oxide 
NF-kB  Nuclear transcription factor kappa-B 
OGTT  Oral glucose tolerance test 
PPARα Peroxisome proliferator activated receptor alpha 
PPARγ Peroxisome proliferator activated receptor gamma 
PBS  Phosphate buffered saline 
PL  Phospholipid 
PS  Phosphatidylserine 
PLTP  Phospholipid transfer protein 
PCR  Polymerase chain reaction 
PBMC  Peripheral blood mononuclear cell 
PEST  Proline-Glutamate Serine-Threonine  
RXR  Retinoid-X receptor 
RCT  Reverse cholesterol transport 
RT  Reverse transcription 
SAA  Serum amyloid A 
SRB1  Scavenger receptor B1 
SREBP Sterol regulatory element binding protein 
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TD  Tangier disease 
TRIS  tris(hydroxymethyl)aminomethane 
DM  Type 2 diabetes mellitus 
VCAM  Vascular cell adhesion molecule 
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1.1 The association of circulating glucose levels and 
cardiovascular disease 
Cardiovascular disease (CVD) remains the main cause for premature death in 
the western world. The alarming rise in the incidence of obesity worldwide is 
expected to increase the burden of diabetes, which currently accounts for 6% of 
total global mortality. 50% of these deaths are attributed to CVD (1). 
 Type 2 Diabetes Mellitus (DM) which is characterised by insulin resistance and 
defective insulin signalling is a known risk factor for developing CVD (2). It is 
estimated the risk of coronary heart disease (CHD) is increased two to four fold 
with established DM. A meta-analysis of multiple studies demonstrated patients 
with DM had a 3.4 fold higher risk of fatal CHD compared to those without 
diabetes (3). A controversial study by Haffner et al., reported the incidence of 
CHD events in men with DM was similar to that in non-diabetic men who had 
already suffered a myocardial infarction (4). This proposed a concept of DM 
being considered as a coronary risk equivalent. This concept has not been 
replicated by later studies and others have implicated that the degree of risk 
from DM is dependent on age (5;6). However, a more recent large population 
based study supported CHD risk equivalence in treated diabetic patients over 
the age of 30 years (7). These reports provide evidence for the need for 
aggressive primary prevention strategies to prevent CHD in people with DM. 
Excess CVD risk has also been attributed to lesser degrees of blood glucose 
elevation. A prospective European study demonstrated excess cardiovascular 
mortality in people with elevated glycated haemoglobin (HbA1c) concentration 
below the threshold of DM (8). These results suggest circulating blood glucose 
levels, similar to blood pressure and cholesterol, increase CVD risk with a 
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continuous relationship. Observations using global data, estimates that 21% of 
all coronary deaths and 13% of fatal stroke may be attributable to high blood 
glucose concentrations (9). A large meta-analysis of prospective studies 
confirmed a two-fold excess risk of cardiovascular disease in patients with 
diabetes mellitus and a modest association in people with impaired fasting 
glycaemia (10).     
The timing of hyperglycaemia in relation to food intake has also been 
investigated. HbA1c represents both fasting and post-prandial glucose, may not 
distinguish between these glucose measurements. Post-prandial 
hyperglycaemia has been implicated to be a stronger risk factor in the 
development of CHD (11;12). Impaired glucose tolerance (IGT), represents a 
pre-diabetic condition with fasting glucose concentration of <7mmol/l and 
elevated glucose response during an oral glucose tolerance test (OGTT) of 7.8-
11.0 mmol/l.  
Studies have illustrated the association of post load glucose and CVD in both 
type 2 diabetic and non-diabetic populations (13-15). The DECODE study 
showed no increase in CVD based on fasting glucose measurements 
comparing diabetic to non-diabetic glucose levels. However, there was a 
significantly greater risk when post-OGTT glucose levels were used and this 
appeared to be an independent predictor of CVD mortality (16). Moreover, 
specific treatment of post meal hyperglycaemia with an α-glucosidase inhibitor 
has been shown to reduce cardiovascular events (17).  
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1.11 The effect of glucose lowering treatments on cardiovascular 
outcomes. 
In general, glucose lowering treatments have shown contrasting effects on CVD 
outcome measures. This may reflect the type of agents used and the severity of 
disease. The UK Prospective Diabetes Study (UKPDS) demonstrated that 
patients taking an insulin sensitising therapy, adenosine monophosphate (AMP) 
kinase activator-Metformin had a 39% lower risk of developing cardiovascular 
disease and a reduction in all-cause mortality (18). This potential protective 
effect has been confirmed in a subgroup, in a 10 year follow-up study (19). 
However, this beneficial effect has not been consistently observed, when 
metformin was supplemented in patients established on insulin secretagogue 
therapy. 
A recent class of treatments-thiazolidinedione may also influence the 
development of CVD. A trial using Pioglitazone, a Peroxisome proliferator-
activated receptor-α (PPARα) and Peroxisome proliferator-activated receptor-γ 
(PPARγ) agonist, demonstrated a decrease in secondary cardiovascular 
endpoints in over two thousand patients (20). In contrast, a meta-analysis of 
Rosiglitazone, predominantly a PPARγ agonist, suggests this agent may be 
associated with adverse cardiovascular outcomes (21). This remains 
controversial and mechanisms underlying this observation as well as the 
magnitude of effect are currently unknown.  
Recent trials investigating the effects of intensive glucose lowering in patients 
with a 10 year history of DM show a possible deleterious effect on the incidence 
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of CVD (22). Autoimmune insulin deficiency (Type 1 diabetes) is also 
associated with an increased risk of CHD, but long term intensive insulin 
therapy has been associated with a 42% reduction in cardiovascular events 
(23). 
Several common mechanisms have been proposed for the detrimental effect of 
hyperglycaemia, including free radical damage and protein glycosylation (see 
section 1.3) although definitive mechanisms that lead to atherosclerosis are yet 
to be clarified. 
1.2 Diabetes and surrogate markers of cardiovascular disease  
 
Carotid Intima-media thickness 
Surrogate markers have been used as non-invasive tools to assess 
atherosclerotic burden as well as to predict clinical cardiovascular events. The 
most validated technique is the measurement of arterial wall intima-media 
thickness (IMT) using high resolution B-mode ultrasound. This was originally 
used to assess atherosclerotic changes in the aorta (24). Large prospective 
studies have confirmed Carotid IMT (CIMT) to correlate with conventional 
cardiovascular risk factors; blood pressure, smoking status and lipid profile and 
predict future coronary events (25;26). It should be noted that while 
atherosclerosis predominantly affects the intima, ultrasound imaging cannot 
discriminate between the intima and media of the vessel wall (27). The 
Rotterdam study in over seven thousand patients estimated a 1.43 fold relative 
risk for future myocardial infarction (MI) with each standard deviation increase 
(0.16mm) in CIMT (26). Absolute IMT has also been demonstrated to predict 
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coronary events. Hodis et al., similarly showed each 0.13mm increment in IMT 
was associated with a relative risk of 1.4 (28).  
The positive association between CIMT and glycaemia is well established. The 
Insulin Resistance Atherosclerosis Study demonstrated diabetes is associated 
with increased carotid artery thickness (29). Newly diagnosed patients with DM 
appear to have increased CIMT (30). Tropeano and colleagues have shown 
glucose to be a major independent determinant of CIMT both in patients with 
impaired fasting glucose and DM, confirming a continuous relationship between 
glucose and atherosclerosis (31). A current study in normal women further 
suggest a relationship with postprandial glucose levels (32).  
We, and others, have shown CIMT is increased in young patients with type 1 
diabetes compared to non-diabetic subjects and there is evidence to show 
similar association with glycaemia as that seen with DM (33-35). CIMT predicts 
CHD in asymptomatic DM patients over a 5 year period. Using regression 
analysis, CIMT improved prediction of events compared to traditional 
Framingham risk scoring (36). This suggests CIMT may have improved 
predictive value beyond conventionally measured cardiovascular risk factors.  
Several glucose lowing agents including thiazolidinediones, metformin,  
acarbose & some insulin secretagogues have been shown to slow progression 
of CIMT (37-40). This is suggestive of anti-atherogenic potential, although the 
mechanisms by which this is achieved have not been characterised. In one 
study, using Pioglitazone, increases in high density lipoprotein cholesterol 
(HDL-C) predicted the improvement in CIMT (41). Moreover, in a randomised 
trial, Pioglitazone was demonstrated to slow the rate of atherosclerosis 
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progression compared to glimepiride, using both CIMT and direct endoscopic 
ultrasound of coronary vasculature (39;42). This provides evidence of potential 
anti-atherosclerotic activity in this class of glucose lowering drugs. 
Newer imaging techniques including carotid magnetic resonance and coronary 
calcification scoring have been more recently evaluated as surrogate markers of 
CVD. Coronary artery calcium (CAC) signifies the presence of atherosclerosis 
and correlates with total plaque burden. However, the pathogenesis of vascular 
calcification is not fully understood and not all atherosclerotic plaques contain 
calcium. The clinical determinants of CAC progression are also unclear (43). 
There is limited evidence that treatments significantly slow or reverse 
progression of CAC (44). However, CAC progression has been shown to 
correlate with CIMT measurements in middle aged men after controlling for 
standard risk factors (43) In a cohort with DM, high CAC score predicted first 
CVD endpoints better than conventional risk scoring. CAC scores in this study 
only related to baseline age, waist-hip ratio and duration of diabetes (45) 
Another study in patients with DM confirmed CAC measurement was superior to 
traditional risk factors in identifying patients with subclinical myocardial 
ischaemia (46) There is emerging evidence, similar to that established with 
CIMT, that significant CAC may be present in people with pre-diabetes (47)  
1.3 Mechanisms of cardiovascular disease in hyperglycaemia.  
Accelerated atherosclerosis in DM may have multiple possible underlying 
mechanisms. Excess cholesterol deposition is recognised to cause 
atherosclerosis. Approximately two-thirds of cholesterol in man is carried by the 
class of lipoprotein, named Low density lipoprotein cholesterol (LDL-C). Excess 
- 22 - 
 
LDL cholesterol is usually cleared from the plasma by interaction with a cell 
surface LDL-receptor which internalises and routes cholesterol to the 
endoplasmic reticulum (ER) for storage or recycling (endosomes). The hepatic 
LDL-receptor is predominantly accountable for clearing excess LDL-C from the 
plasma (48) Excess circulating LDL-C is prone to undergo modification, making 
it more likely to be taken up by scavenger receptors in macrophages. 
Cholesterol-loaded macrophage foam cells represent the hallmark of an 
atherosclerotic plaque.  
At the blood vessel wall, activation of nuclear transcription factor kappa-B (NF-
kB) by hyperglycaemia leads to altered gene expression of several 
inflammatory genes. This process is shown to promote monocyte adhesion to 
endothelial cells in early lesion development (49) In murine models, there has 
been co-localisation of regions prone to develop atherosclerosis and increased 
components of NF-kB (50) At present it is not clear whether NF-kB has 
modulatory effects on macrophage cholesterol influx or removal. 
Chronic hyperglycaemia leads to the formation of non-enzymatic glycated 
proteins and lipids. These advanced glycated end-products (AGE) can generate 
reactive oxygen species as well as bind cell surface receptors to modulate gene 
expression. This process is thought to lead to oxidative stress and tissue 
damage. Endothelial nitric oxide (NO) production has been shown to be 
inhibited by hyperglycaemia and AGE resulting in reduced endothelium 
relaxation (51) This process is considered to represent an early defect leading 
to vascular injury. AGE-modified albumin has been shown to reduce selective 
cholesterol removal from HDL-C interfering with reverse cholesterol transport 
(RCT), the process by which cellular cholesterol is removed by the body (52)  
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Alteration in vascular proteoglycan architecture has been reported in subjects 
with diabetic atherosclerotic lesions which may lead to susceptibility for 
lipoprotein retention (53) Specifically, glycation of collagen increases its ability 
to bind LDL-C (54) Glycation of LDL particles is associated with decreased 
clearance by the LDL receptor, resulting in prolonged transit (55-57) and 
increased likelihood to be taken up by macrophage scavenger receptors (57)  
There are significant changes in plasma lipoproteins due to DM, leading to 
diabetic dyslipidaemia. This will be explored in more detail in section 1.6. 
The hallmark of DM, insulin resistance, may directly contribute to 
atherogenesis. Vascular insulin resistance has been shown to be associated 
with impaired NO-mediated arterial dilatation (58) At a cellular level, increased 
macrophage ER stress and consequent apoptosis and increased cell-surface 
scavenger receptor expression are additional mechanisms that may contribute 
to advanced lesion development in insulin resistant states (59)  
 
The metabolic syndrome (MS) is a clinical constellation of factors associated 
with insulin resistance; these include hypertension, central obesity, fasting 
hyperglycaemia and dyslipidaemia (60) A recent European prospective study 
showed this disorder predicted CVD events regardless of the presence of 
impaired glucose homeostasis (IGH) or DM (61) As individual components of 
MS have been independently associated with CVD, it is difficult to ascertain the 
specific contribution of insulin resistance per se.  
1.4 Cholesterol Transport 
Cholesterol cannot be converted directly into an energy source. The primary 
role of cholesterol in mammals is that of a membrane constituent and a 
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precursor for steroid hormone synthesis. The main sources are dietary 
cholesterol and hepatic de novo synthesis. Dietary cholesterol is transported to 
the liver and secreted with triglycerides as very low density lipoproteins (VLDL) 
which contains an apo-lipoprotein B (ApoB) particle. Peripheral metabolism of 
triglyceride content and cellular uptake of cholesterol esters via the LDL 
receptor largely enables the transfer of this potential energy source to tissues. 
With the exception of the liver and steroidogenic tissues, cellular cholesterol 
cannot be metabolised. Cellular cholesterol removal is based on the formation 
of HDL-C and export occurs via the plasma membrane by either diffusion or 
active transport mechanisms. 
1.41 Reverse cholesterol transport 
HDL-C can be formed by the removal of intracellular cholesterol and therefore 
serves as a crucial vehicle to return cholesterol to the liver for biliary excretion. 
This process is termed RCT (62-64). The ATP-Binding Cassette Transporter A-
1 (ABCA1) is a member of the ATP-Binding Cassette (ABC) transporter family. 
Its principal function is the transfer of cellular unesterified (free) cholesterol and 
phospholipids across the plasma membrane to the surface of a lipid poor ApoA-
I particle to form “nascent” or preβ-HDL (62;65;66). The step is considered rate 
limiting for HDL particle formation. Once ApoA-I is lipidated via the action of 
ABCA1, further cholesterol export is possible by other recently discovered 
transporters, ATP Binding Cassette Transporter G1 (ABCG1) and possibly 
Scavenger Receptor B1 (SR-B1) (67;68). 
In addition to initiating cholesterol removal from arterial wall cells, ABCA1 is 
primarily responsible for native HDL formation. Animal studies suggest this 
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mainly occurs at the liver (70%) and intestine (30%) (69;70). In contrast, 
ABCG1 removes cholesterol from macrophages but is not thought to influence 
plasma HDL concentration (71;72).  
1.42 The role of ABCA1, ABCG1 and SR-B1 membrane transporters 
Transmembrane transporters, ABCA1 and ABCG1 act in concert in a 
unidirectional manner. ABCA1 lipidates lipid free or lipid poor ApoA-I to 
generate nascent or preβ−HDL. It only modestly stimulates cholesterol removal 
to small (HDL-3) molecules (73). Subsequent cholesterol export to these 
particles is facilitated by ABCG1 (68). These processes are thought to account 
for 60-70% of cholesterol removed by HDL or serum from cholesterol loaded 
macrophages (74). In contrast, Out R et al., report a 100% decrease in efflux 
without ABCA1 and ABCG1 (75). Any residual efflux to HDL may be due to 
passive diffusion or mediated by an as yet unknown transporter (76). Yvan-
Charvet and colleagues suggest SR-B1 may not contribute significantly to net 
cholesterol efflux in macrophages (77). 
 In double ABCA1 and ABCG1 knockout (KO) mice models (A1-/G1-) there was 
dramatic evidence of increased macrophage cholesterol accumulation with 
foam cell formation despite low cholesterol levels using LDL KO mice (74;75). 
This provides good evidence that these transporters are vital in preventing early 
atherosclerotic plaque formation. However, when either ABCA1 or G1 are 
knocked down individually, there is a compensatory rise in expression of the 
complementary transporter, limiting atherosclerosis. This implies some 
redundancy in their function. The observed mechanisms leading to 
atherosclerosis in these models were decreased cholesterol efflux, decreased 
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apolipoprotein E (ApoE) secretion (a putative function of ABCA1), increased 
inflammatory gene expression and increased apoptosis (74). 
ABCG1 is considered to have an additional, specific role of exporting 7-
ketosterol and related oxysterols from macrophages. 7-ketocholesterol is the 
major toxic oxysterol found in oxidized-LDL and atherosclerotic plaques. As 
ABCG1 is highly expressed in vascular endothelium, it has been implicated to 
protect against oxidized-LDL mediated endothelial dysfunction (78). Early SR-
B1 knockout models in mice demonstrated increased atherosclerosis despite a 
doubling of HDL-C (79). Genetic over expression of SR-B1 resulted in greater 
removal of HDL associated cholesterol ester and increased HDL catabolism, 
resulting in lower HDL-C concentrations. Overexpression was associated with 
regression of atherosclerosis in LDL and ApoE KO mice. These experiments 
indicate discordance between HDL-C levels and atherosclerosis and indicate 
HDL-C flux may be a better marker of RCT than plasma HDL-C concentration. 
As SR-B1 functions as a bidirectional transporter it may not significantly 
contribute to net macrophage cholesterol efflux in-vivo (77;80). In mice, SR-B1 
may function as a backup transporter to clear circulating remnant lipoproteins 
which may help to explain some of the conferred atheroprotection (81). Overall 
the contribution of SR-B1 to cholesterol efflux and atherosclerosis is currently 
uncertain. A summary of the steps in cellular cholesterol efflux by membrane 
transporters is shown in figure 1.1. 
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Figure 1.1 Cholesterol efflux from peripheral cells  
  
Schematic diagram illustrating mechanisms on how HDL accepts membrane cholesterol via 
multiple mechanisms. Initial lipidation of lipid-poor ApoA-I takes place by the action of ABCA1, 
with subsequent contributions from ABCG1 and SR-B1 as well as diffusion, to generate large 
spherical particles. Free cholesterol (FC), phospholipid (PL), Lecithin-cholesterol acyl 
transferase (LCAT) (82). [Adapted from Barter & Kastelein JACC 2006].  
 
 
1.43 The role of lecithin cholesterol acyl transferase (LCAT) 
Esterification of cholesterol occurs on the surface of HDL particles. This occurs 
by ApoA-I activation of the enzyme Lecithin cholesterol acyl transferase (LCAT) 
(83).  This catalyses the transfer of an acyl group from phosphatidyl choline to 
cholesterol forming esterified cholesterol and lysophatidylcholine (63;84). This 
reaction accounts for the formation of most of the esterified cholesterol in 
human plasma and serves to maintain a concentration gradient for unesterified 
(free) cholesterol between peripheral cells and HDL. This reaction transforms 
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HDL from a discoidal structure to a larger, spherical and more buoyant particle 
with cholesterol esters enclosed within a central lipid core. 
Human LCAT deficiency states have been associated with premature 
atherosclerosis in some but not all patients (85). Although murine LCAT 
knockout models cause HDL deficiency, this has not consistently resulted in 
increased atherosclerosis, which may be partly due to the resulting low LDL-C. 
A more recent study measured faecal labelled cholesterol as a marker of RCT 
in LCAT deficient mice and provisionally report promotion of ABCA1 mediated 
cholesterol efflux in macrophages as well as high levels of lipid poor ApoA-I 
(86). 
Transgenic LCAT overexpression predictably increased HDL levels in mouse 
and rabbit models, but was associated with unaffected or accelerated 
atherosclerosis in mice (87;88). Overexpression was considered anti-
atherogenic in rabbits, possibly due to the presence of cholesterol ester transfer 
protein (CETP). The current evidence, therefore, does not indicate LCAT to be 
a crucial factor in preventing atherosclerosis. 
Large, spherical HDL is transported in the circulation for uptake primarily by 
hepatic SR-B1, whereby esterified cholesterol is selectively removed and 
eliminated by conversion into bile (89). This is subsequently re-used in the 
entero-hepatic circulation. Recycling of HDL particles, result in smaller, lipid 
poor ApoA-I which are able to further circulate to attain more cholesterol from 
peripheral cells. The RCT cycle is illustrated in Figure 1.2. 
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Figure 1.2 Reverse Cholesterol Transport 
ApoA-I is mainly synthesised by the liver. Unidirectional export of cellular free cholesterol occurs 
via action of the transmembrane transporter, ABCA1. Subsequent cholesterol esterification is 
stimulated by LCAT action which results in a more buoyant particle conformation. Further 
cholesterol is exported by ABCG1 to mature HDL particles. Esterified cholesterol is selectively 
taken up at the liver via SR-B1 for removal into bile liberating lipid-free ApoA-I for further 
recirculation. Intravascular remodeling can occur predominantly by the action of cholesterol 
ester transfer protein (CETP) and hepatic lipase (HL). 
 
1.44 The role of cholesterol ester transfer protein (CETP) in murine 
models of RCT 
In RCT, cholesterol esters can be redistributed by the action CETP. This 
glycoprotein was originally isolated from humans in 1978. It is secreted from the 
liver and circulates in plasma, mainly bound to HDL (90;91). CETP mediates 
transfer of cholesterol esters from HDL to triglyceride rich lipoproteins and LDL. 
This is in equal exchange for triglyceride which is transferred to HDL. The net 
effect is the redistribution of cholesterol esters from HDL to LDL, for more 
efficient delivery to peripheral cells. Similar exchanges of cholesterol esters can 
also occur between LDL and VLDL. This protein is only present in certain 
species. Mice do not possess CETP and have lower plasma HDL-C levels 
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compared to humans. However, despite this, mice are resistant to developing 
atherosclerosis. Activity of CETP can be increased by a high fat diet. Studies in 
murine models have usually involved transgenic introduction of human CETP to 
mimic human cholesterol kinetics. Rabbits have relatively high CETP activity 
and have been shown to be prone to diet induced atherosclerosis (92). 
Conversely, CETP inhibition in rabbits was associated with a 97% rise in 
plasma HDL and reductions in atherosclerosis (93).  
In pro-atherogenic animal models induced by LDL KO and ApoE KO, the 
introduction of human CETP has been shown to increase atherosclerotic 
progression. ApoA-I over expression in these experiments showed some 
protection against these effects (94). Measurements of in-vivo RCT in mice 
have been performed using a technique of labelling elicited peritoneal 
macrophages in-vitro, before injecting them into different transgenic mouse 
models. Hepatic and faecal cholesterol content is subsequently analysed after 
48 hours as a measure of RCT. One such study showed no difference in 
hepatic or faecal delivery of labelled cholesterol in transgenic CETP mice (95). 
It seems CETP may be pro-atherogenic when ApoB lipoprotein transport is 
transgenically interrupted and conversely athero-protective when intact (96). 
 
From an evolutionary perspective, the addition of CETP to existing transport 
mechanisms may be thought to be useful in an environment of relative lipid and 
caloric depletion. In this situation, CETP activity would provide more efficient 
peripheral redirection of cholesterol without the need for hepatic repackaging 
and secretion of HDL derived cholesterol. 
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1.45 The role of CETP in atherosclerosis in humans 
It has been evident that CETP activity significantly affects plasma HDL-C 
concentration both in animal models and humans. It has therefore become an 
increasingly attractive therapeutic target to help prevent atherosclerosis. 
Concordant with animal data, increased CETP activity in human studies is 
associated with low plasma HDL-C concentration. 
Human CETP deficiency has been described by a number of mutations, 
observed mainly in a Japanese population. Affected homozygote and 
heterozygote individuals have been reported to have an elevated plasma HDL-
C concentration by 30% and 60% respectively. Analysis of these particles using 
electrophoresis, indicates HDL-C particles are large and have mainly α1 or pre-
α mobility. A concomitant reduction in catabolism of ApoA-I and ApoA-II is also 
observed (97). Plasma deficient of CETP was associated with increased 
cholesterol removal from macrophages which has been shown to be mediated 
by ABCG1 (98). HDL LCAT and ApoE levels were increased compared to 
control plasma contributing to enhanced cellular efflux (98). In homozygote 
subjects there is an additional reduction in LDL-C in keeping with an anti-
atherogenic lipid profile (99). 
Early reports suggested CETP deficiency was associated with higher CHD risk 
in Japanese-American men (100), although a subsequent analysis, in fact, 
showed a conflicting trend. A further study in Japanese subjects with a high 
HDL-C observed a significantly lower chance of developing CHD irrespective of 
any CETP mutations (101). Collectively, evidence suggests CETP deficiency 
combined with elevated HDL-C levels may protect against CVD. 
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With regard to human CETP polymorphisms, the Taq1B genotype has been 
extensively studied. B2/B2 homozygotes have been reported to have a 30% 
reduction in CVD risk compared with B1B1 in non-smokers (102). In both the 
Framingham and Veteran Affairs studies, carriers of the B2 allele had 
significantly lower CETP activity and higher HDL-C levels than B1 homozygotes 
(103;104). In contrast, Borggreve and colleagues reported -B2 and 1405VV 
alleles of CETP gene to be paradoxically associated with an increased risk of 
coronary disease, despite these variants being associated with higher HDL-C in 
the general population (105). A prospective study in healthy subjects 
demonstrated that future risk of CHD was positively associated with increasing 
CETP level, but this relationship was only observed in combination with 
elevated triglyceride levels (106). 
These studies highlight the complex relationship between CETP, HDL-C and 
atherosclerosis and studies have not consistently assessed HDL-C function. 
CETP may have important effects on other important genes and proteins 
involved in atherosclerosis, independent of its effects on HDL-C. Indeed, a 
study in over 500 men concluded that variations in genes affecting RCT only 
accounted for approximately 12% of the variance in HDL-C levels (107). 
1.46 The effect of drugs on RCT 
RCT is a complex process with multiple steps, illustrated in figure 1.2. The 
effect of several drugs has been evaluated on this dynamic process using 
murine models. In humans, until recently PPARα agonist clinical therapy has 
been the main treatment shown to improve HDL-C levels. Current clinical 
therapies and their effectiveness are discussed in section 1.54. 
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1.5 The role of HDL Cholesterol in cardiovascular disease 
 
1.51 Epidemiology of HDL-C and atherosclerosis 
There is ample evidence to imply higher HDL-C concentrations are protective 
against the development of atherosclerotic disease in humans. The 
Framingham heart study showed that people whose HDL was below 0.91mmol/l 
(35mg/dL) at baseline had a coronary risk eight times that of subjects whose 
HDL concentration was greater than 1.68mmol/l (108). Several studies have 
since confirmed these findings.  
Indeed, this negative association is preserved at varying levels of LDL 
cholesterol as seen in figure 1.3. The intimate relationship between CHD, HDL-
C and LDL-C was confirmed in a multinational study (Interheart) in almost 
30,000 subjects, where the ratio of ApoB to ApoA ratio was analysed in 
quintiles. A linear relationship with CHD risk was evident with an odds ratio of 
3.81 comparing the highest and lowest quintiles. It was concluded that smoking 
and dyslipidaemia accounted for two thirds of the attributable risk for myocardial 
infarction (109). 
Recent analysis of two large prospective studies, however, indicate having a 
very high HDL-C concentration and very large particle size may actually 
increase risk of atherosclerosis. This was despite accounting for ApoA-I and 
ApoB levels. Higher ApoA-I concentration appeared to be associated with lower 
risk in both studies (110). A possible biological explanation is that very high 
HDL-C levels may represent accumulation of large, dysfunctional HDL-C 
molecules which are not cleared from plasma. These studies suggest studying 
HDL-C transport kinetics may be more informative to gauge CVD. 
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1.52 HDL particle heterogeneity 
HDL molecules are a heterogeneous group of particles that can be subdivided 
on size by electrophoretic mobility or by apolipoprotein composition.  
HDL1, HDL2 and HDL3 represent spherical particles of α-mobility, in descending 
size and preβ-HDL represent small, discoidal particles. Preβ-HDL particles 
represent 5-7% of total plasma ApoA-I in humans and have been shown to 
conform in a stacking arrangement (111). HDL can be subdivided into particles 
that contain only ApoA-I (Lp AI) and particles that contain both ApoA-I and 
apolipoprotein AII (ApoA-II) (Lp AI:AII). Kinetic studies have discovered that 
concentrations of ApoA-I are predominantly determined by rates of catabolism 
and conversely, ApoA-II levels are governed mainly by rates of synthesis. 
Schaefer and colleagues, using a radio-iodination method, showed  ApoA-I has 
a shorter residency time than ApoA-II and that this was an important 
determinant of ApoA-I concentration (112). Brinton confirmed these findings 
concluding the ApoA-I catabolic rate accounted for 66% of the variability of 
HDL-C (113). 
Whether ApoA-II protects against atherosclerosis is currently uncertain, 
however, the presence of ApoA-II may have a secondary effect by influencing 
the distribution of ApoA-I in HDL particles. Newer proteomic techniques have 
revealed multiple additional proteins are present in HDL particles including 
apolipoproteins A-IV, M, CII and CIII. This has been recently reviewed by 
Davidsson and others (114). The function of many of these proteins and their 
isoforms are, as yet unknown. It is likely the combination of apolipooproteins will 
play a role in the various functions of HDL. 
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1.53 Anti-inflammatory and antioxidant roles of HDL-C 
In addition to the primary role of cholesterol transport, HDL has been shown to 
have anti-inflammatory and antioxidant action. 
1.531 Effect of inflammation on HDL and atherosclerosis 
HDL may play a central role in regulating inflammation and is involved in innate 
immunity. During acute inflammation, HDL levels are reduced and this may 
represent a permissive state for inflammation to occur. Chronic inflammation is 
associated with a reduction in HDL-C concentrations. Serum Amyloid A (SAA) 
is an acute phase reactant that is increased up to one thousand fold during 
acute infection. During these times SAA has been shown to replace ApoA-I as 
the major protein component of HDL inhibiting its anti-inflammatory function 
(115). Key proteins involved in RCT have been shown to be down-regulated 
during periods of inflammation. Evidence from childhood studies propose an 
early atherogenic effect of inflammation, demonstrated by elevated antibody 
titres against oxidised LDL and increased CIMT (116). 
DM and MS are recognised conditions associated with chronic low grade 
inflammation. This process may contribute to the altered lipid transport and low 
HDL seen in these conditions. Ridker and colleagues provided further evidence 
in a pivotal study showing elevated C-reactive protein (CRP) was a good 
predictor of CHD and provided additional predictive information compared to 
conventional risk factors alone (117). 
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1.532 Anti-inflammatory and antioxidant effects of HDL 
 
An early step in atheroma plaque development is adhesion and migration of 
monocytes through endothelial cells. These subsequently differentiate into 
macrophages which can take up modified LDL-C via scavenger receptors. 
Activated or injured endothelial cells secrete adhesion molecules to promote 
monocyte binding which is thought to be an early signal in lesion development. 
Native and reconstituted HDL has been shown to inhibit cytokine-induced 
expression of adhesion molecules vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and E-selectin in cultured human 
umbilical vein endothelial cells (HUVEC) in a dose dependent fashion with a 
preserved effect after HDL was removed (118). Unsurprisingly, HDL isolated 
from different humans exhibit differential inhibitory activities which may be partly 
explained by size and composition. Variation in particle size, cholesterol ester or 
triglyceride content did not affect this function, in contrast, varying the 
phospholipid composition significantly inhibited anti-inflammatory effects in 
endothelial cells (119). It is likely that ApoA-I exhibits an antioxidative effect that 
protects against phospholipid oxidation, absence of this effect would otherwise 
lead to endothelial cell activation. Wadham and co-workers have further 
demonstrated HDL inhibits CRP-induced expression of adhesion molecules 
(120). 
HDL-induced release of NO has been shown to inhibit monocyte binding to 
endothelial cells. Inhibition of human LDL-C oxidation has been demonstrated 
in-vitro by Navab and others using ApoA-I and a synthetic ApoA-I mimetic 
(121;122). This occurs both by protecting LDL particles directly and guarding 
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arterial endothelial cells from the oxidising effects of LDL (122). Importantly, 
HDL-C taken from patients with CHD did not show equivalent inhibition of LDL 
oxidation nor LDL-induced endothelial adhesion molecule secretion (123;124). 
This implies HDL particle dysfunction in patients with established 
atherosclerosis. 
Animal studies further associate HDL anti-inflammatory function directly to 
atherosclerotic lesion size (125). Bloeden and colleagues recently reported a 
study in which the majority of patients with CHD or equivalent had evidence of 
pro-inflammatory HDL-C (126). In this study there was evidence that 
administration of a novel ApoA-I mimetic molecule improved the in-vitro anti-
inflammatory function of HDL without altering lipoprotein levels. 
There is evidence to implicate dysfunctional antioxidant HDL function in patients 
with MS and IGH (127). De Souza and colleagues, who studied patients with 
MS, observed lower capacity of small HDL3 species to prevent LDL oxidation 
and inhibit oxidised-LDL induced endothelial apoptosis. There was also 
diminished protection against free radical formation in human endothelial cells 
compared to similar HDL isoforms taken from control subjects (128). These 
particles were triglyceride enriched through mechanisms described in section 
1.6. These data suggest increasing HDL function or increasing longevity in the 
circulation may prove a successful approach to effective HDL therapies in the 
future. 
1.54 Current evidence from drug intervention trials 
A number of pharmacological agents used to modify plasma lipoproteins have 
been studied in trials in an attempt to prevent CVD. 
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Several clinical trials have utilised fibrate therapy to investigate its effects on 
CHD. This class of agents activates a nuclear transcription factor, PPARα and 
results in the synthesis of ApoA-I, the main protein component of HDL. ApoA-II 
and ABCA1 synthesis is also increased. This mechanism results in a net 
increase in blood HDL-C levels and delivers plasma triglyceride to the liver via 
HDL particles (129). Fibrates primarily lower circulating triglyceride 
concentrations by a number of mechanisms including reducing hepatic VLDL 
secretion, increasing lipolysis by activating lipoprotein lipase and increasing 
triglyceride disposal by increasing VLDL particle clearance (130;131). 
  
Figure 1.3 Risk of coronary heart disease and HDL-Cholesterol 
Illustrates the independent relationship between coronary heart disease (CHD) risk and HDL-C 
concentration (quartiles) which is independent of LDL-C concentration (tertiles) in men aged 50-
70. Reprinted from Castelli WP. Can J Cardiol. 1988 (132) with permission from Pulsus Group 
Inc.(lipids on line). 
The Helsinki Heart Study investigated approximately 4000 men over 5 years. 
Subjects were middle aged, free of CVD with mean baseline HDL-C level of 
1.22mmol/l. Gemfibrozil increased HDL-C levels by 11% and reduced plasma 
triglyceride and LDL-C by 35% and 11% respectively. A 34% reduction in total 
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coronary events was observed (133). Gemfibrozil was further tested in the 
Veterans Affairs HDL intervention trial in men with known CHD over an average 
of 5 years. HDL-C was raised by 6% and triglyceride concentrations were 
reduced by 31% without significantly altering LDL-C concentrations. Therapy 
was associated with a reduction in non-fatal MI and CHD death of 22% 
compared to placebo (134). The incidence of stroke was reduced in the treated 
group. Of interest, participants with insulin resistance seemed to experience the 
most risk reduction implying a possible specific benefit to this group of patients.  
In contrast, a more recent large trial exclusively studied men with DM. The 
Fenofibrate intervention and event lowering in diabetes (FIELD) study was 
conducted in over nine thousand subjects. Fenofibrate raised mean HDL-C 
concentration by only 2% from a mean baseline of 1.10 mmol/l. Total CVD 
events were reduced, however, the primary endpoint of nonfatal MI and CHD 
death was not significantly altered (135). It has been proposed that introduction 
of statin therapy to the placebo group in this study may have diminished any 
potential beneficial effects of fibrate treatment as this was designed as a 
monotherapy study in statin-naive patients. Clinical benefits were observed in 
patients with marked hypertriglyceridaemia and low HDL-C. There were also  
reductions in diabetes related microvascular disease in those assigned to 
Fenofibrate (136).  
A further investigation of patients with DM observed changes in coronary 
angiographic findings in response to fenofibrate. The Diabetes atherosclerosis 
intervention study (DAIS) concluded a 40% reduction in progression of 
atherosclerosis using measurements of minimal luminal diameter (137). 
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Collectively, these studies indicate uncertainty to whether fibrate therapy 
reduces CVD. 
Nicotinic acid has been used as a therapeutic agent to treat dyslipidaemia for 
many years. It lowers triglyceride by up to 50% and raises plasma HDL-C by up 
to 30%. Currently, this represents the most efficacious clinical treatment to raise 
plasma HDL-C concentration. However, its tolerability limits widespread usage. 
Flushing, dizziness and palpitations as well as hyperglycaemia are commonly 
reported adverse effects. A prolonged-release formulation has reduced this to 
some degree and future combination with prostaglandin D2 inhibition, could 
help resolve some of these inconvenient effects. The exact mechanism of 
action is still unknown, although a receptor for nicotinic acid has been 
discovered (138). Receptor-mediated inhibition of adenyl-cyclase blocks 
lipolysis in adipose tissue, this has been shown to reduce free fatty acids and 
triglyceride levels (139). Most clinical trials investigating the effects of nicotinic 
acid treatment have shown cardiovascular benefit. The Coronary drug project in 
1975 treated patients after a MI with Niacin and compared this with placebo. A 
26% lower non-fatal CHD event rate was reported in the treatment group after 6 
years. Despite these results, a mortality benefit was only apparent after 15 
years (140). A smaller trial in one hundred and sixty patients with coronary 
artery disease showed angiographic improvements over 3 years as well as 
reduced clinical endpoints using niacin in combination with simvastatin (141). A 
small increment in blood glucose levels was observed as a result of therapy. 
Surrogate endpoint studies using CIMT have investigated subjects with CVD 
established on statin therapy. These were randomised to Niacin or placebo and 
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although the treatment arm resulted in a 21% increase in HDL-C, there was 
only a trend towards lower CIMT progression (142). A follow up 12 month open 
label analysis of 130 participants did show significant reductions in CIMT 
compared to baseline (143). Results of ongoing trials should help to clarify 
whether nicotinic acid, in combination with simvastatin, prevents CVD more 
than statin therapy alone. 
A contemporary trial using a novel CETP inhibitor, Torcetrapib has 
demonstrated up to a 60% increase in plasma HDL-C concentration. This 
degree of HDL elevation is beyond the current available therapy and was 
achieved in a dose dependent manner in combination with Atorvastatin. 
However, this trial was prematurely terminated due to an unexpected increase 
in cardiovascular events and observed mortality in the Torcetrapib treated 
cohort compared to those who were treated with statin alone (144;145). 
Furthermore, a separate study using Torcetrapib failed to demonstrate 
improvements in CIMT despite substantial increases in plasma HDL-C 
concentration in patients with familial hypercholesterolaemia or mixed 
hyperlipidaemia (146;147). It is thought that mineralocorticoid-mediated off-site 
toxicity may be responsible for these unexpected findings as hypertension and 
minor electrolyte differences were observed. There is now some evidence to 
support this drug related mechanism (148). In spite of this, CETP remains an 
attractive therapeutic target for prevention of CVD based on animal studies and 
naturally occurring mutations in humans. 
Statin therapy remains the most effective pharmacological intervention and 
demonstrates consistent reductions in CVD events in multiple trials. The main 
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mechanism of action is inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A 
reductase, which is the rate limiting step for cholesterol synthesis. It is 
estimated 60-70% of plasma cholesterol is derived from hepatic synthesis. 
Reduced cholesterol synthesis results in increased cellular cholesterol uptake 
via the LDL receptor which results in the observed decrease in plasma LDL-C 
levels (149).  
The UK collaborative Atorvastatin study investigated patients with DM and a 
additional risk factor for CHD. A mean reduction of LDL cholesterol by 40% 
along with a small (1%) increase in HDL was achieved. This resulted in a 37% 
reduction in major CVD events (150). A meta-analysis of over 18,000 patients 
with diabetes from fourteen randomised trials estimated a 20% risk reduction in 
CHD and stroke per mmol/L reduction in LDL-C over a 5 year period. This was 
irrespective of other risk factors or established CVD. It is estimated these 
benefits were observed when baseline LDL-C concentrations were above 2.6 
mmol/l (151). Statin treatment has been observed to only mildly raise HDL-C 
levels by less than 10%. Mechanisms for this include indirect CETP inhibition 
and possibly ApoA-I synthesis (152). In a randomised study, Rosuvastatin was 
shown to increase HDL-C in patients with MS. This was in a dose dependent 
manner by reduction in particle catabolism resulting in increased HDL size 
(153). 
There is evidence that statins may have beneficial effects beyond lipid lowering. 
This alternative mechanism was proposed as cardiovascular protection seemed 
to occur earlier than with previous treatments used to lower LDL-C. Possible 
pleotropic mediators include guanosine triphosphatase proteins which are 
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involved in molecular signalling to control cell growth, cytokine release and 
molecular trafficking (154). Proven translational benefits from these 
mechanisms are still to be confirmed. Elevated plasma cholesterol levels are 
known to cause endothelial dysfunction by interrupting the NO biosynthesis 
pathway (155). Statins, therefore, have been shown to improve vascular 
endothelial function by reducing LDL-C similar to that seen with plasma LDL-C 
apheresis (156). Conversely, when statin-induced plasma LDL-C reduction was 
compared similar changes using Ezetimibe, which inhibits intestinal absorption 
of cholesterol, only statin treatment was associated with medium term 
improvements in endothelial function. These results indicate statin therapy may 
have pleotropic actions independent of their lipid lowering effect (157). 
Trials have demonstrated an anti-inflammatory activity of statins which seems to 
have additional protective effects beyond lipid reduction. A primary prevention 
trial investigated subjects with relatively normal lipid levels (LDL-C <3.4mmol/L) 
and elevated high sensitivity CRP levels. Subjects were randomised to either 
Rosuvastatin or placebo. The study demonstrated CRP levels after treament 
predicted cardiovascular events independent of lipid parameters (158). This 
provides some evidence that decreasing CRP may result in CVD benefits 
beyond LDL-C reduction. 
Despite the proven efficacy of intensive statin therapy, a post-hoc analysis of 
patients with CHD treated with a high dose of statin demonstrated HDL-C 
remained an independent inverse risk factor to predict major cardiovascular 
events (159). A further analysis of patients undergoing coronary intervention 
showed similar effects. In this study, low baseline HDL-C was associated with 
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increased early events at 30 days and higher event rate and mortality at one 
year irrespective of LDL-C and statin therapy (160). 41% of patients with low 
HDL-C had DM and were more likely to have hypertriglyceridaemia. These 
findings indicate that patients with DM continue to be at risk of developing CVD 
despite statin therapy; it is, therefore, important to identify the specific 
abnormalities in lipoprotein metabolism that exist in such conditions.  
1.6 Type 2 diabetes and alterations in reverse cholesterol 
transport 
DM and states of insulin resistance are commonly accompanied by low plasma 
HDL-C and high triglyceride concentration, a phenomenon that is more widely 
known as diabetic dyslipidaemia and is primarily due to lack of normal insulin 
action. Insulin resistance and associated dyslipidaemia may therefore long 
precede, and even contribute to, the onset of DM (161). Hepatic insulin 
resistance leads to an elevated postprandial triglyceride concentration with 
delayed clearance (162). There is also evidence of increased hepatic VLDL 
production in DM and the MS (163). VLDL-triglyceride levels are estimated to 
be 1.5 to 3-fold higher in DM and excursions are largely due to obesity or poor 
glycaemic control (164).  
Kinetic studies of ApoA-I are more difficult to perform than with ApoB as there is 
usually more than one ApoA-I particle per HDL molecule (see figure 1.1). ApoA-
I can be shed by HDL particles during the remodelling process. Studies have 
demonstrated increased ApoA-I catabolism in DM contributing to low plasma 
HDL-C concentrations (165). Catabolism is further increased in the presence of 
excess triglyceride enrichment of HDL. Plasma lipid exchange by CETP 
between HDL and VLDL or LDL is elevated in hypertriglyceridaemic subjects 
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with DM (166;167). CETP activity correlates with plasma triglyceride levels in a 
process that seems to be substrate driven. Excess HDL triglyceride and 
phospholipid undergoes hydrolysis by hepatic lipase (HL) at the surface of 
hepatic endothelial cells (168). This process generates smaller spherical HDL 
and discoidal pre-β particles (168;169). High HL activity is associated with 
smaller particles as well as lower HDL-C concentrations (169). HL activity 
positively relates with insulin resistance which contributes to the formation of 
smaller, dense HDL particles. These are more susceptible to catabolic 
pathways and ApoA-I detachment, this mechanism is thought to mediate the 
observed lower plasma HDL concentrations (170;171).  
There is little data to show consistent changes in the Apo A-I and AII 
composition of HDL particles in DM, although there are reports that excess HDL 
remodelling occurs in DM increasing discoidal pre-β HDL levels. This has been 
reported mainly in patients with hypertriglyceridaemia and obesity (172). Similar 
mechanisms are likely to be responsible for low plasma HDL-C levels in MS as 
central adiposity has also been associated with increased ApoA-I and ApoA-II 
catabolism (173). Triglyceride enriched LDL particles are additionally subject to 
hydrolysis, mainly by lipoprotein lipase, resulting in small, dense particles in DM 
which are considered to have greater atherogenic potential (174). 
1.7 Cellular cholesterol removal 
It is estimated that approximately 60-80% of the total cellular cholesterol resides 
in the plasma membrane (175). It is likely that early endosomes have a higher 
cholesterol content than late endosomes or golgi apparatus. Although the ER is 
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able to synthesise cholesterol, its overall content is thought to be low (176). 
Cellular cholesterol can either be attained by receptor-mediated uptake of LDL-
C, or de-novo synthesis by the ER. Given that cholesterol cannot be used as an 
energy source and few tissues are able to catabolise cholesterol directly, the 
export of cholesterol remains a vital mechanism through which excess cellular 
cholesterol can be removed. 
ApoE in mice is usually carried by HDL (177). It has been shown that ApoE and 
HDL-C can independently promote cholesterol efflux (178). It is currently 
unclear whether ApoE plays a definitive role in RCT. Nevertheless, ApoE 
deficient mice spontaneously develop atherosclerosis and are commonly used 
as an experimental model to study atherosclerosis (179;180). Moreover, 
atherosclerotic lesions are found to contain both ApoA-I and ApoE proteins. The 
ApoE3 isoform in its free form has been shown to compete with ApoA-I binding 
to ABCA1 (181). All three isoforms, which differ by one amino acid, have been 
demonstrated to mediate cholesterol efflux in a dose-dependent manner. This 
effect was abolished in fibroblasts taken from Tangier disease (TD) patients 
which suggests ApoE selectively binds ABCA1 (181). Endogenous macrophage 
ApoE may have the added ability to mediate lipid efflux independent of ABCA1 
(182). Macrophage ApoE secretion may, therefore, protect against 
atherosclerosis. Yamato et al., observed a positive relationship between ApoE 
secretion and plasma HDL-C in patients with DM (183). In this study ApoE 
secretion significantly improved after initiation of hypoglycaemic therapy. This 
proposes reduced HDL-C observed in DM may be associated with lower ApoE 
secretion which may predispose to atherosclerosis. However, the utility of this 
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study was limited by the use of a heterogeneous group of Japanese patients 
with no control group comparison (183). 
Differences in cellular lipid removal, which is rate limiting in HDL assembly, has 
to date not been widely demonstrated in DM, nor is it known whether this 
contributes to low plasma HDL-C concentration. A study by Alenezi and 
colleagues aimed to address this question by studying patients with MS and low 
HDL-C with and without hyperglycaemia. Authors reported there was no defect 
in lipid efflux using skin fibroblasts from subjects and purified human ApoA-I 
(184). A pivotal study by Maulden et al., demonstrated lower ABCG1-mediated 
efflux in patients with DM and subsequent foam cell development (185). This 
group earlier demonstrated decreased ABCG1 gene expression and function in 
a mouse model of diabetes (84). 
Using severely hyperglycaemic plasma as an acceptor for cholesterol, impaired 
cholesterol transport has been shown to occur from cultured fibroblasts. This 
reduction was subsequently reversed after insulin treatment (186). A decreased 
LpA-I/A-II ratio may also be implicated in lower cholesterol efflux (187). ApoA-II 
has been shown to bind both ABCA1 and SR-B1 but has variable effects on 
efflux depending on the cell type studied and conditions used (187;188).  
The effect of HDL particle glycation has been examined in relation to excess 
glucose and diabetes. Hoang and colleagues examined this using ApoA-I 
incubated with either ribose and glucose (189). Modified ApoA-I resulted in 
lower efflux in both human monocyte-macrophage cell lines (THP-1) and human 
monocytes. This was observed at physiological concentrations of glycated 
ApoA-I similar to that seen in diabetic patients with complications. The effect 
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was attenuated by the use of drugs which inhibit AGE formation or disrupt 
cross-linking to glucose (189). Similar defects in efflux were observed with 
AGE-modified HDL. Another study showed AGE-modified albumin impaired 
membrane binding of HDL3 particles in murine peritoneal macrophages. The 
reduction in HDL-mediated lipid export was consistently attenuated with 
inhibitors of AGE formation-Aminoguanidine and Metformin (190).  
The effect of modified plasma lipoproteins on cellular cholesterol removal in 
diabetes has been explored using standardised cellular models. In type I 
diabetes, it has been reported that cellular cholesterol removal may be 
increased (191). This observation was assessed using plasma taken from 
diabetic subjects which was diluted and subsequently added to cultured 
fibroblasts taken from healthy subjects. This model examined the effects of 
plasma lipoproteins on cholesterol efflux. Cellular cholesterol removal was 
unaltered after treating these patients with Simvastatin. Serum HDL levels in 
these patients appeared lower than is usually seen in patients with type I 
diabetes (191). As type I diabetes is associated with increased plasma AGE, 
these findings oppose results from that of in-vitro studies. Using a similar 
experimental design in patients with DM, de Vries and colleagues report 
increased cholesterol export to plasma taken from hypertriglyceridaemic DM 
patients. It was thought this was related to increased preβ-HDL formation (192). 
Other studies have since confirmed this finding in patients with 
hypertriglyceridaemia (172). No difference in cellular cholesterol removal was 
observed using plasma taken from normolipidaemic DM subjects compared to 
controls (192). These results would suggest diabetic status did not adversely 
modify the ability of plasma lipoproteins to remove cellular cholesterol. 
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Concordant with these findings, no difference in cellular efflux to plasma was 
observed in patients with the MS (193). Cholesterol export in this study was 
independently related to plasma cholesterol esterification, cholesterol ester 
transfer, phospholipid transfer protein (PLTP) activity and ApoE concentration. 
Of note, there were a moderate number of DM subjects included and a 
marginally higher lipid efflux was seen in DM patients with MS compared to DM 
without MS (193). These data would suggest any defect in cellular cholesterol 
removal in DM is more likely to be due to defects in a cellular transporter or 
transporter-acceptor interaction. 
1.71 The role of hepatic and macrophage ABCA1 in murine models 
 
In-vitro work using hepatocytes indicates HDL particles may be synthesised in 
an autocrine manner; As an HDL particle enlarges by the central accumulation 
of cholesterol ester, ApoA-I particles are able to dissociate. These are 
subsequently re-lipidated by hepatic ABCA1 to form further HDL particles (194). 
Organ-specific mouse KO studies have implicated hepatic ABCA1 activity to be 
the main source for maintaining plasma HDL-C levels. It is estimated that in 
animals 80% of plasma HDL-C originates from hepatic ABCA1 lipidation of 
nascent apoA-I molecules (70). In hepatic-specific KO animals, there is a two to 
three-fold increase in ApoA-I clearance, which was predominantly renal, 
compared to wild-type animals. This was associated with a 2-fold higher 
turnover of ApoA-I but HDL tracer uptake at the liver was unchanged (195). 
These data indicate hepatic ABCA1 inactivation leads to decreased plasma 
HDL-C residency and accelerated renal clearance. A similar kinetic profile has 
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been demonstrated in naturally occurring human ABCA1 mutations, with rapid 
turnover persisting when donor wild-type HDL particles were injected (196).  
The contribution of macrophage ABCA1 to maintaining plasma HDL-C has been 
investigated using transplanted macrophages taken from ABCA1 KO animals. 
These were transplanted into irradiated wild-type mice, resulting in mice 
specifically deficient in macrophage ABCA1. This technique demonstrated 
macrophage ABCA1 activity had little effect on plasma HDL-C concentration 
(197;198). Nevertheless, macrophage selective ABCA1 depletion lead to 
accelerated atherosclerosis despite the little difference in plasma lipoproteins 
(197-199). Further evidence indicating the importance of peripheral blood cell 
ABCA1 in atherosclerosis is demonstrated by a study of leukocyte ABCA1 
deficiency in a background of LDL-C receptor KO mice. These transgenic 
animals were observed to have a 60% increase in aortic atherosclerosis with 
histological features of advanced disease despite no change in plasma HDL-C 
levels. The study concluded this effect was mediated by altered macrophage 
recruitment (198). It is noteworthy that accelerated atherosclerosis was not 
observed in whole body ABCA1 inactivation in mice (199).  
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1.8 The association of ABCA1 with cardiovascular disease in 
humans  
1.81 Structure and function of ABCA1 
This membrane transporter is part of the ATP-binding cassette (ABC) protein 
superfamily. This group of proteins transport a variety of organic and inorganic 
compounds. Higgins and Gottesmann initially observed that ABC transporters 
acted like a “flippase” which are able to transport lipids from the inner to the 
outer leaflet of the plasma membrane (200). The family now contains seven 
subclasses (ABCA to ABCG). Mutations in these genes have been shown to be  
responsible for several human diseases, including cystic fibrosis, 
adrenoleukodystrophy, sitosterolaemia and TD (201). The latter two diseases 
are due to abnormalities in lipid transport. ABC transporters are structurally 
configured either as homodimers or half transporter heterodimers. Structural 
motifs known as Walker A and Walker B are present in many transporters that 
use ATP, but a Walker C motif is unique to ABC transporters (202).  
At least seven ABC transporters have demonstrated cholesterol as being a 
direct or indirect substrate for transport; ABCA1, G1, G5, and G8 have been 
shown to have a major role in cholesterol transport, significantly influencing 
lipoprotein metabolism (203). 
ABCA1 is a 2261 amino acid plasma membrane protein comprising of two 
heterodimers (figure 1.4). Each contain Walker A, B and C motifs, the latter 
motif consists of two large extracellular loops that are usually glycosylated and 
connected by one or more cysteine bonds (204;205). ABCA1 has been shown 
to transport cholesterol, phospholipid (PL) and other lipophilic compounds such 
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as ApoE (178). Its homology to other transporters in the ABC family suggests 
transport may be facilitated by formation of a channel that helps lipids “flip” from 
the inner to the outer membrane bilayer, though the precise mechanism of 
efflux is not fully characterised.  
The ‘flippase’ model implicates two separate conformations of the transporter, 
this allows binding of substrates on the cytoplasmic leaflet and release into the 
outer leaflet for subsequent access to extracellular acceptors. An alternative 
theory proposes a channel is formed within the membrane which is responsible 
for extracellular lipid translocation (206). 
PL transport is thought to be another putative function of ABCA1. It is currently 
unclear whether ABCA1 transports both PL and cholesterol together or by two 
separate processes. It is possible to uncouple this process using a protein 
kinase inhibitor which has been shown to predominantly inhibit cholesterol efflux 
(207). Removal of cellular cholesterol by using an artificial acceptor-cyclodextrin 
did not affect PL transport but eliminated cholesterol efflux (208). These studies 
indicate PL transport may be an active function of ABCA1 with cholesterol efflux 
being a secondary passive process. 
Phosphatidylserine (PS), a phospholipid, is largely confined to the inner 
membrane leaflet in healthy cells. Translocation, or “flop” of this phospholipid to 
the outer membrane leaflet is thought to trigger cellular apoptosis (209). Our 
group observed abnormal PS flop in B-lymphocytes in a patient with a rare 
bleeding disorder-Scott syndrome (210). Decreased ABCA1 expression in 
leukocytes taken from this individual was demonstrated and was caused by a 
novel missense mutation in ABCA1 (210). Obvious lipid abnormalities in this 
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patient were not apparent (HDL-C concentration 1.3mmol/l) indicating ABCA1 
may have a tissue specific role. In keeping with this study, defects in 
coagulation have been reported in TD patients (211). It is unclear whether 
ABCA1 promotes PS flop directly or regulates other permissive proteins (212). 
ABCA1 promotes calcium-induced microvesicular membrane protrusions which 
may promote PL transport physicochemically. Alterations of PS distribution is 
also thought to transduce non-apoptotic signals (213). Increased platelet PS 
flop has been observed in patients with type I diabetes and nephropathy. This 
may predispose to an excess risk of thrombosis (214). Indeed studies in 
humans have found an inverse relationship between HDL-C levels and risk of 
recurrent thrombosis (215). Large pulmonary emboli have been demonstrated 
to occur in patients with lower HDL-C concentrations (216). Van Leuven and 
others have, more directly, demonstrated that infusion of Apo-AI-
phosphatidylcholine in humans abrogates the thrombotic effect induced by CRP 
(217). These studies implicate HDL-C to have direct anticoagulant action and 
this lipoprotein may play an important role in preventing arterial thrombosis. 
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Figure 1.4 Structure of ABCA1 transmembrane spanning protein  
ABCA1 consists of two transmembrane domains of six alpha helices (blue) and two intracellular 
nucleotide binding domains. The nucleotide binding folds are linked by a cytoplasmic peptide. 
The ATP-binding cassette on ABCA1 consists of Walker A and B motifs(coloured boxes) which 
are commonly found in proteins that utilise ATP (218). [Adapted from Maxfield & Tabas Nature 
2005]. 
 
1.811 Intracellular cholesterol transport 
ABCA1 targets membrane regions prone to accumulating cholesterol. The 
inward direction of movement of cholesterol from the plasma membrane toward 
intracellular storage occurs using the action of Acyl-Coenzyme A:cholesterol 
acyltransferase (ACAT). Excess free cholesterol is cytotoxic and this enzyme 
esterifies cholesterol in the ER which accumulates as lipid droplets in the 
cytoplasm (218). Efflux of cholesterol from the plasma membrane is associated 
with a rapid reduction of the ACAT sensitive cholesterol pool (219). Lipid esters 
in droplets can be hydrolysed by neutral cholesterol ester hydrolases to liberate 
free cholesterol for efflux. Some cells have an additional hormone sensitive 
lipase for triglyceride hydrolysis from fat cells (220). ACAT activity is positively 
regulated by cellular cholesterol levels acting as a homeostatic sensor.  
The protein Caveolin-1 binds cholesterol and has been implicated in shuttling 
cellular cholesterol to and from the plasma membrane. This may transfer 
cholesterol to specific regions rich in cholesterol and sphingomyelin (221). 
Caveolin forms small membrane invaginations (caveolae) of 50-100nm 
diameter, these are considered a type of lipid raft (222). The interaction 
between these lipid rafts, ABCA1 and apolipoproteins may be an important 
determinant for transport. 
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1.812 Models of ABCA1 mediated intracellular cholesterol removal 
 
There are currently two models which postulate how intracellular cholesterol is 
exported by ABCA1. The exocytosis model indicates excess intracellular 
cholesterol is packaged in vesicles or rafts and transported to ABCA1 within the 
plasma membrane. To support this, ABCA1 induction in the absence of 
apolipoprotein is associated with an increase in cell membrane cholesterol 
(223). In contrast the retroendocytosis model, proposes that a apolipoprotein-
ABCA1 complex is initially endocytosed toward intracellular lipid stores which 
pumps cholesterol into this complex for transport to the plasma membrane and 
subsequent release by exocytosis. Studies in support of this have demonstrated 
intracellular trafficking of ABCA1 from the ER to the plasma membrane (224). A 
seminal paper by Neufeld demonstrated non-functional human ABCA1 
accumulated at intracellular sites with apolipoproteins (225).  Pharmacological 
inhibiton of ABCA1 function has been reported with the use of Probucol. No 
changes in gene expression were observed by probucol in fibroblasts but 
binding of Apo-AI was abolished. This drug has been shown to cause 
accumulation of non-functional protein at the plasma membrane with resistance 
to degradation to calpain (226). This supports the functional requirement of 
ABCA1 to shuttle between intracellular sites and plasma membrane (227). A 
similar trapping mechanism has been reported to occur from Cyclosporin 
treatment (228). It is possible both mechanisms co-exist but the dominant 
mechanism by which efflux occurs is still subject to debate (229).  In addition to 
specific transporter-mediated cholesterol removal, cholesterol can be non-
specifically released, probably via diffusion, to a variety of extracellular 
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acceptors including lipoproteins (230). LCAT is considered to drive the rapid 
release of cholesterol by maintaining a free cholesterol concentration gradient. 
This occurs predominantly in HDL due to LCAT localisation and HDL particle 
capacity. The interaction of ApoA-I with ABCA1 stabilises and protects the 
transporter from proteolysis (231).  
 
1.813 The binding of ApoA-I 
 
ApoA-I is thought to bind with ABCA1 in its free form and lipidation of ApoA-I 
reduces further binding (232). In support of this Okuhira et al., demonstrated 
binding was inhibited by a monoclonal antibody against ApoA-I and this lead to 
a 70% reduction in efflux (233). Vedhachalam, using a competition assay with 
labelled ApoA-I, showed that ABCA1 creates two binding sites for ApoA-I which 
separately confer its regulatory and lipid transport function (234). Vedhachalam 
further proposed a three-step model for the efflux process;  ApoA-I binding, 
phospholipid translocation and subsequent membrane bleb formation, this is 
followed by lipidation of ApoA-I (235). 
Free ApoA-I is not the major form of HDL in plasma and although the 
dissociation constant of HDL surface is unknown, it is estimated this is less than 
1% of plasma ApoA-I concentration so that only a small proportion of ApoA-I is 
free to bind to ABCA1 (232). There are several mechanisms that yield free 
ApoA-I particles from HDL, as explained above, including the action of CETP 
and PLTP (236;237). The latter remodels HDL into smaller particles releasing 
ApoA-I. This process is increased as triglycerides replace the cholesterol ester 
core (238). Furthermore, ApoA-I can be released from HDL particles to the cell 
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surface due to a higher affinity (239). This process is responsible for the 
formation of nascent HDL. In a landmark study, patients who presented with 
acute coronary syndrome were injected with a naturally occurring, mutated form 
of ApoA-I associated with longevity. Coronary atherosclerosis, as measured by 
intravascular ultrasound, showed evidence of regression after 5 weekly doses 
(240). There has been some subsequent debate whether this mutated form of 
ApoA-I, termed “ApoA-I Milano”, shows superior lipid removal properties 
compared to wild-type ApoA-I (241;242). These results indicate ApoA-I 
analogue or mimetic therapy may be an effective therapeutic option to augment 
cellular cholesterol removal. 
1.82 Genetics of ABCA1 and cardiovascular disease 
The human model of dysfunctional ABCA1 has been characterised by TD. This 
rare autosomal recessive disorder was first reported in 1960 where 
characteristic features of cholesterol ester accumulation were manifest in a 
variety of tissues leading to enlarged orange tonsils, hepatosplenomegaly, 
peripheral neuropathy and near absent HDL-C levels (243). 
Homozygote individuals exhibit plasma HDL-C concentrations of less than 5% 
of normal. ABCA1 is located on chromosome 9q21 and various mutations have 
been shown to be responsible for TD and familial HDL deficiency. This was first 
identified by multiple groups in 1999 (244-246;246;247). These studies 
confirmed ABCA1 mutations were responsible for diminished ApoA-I mediated 
cellular cholesterol removal in skin fibroblasts taken from affected patients 
compared to healthy individuals. Currently over 70 mutations are known. Low 
ApoA-I levels arecaused by accelerated catabolism of ApoA-I and ApoA-II with 
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excretion mainly via the kidneys. This condition is not associated with significant 
alteration in ApoA-I production (248;249). Defective endosomal cholesterol 
trafficking to the plasma membrane has  been demonstrated to occur in 
fibroblasts taken from patients with TD and in murine models of this disease 
(225;250). A similar naturally occurring ABCA1 mutation, has also been 
demonstrated to occur in chickens (251). 
The incidence of premature coronary disease in TD is four to six fold higher 
(252). This is not as high as common genetic predispositions such as familial 
hypercholesterolaemia because concentrations of LDL-C are reduced, typically 
to 40% of normal in homozygotes. Heterozygotes have higher HDL-C levels-
estimated to be 50% of normal, however, they still appear to have higher CHD 
risk despite normal LDL levels (253;254). Clee and colleagues, in a pivotal 
study, demonstrated ABCA1 activity in cultured skin fibroblasts taken from 
heterozygote individuals was inversely correlated to plasma HDL-C. There was 
also a relationship between ABCA1 activity and prevalence as well as severity 
of CVD. This crucial study provided the clearest evidence to link the degree of 
ABCA1 activity to the age of onset and severity of CVD. Van Dam et al., studied 
four different missense mutations in heterozygotes and showed ABCA1-
mediated fibroblast efflux negatively correlated with the CIMT. An upper limit of 
normal, set at 0.8mm, was reached twenty five years earlier in affected 
individuals (255). Singaraja has since characterised the effect of several ABCA1 
mutations on function and concluded that complete loss of function mutations 
were associated with absent plasma membrane localisation and/or ApoA-I 
binding. However, other mutations such as the W590S, which was associated 
with preserved localisation and binding, remained unable to elicit lipid efflux. 
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Interestingly, this mutation is associated with reduced PL efflux as 
demonstrated by reduced annexin V binding. It is possible this plays a 
permissive role for cholesterol efflux to occur (256). This important work 
separated the severity of various ABCA1 mutations by efflux function and 
degree of HDL reduction (257). Further work by this group have reported that 
several gene polymorphisms are associated with modified CVD risk without 
alterations in plasma HDL-C concentrations (254). Soro-Paarvonen explored 
cholesterol efflux in macrophages from subjects with familial low HDL-C without 
a known TD mutation. Results did not confirm defects in ApoA-I mediated efflux 
and no significant relationship between efflux and CIMT was observed. Patients 
however, exhibited decreased macrophage ABCA1 gene expression in 
response to cholesterol loading, implying low HDL-C stemmed from an altered 
gene expression set-point (258). At a population level, the Copenhagen heart 
study has screened over 9000 individuals in the general population. 10% of 
individuals with the lowest HDL-C were found to be heterozygote for an ABCA1 
mutation (189). Specifically, heterozygosity for the common K776N mutation 
was showed to convey elevated risk for developing CHD with a hazard ratio of 
2.4 (259). It is noteworthy that little functional information on this mutation was 
known at that time of the reporting. In contrast, current analysis of this cohort 
concluded heterozygote loss of function mutations were not associated with 
increased CHD (260). Frikke-Schmidt further reported common variants of 
ABCA1 were associated with HDL-C levels in the Danish population and some 
of these variants predicted ischaemic heart disease (261;262). These findings 
were not supported by a smaller, population study (222). The common genetic 
polymorphism, R219K, is estimated to have a carrier frequency of 46% in 
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european people. Clee and colleagues report this variant to be independently 
associated with higher HDL-C and lower triglyceride levels. Carriers of this 
polymorphism were observed to have reduced CVD risk, and slower 
progression of CHD based on angiographic data (263). No obvious differences 
in cholesterol efflux were observed but it should be noted that a small numbers 
of individuals underwent detailed analysis yielding a relatively high inter-assay 
coefficient of variation (CV). In a separate investigation, common functional 
polymorphisms have been reported to influence the age of onset of symptoms 
resulting from CHD (264). It is likely common genetic variants have a minor to 
moderate phenotypic effect on HDL-C concentrations but predisposition to CVD 
is probably subject to interaction with other environmental factors. 
With regard to glucose homeostasis, there have been reports that some genetic 
variants may occur more commonly in certain ethnic groups with DM compared 
to the background population. This has been reported by Brunham and 
colleagues (265-267). The R230C variant is associated with early onset DM in 
Mexicans with increased body weight and reduced fasting insulin levels (265). 
This variant is also seen in populations with a high prevalence of diabetes but is  
not seen in Caucasians (268). The interaction of several genes as well as 
environmental factors are more likely to be responsible for the development of 
the common form of DM, though monogenetic predisposition remains a 
possibility. Functional studies in these individuals are still lacking and altered 
ABCA1 gene expression or reduced transporter function has not been reported.   
Physiological studies have established that Tangier ABCA1 heterozygotes have 
evidence of endothelial dysfunction secondary to defective NO synthesis. This 
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was rapidly corrected after ApoA-I infusion confirming ABCA1 is likely to confer 
direct beneficial effects on blood vessels (269). 
1.83 ABCA1 expression and regulation 
Although widely expressed, high levels of ABCA1 messenger RNA (mRNA) 
(defined as greater than ten-fold compared to housekeeper genes) using 
polymerase chain reaction (PCR) are found in human macrophages, liver, 
placenta, small intestine and lung in decreasing order (270). Mouse studies 
have shown a similar pattern of tissue expression with high expression also 
noted in heart, brain and testicular tissue. However, importantly, a discordance 
between mRNA expression and protein abundance has been reported in mice 
in multiple organs except liver, kidney and testicles where a high level of protein 
is concordantly expressed (271). This suggests additional tissue specific 
regulation may occur at a post-transcriptional stage. Mouse adipose tissue was 
reported to have moderate expression but this was not localised using the in-
situ hybridisation technique (271). It is estimated induction of ABCA1 in tissue 
macrophage cells represents the largest pool of ABCA1 in humans based from 
work on cultured cells (272).  
ABCA1 protein levels are increased in the liver and in macrophages in response 
to a high fat diet (271;273). The specific gene transcripts induced in these 
tissues have been identified (274). Our group have reported ABCA1 gene 
expression is up regulated in human atherosclerotic plaques as well as 
aneurysmal arteries compared to non-atheromatous arteries and this was  due 
to increased Liver X Receptor-α (LXRα) expression. ABCA1 protein levels were 
diminished in plaque tissue owing either to protein degradation or instability 
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(275). This study, importantly, demonstrated a positive relationship between 
peripheral blood leukocyte and monocyte ABCA1 gene expression. 
In the absence of gene inducers, ABCA1 mRNA and protein are rapidly 
degraded with an estimated half life of 1-2 hours (276). This is due to 
phosphorylation of an amino acid sequence in the first intracellular loop known 
as PEST (Proline-Glutamate-Serine-Threonine) motif (277). Phosphorylation at 
these sites promotes proteolysis by a calpain protease but interaction with 
apolipoproteins promotes cell surface protein accumulation by inhibiting 
degradation (278). Protein stability has been demonstrated to increase ABCA1 
levels by positive feedback (277). Human skin fibroblasts have historically been 
used as a model to study cellular cholesterol transport in humans. Using this 
model, cellular cholesterol loading did not stabilise ABCA1 gene expression but 
positively regulated expression via LXR (279). Fibroblasts also express ABCG1, 
another ABC cholesterol transporter which transports cholesterol to more 
mature HDL particles (280). Conversely, these cells do not express significant 
amounts of SR-B1 (281)  
PLTP has also been shown to interact with and stabilise ABCA1 to enhance 
cholesterol removal in fibroblasts and macrophages by mimicking 
apolipoproteins (282). However, PLTP was not shown have a protective effect 
in LDL-KO mice when ApoA-I was overexpressed (283). Moreover, PLTP is 
highly expressed in atherosclerotic plaques which brings uncertainty to whether 
it represents an atheroprotective protein (284).  
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1.831 The role of nuclear transcription factors and drugs in the 
regulation of ABCA1 
It is known that oxysterols, produced by intracellular cholesterol hydroxylation 
rather than cholesterol per se, upregulates ABCA1 gene expression by binding 
to the nuclear transcription factor LXRα (285). In support of this, fibroblasts 
taken from patients with 27-hydroxylase deficiency did not increase ABCA1 
gene expression in response to cholesterol loading (285). This clinical disorder 
is characterised by cholesterol accumulation forming cerebrotendinous 
xanthomata and testifies to the dominant regulatory role played by 27-
hydroxycholesterol in humans (286;287). 24-hydroxylation plays an important 
regulatory role to allow excess cholesterol to pass from the brain to circulation 
(288).  
LXRα and retinoid-X receptor (RXR) join to form an obligate heterodimer which 
binds the DR4 response element in the ABCA1 promoter region, inducing gene 
expression (289). Retinoic acid, a ligand of the orphan receptor RXR, can also 
induce expression. Together, these ligands have been shown to act in a 
synergistic fashion to upregulate expression (290). The LXR/RXR heterodimer 
confirmation can recruit further ligands to form co-activator and co-repressor 
complexes with opposing effects on subsequent target gene transcription (291). 
This activating mechanism is thought to result in the removal of excess 
cholesterol in cells expressing ABCA1 and represents a dominant mechanism 
in macrophages (292). LXRα is mainly expressed in the liver, adipose tissue, 
intestine, kidney and macrophages. This transcription factor regulates multiple 
genes including ABCG1, ABCG5 and ABCG8 to increase efflux and aid biliary 
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cholesterol excretion (293;294). LXRα also increases fatty acid synthesis by 
actions on sterol regulatory element binding protein-1c (SREBP-1c), fatty acid 
synthase and stearoyl-CoA desaturase (295). 
Mitro and colleagues had demonstrated that glucose itself may positively 
regulate LXRα and LXRβ. Glucose was shown to upregulate LXRα levels in 
human hepatoma cells (Hep G2) and in liver from mice fed with glucose. This 
effect seemed to be specific to glucose and was dose dependent at 
physiological concentrations (296). In this study, LXR target genes including 
ABCA1 and ABCG1 were upregulated in hepatocytes of glucose fed mice. The 
results of a subsequent study did not support these provisional findings and 
implicate carbohydrate response element binding protein (ChEBP) as a hepatic 
glucose sensor (297). 
The transcription factor PPARγ is a permissive binding partner of LXR and 
induces LXRα (298). PPARγ activation is associated with a glucose lowering via 
peripheral insulin sensitisation and PPARγ agonists are used as treatments for 
DM. PPARγ agonists stimulate cholesterol efflux via LXRα with subsequent 
ABCA1 induction and this has been shown to improve atherosclerosis in animal 
models (292;298). We have reported PPARγ gene expression is lower in 
atheromatous plaques and ectatic arteries (299). ABCA1 gene induction and 
subsequent cholesterol efflux has also been stimulated by PPARα agonists in 
macrophage cell lines (292). In hepatocytes, ABCA1 expression contributes to 
HDL synthesis which is shown to be PPAR-dependent (300). PPARα agonists 
are currently used in clinical practice to lower triglyceride and raise HDL 
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cholesterol levels as outlined above and have been demonstrated to increase 
ABCA1 gene expression in monocytes (301). 
A number of statins have been shown to inhibit induction of ABCA1 using in- 
vitro models of murine and human macrophages. The effect was dose 
dependent and was inhibited by the addition of the post-reductase product 
mevalonate (302). Both Pitivastatin and Atorvastatin have been demonstrated 
to decrease ABCA1 in a LXRα-dependent manner (303;304). Conversely, in a 
hamster model of insulin deficiency, macrophages treated with Atorvastatin in 
the presence of ApoA-I showed a disparate increase in ABCA1 gene 
expression and efflux (305). 
Pravastatin fed mice were associated with a decrease in ABCA1 but not LXRα 
expression in both hepatic cells and leukocytes (306). The decrease in LXRα 
and ABCA1 expression reported by most studies is probably secondary to 
reduced oxysterol generation secondarily to inhibition of cholesterol synthesis. 
Wong and colleagues further demonstrated the statin effect on ABCA1 
expression is dependent on cellular cholesterol status, with cholesterol 
supplementation inhibiting, and cholesterol depletion augmenting the response 
(307). This mechanism is likely to be mediated through the cellular cholesterol 
sensor SREBP-2 (307;308). The additional effect of diabetes, similar to that 
seen in some animal models, may modify this interaction. Guan recently 
reported increased mononuclear cell gene expression in hyperlipidaemic, DM 
patients receiving simvastatin compared to untreated diabetic patients with 
either a normal lipid profile or hyperlipidaemia (309). In conclusion, the effect of 
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statin treatment on ABCA1 depends on the cholesterol status and diabetes 
status of the model used. 
 
1.832 ABCA1 regulation in metabolic disease 
 
It has been postulated that disorders associated with increased blood glucose 
and fatty acids may destabilise ABCA1. Both saturated and mono-unsaturated 
fatty acids exacerbate insulin resistance and free fatty acids have been directly 
shown to inhibit insulin signalling (310). Unsaturated fatty acids have been 
shown to inhibit cholesterol efflux from macrophages (311). Uehara and co-
workers further identified that unsaturated fatty acids targeted a specific site in 
the DR4 promoter region which is a known regulatory site of LXRα. Fatty acid 
binding at this site resulted in an inhibition of ABCA1 and ABCG1 gene 
expression in cultured macrophages (312). Senanayake and colleagues report 
macrophages taken from patients with DM have elevated unsaturated fatty acid 
concentrations compared to cultured macrophages of healthy individuals. 
Despite this, in this study, there was no difference in macrophage ABCA1 
expression observed whether macrophages were cultured in physiological or 
supraphysiological glucose concentrations (313).  
1.9 The effect of glucose on the ABCA1 transporter  
The direct effect of glucose on ABCA1 gene expression has been investigated 
with conflicting results. Human hepatoma (HepG2) cells grown in medium 
containing 5.5, 12.5 and 25mmol/l glucose increased gene expression with 
increasing glucose concentration (314). Uehara, in contrast, reported no such 
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dose dependent differences in gene expression in HepG2 cells or mouse 
macrophages lines (RAW246.7) (315). However, this study did demonstrate 
marked reduction in hepatic and macrophage ABCA1 gene expression in 
streptozotocin-induced diabetic mice (a model for type I diabetes) with insulin 
treatment correcting this defect (315).  
AGE may have a negative effect on cholesterol export secondary to effects on 
ABCA1. Albumin represents 80% of proteins in plasma susceptible to glycation 
and oxidation. AGE formation is associated with ageing, enhanced in diabetes 
and is associated with diabetes related vascular complications (316). Moreover, 
serum AGE levels have been shown to increase with duration of DM (317). 
Post-mortem work indicates a greater number of receptors for AGE in coronary 
plaques taken from diabetic patients, which may influence plaque instability 
(318). Currently, there is little human in-vivo data directly examining the effect of 
AGE on this transporter. ABCA1-mediated cholesterol efflux is severely 
impaired when precursors of AGE are added to either cultured human 
fibroblasts or murine macrophages (319). Inhibition of ApoA-I binding and 
ABCA1 degradation have been reported mechanisms for this effect with no 
alterations in ABCA1 mRNA. Steptozotocin induction of diabetes in 
hyperlipidaemic swine was associated with increased coronary cholesterol 
plaque area with decreased ABCA1 staining in lesions compared to the non-
diabetic animals (320). In contrast to these observations, Isoda and colleagues 
demonstrated the addition of glycated albumin was not associated with any 
changes in ABCA1 mRNA, protein or ApoA-I-mediated efflux in cultured 
macrophages (321). ABCG1 mRNA in these macrophages was, however, 
reduced with a corresponding decrease in protein and HDL-mediated efflux 
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(321). This indicates the possibility of differential gene regulation despite 
unaltered LXRα gene expression. Collectively, these studies do not indicate a 
clear mechanism of ABCA1 disruption by AGE formation.  
A single study has reported reduced ABCA1 RNA levels in human peripheral 
monocytes taken from patients with DM and dyslipidaemia. ABCA1 levels were 
improved using a PPARα agonist Fenofibrate (301). Subsequent studies have 
failed to show differences in peripheral blood cell ABCA1 expression in patients 
with DM (185;309;322;323). We have reported an inverse linear relationship 
between fasting blood glucose and ABCA1 expression in blood leukocytes 
taken from 32 healthy men (324). These results, in context of inconsistent 
findings from studies outlined above, have lead to the hypotheses in section 
1.91.  
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1.91 Hypotheses and Aims 
• We propose the inverse relationship observed between fasting plasma 
glucose (FPG) and ABCA1 mRNA extends over a wider range of glucose 
concentrations in patients with Imparied glucose homeostasis (IGH) 
(wich includes impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT) as per the American Diabetes Association classification 
2005) (325). Gene expression will also be assessed in patients with DM 
who are naive of hypoglycaemic and lipid lowering therapies.  
• We hypothesise this relationship with gene expression will lead to 
reduced ABCA1 function.  
• We further postulate, changes in ABCA1 may mediate premature 
atherosclerosis in patients with impaired glucose regulation. 
Aims 
• To investigate whether acute changes in glucose levels within an 
individual during an oral glucose tolerance test (OGTT) result in 
differences in leukocyte ABCA1 mRNA and protein as well as function as 
measured by lymphocyte PL translocation. 
• To measure and compare functional cholesterol efflux in primary dermal 
fibroblasts as well as PL transport in CD4+ T-lymphocytes between 
groups of patients with DM, IGH and healthy men. 
 
• To investigate the relationship of ABCA1 gene expression and function 
with CIMT, a surrogate measurement of atherosclerosis. 
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• Finally, to examine the effects of chronically lowering hyperglycaemia in 
drug naïve patients with DM. ABCA1 expression and protein 
concentrations will be measured before and after glucose lowering 
therapy. 
Plan of investigation 
 
For our power calculations, we wished to test the null hypothesis that the 
magnitude of the β coefficient (slope of the regression line) between ABCA1 
expression and fasting plasma glucose is zero.  Using our previous data, the 
standard deviation (SD) of log ABCA1 gene expression is 0.35, and of glucose 
0.37 with a regression coefficient of –0.4556 (324). With 80% power and 5% 
significance, our hypothesis could be tested with 27 subjects in each glycaemic 
category.  There are few robust data on any association between ABCA1 gene 
function and fasting plasma glucose. Assuming a 1:1 relationship between 
expression and function, our numbers should be sufficient to detect a significant 
relationship between function and FPG.  Finally, we estimate a log SD of IMT of 
0.198 (33), and a β coefficient between IMT and ABCA1 expression of –0.011.  
Our sample size would be sufficient to demonstrate that this coefficient is 
significantly different from zero.  
The following parameters will be assessed. 
• Measurement of baseline leukocyte ABCA1 mRNA and protein. 
• Assessment and measurement of CIMT 
• Functional assessment of PS translocation in peripheral blood 
lymphocytes. 
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• A subset of subjects will undergo assessment of cholesterol efflux using 
skin fibroblasts from participants. 
• Assessment of leukocyte ABCA1 expression after glucose lowering over 
six weeks using metformin therapy. 
 
The study is limited to men in order to minimise variability in insulin sensitivity 
and lipid metabolism caused by changes in sex hormones during a menstrual 
cycle as well as to avoid differences caused by contraceptive use and 
menopausal status (326). This study is original as two tissue measurements of 
ABCA1 are planned in individuals and participants will be naive of medications 
known to affect glucose and lipid metabolism. A glucose lowering medication, 
Metformin, will be used to lower blood glucose over six weeks. Other commonly 
used treatments in DM have been shown to affect ABCA1. This work will 
complement another sub-study within the department (Rosiglitazone Plaque 
Study, GlaxoSmithKline) which investigates the effect of PPARγ agonist 
treatment on leukocyte ABCA1 mRNA in high risk patients with DM. 
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2.0 METHODS AND MATERIALS 
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2.01 Patient recruitment 
Men with a history of drug naïve DM or IGH were recruited from metabolic 
clinics at St Mary’s hospital as well as from community practices. The local 
Diabetes Research Network (DRN) provided assistance in this process. Healthy 
volunteers were recruited through advertisement at St Mary’s Hospital and via 
the DRN. Recruitment criteria are listed: 
Patient inclusion criteria: 
• Male subjects  
• Age 18-70 years  
• Ability to give written informed consent  
 
Medical exclusion criteria: 
• Known Type 1 diabetes.  
• Significant cardiovascular disease, including atrial fibrillation, peripheral 
vascular disease, coronary heart disease, cerebrovascular disease or 
known carotid stenosis. 
• Known microvascular complications from DM. 
• Use of glucose altering or lipid lowering medications or drugs known to 
alter glucose or lipid metabolism. 
  
After a 10 hour overnight fast, a clinical assessment was conducted using 
standard measurements of height and weight. Blood pressure was measured at 
the right brachial artery (Automated Omron sphygmomanometer). Waist 
circumference was measured mid-way between the costal margin and iliac 
crest.  All clinical procedures were performed in the departmental metabolic 
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investigation unit. Written consent was sought from all participants and ethical 
approval for the study was obtained from Hammersmith, Queen Charlotte’s and 
Chelsea Research Ethics Committee (REC Reference 05/Q0406/33). The study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.  
2.02 Blood specimens 
Control participants and those known to have IGH underwent a 75g OGTT. 
Glucose measurements were taken at baseline, 1 hour and 2 hours. Fasting 
blood samples were taken from DM patients and these patients did not undergo 
an OGTT.  
2.03 Skin biopsy 
A cohort of participants underwent a 4mm dermal punch skin biopsy at their first 
or second visit. This was taken from the non-dominant forearm under sterile 
conditions using local anaesthesia (1% Xylocaine) and suture pack (Rochialle 
inHealth, Cambridge, UK). A non-absorbable 4/0 ethilon suture (Southern 
Syringe Ltd, Enfield, UK) was used to close the biopsy site with application of a 
sterile dressing. Arrangements were made for suture removal. 
2.04 Carotid artery imaging 
 
All subjects underwent B-mode ultrasound assessment of both carotid arteries. 
This was performed in the Irvine vascular studies department at St Mary’s 
Hospital. Measurements were made by a single experienced observer who was 
blinded to the glucose status of the participant. CIMT was measured at the 
posterior wall of the common carotid artery, 1.5cm proximal to the bifurcation 
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(Phillips iU22). A qualitative assessment of the internal carotid arteries was also 
performed.  
2.05 Glucose lowering treatment 
After the first visit, patients with DM were offered pharmacological treatment to 
lower blood glucose using the recommended first line oral treatment for DM. 
Metformin tablets were administered at a maintenance dose of 500mg twice 
daily for a total of six weeks. Further fasting blood samples were taken upon 
completion of treatment. HbA1c, fasting glucose and standard clinical measures 
were repeated at this time point. 
 
2.06 Demographic data 
 
A total of 68 participants were recruited and underwent leukocyte gene 
expression studies. The demographic data is shown in Appendix III and 
biochemical data in Appendix IV. A summary of these data are shown in table 
2.0. 
Subjects were matched for age, there were no differences in age between 
groups (p=0.55). I also aimed to match study subjects for total cholesterol, 
smoking status and blood pressure as these parameters are independently 
associated with increased CIMT and CVD. There were no differences in these 
parameters between groups (see below). There was some overlap in HbA1c 
between subject groups in keeping with glycaemia being a continuous variable 
(figure 2.1). Patients with a known history of IGH were allocated to this group 
even if the study OGTT results did not show significant abnormalities. Patients 
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who were known to have glucose results borderline for diabetes were 
categorised to either IGH or DM according to results of the study OGTT.  
As expected, patients with IGH and DM had higher BMI than healthy volunteers 
(p<0.05). BMI was not different between patients with DM and IGH. DM patients 
had higher waist measurements compared to controls (P<0.05). 
There were no differences in systolic, diastolic and pulse pressure, between 
groups (p=0.41, p=0.69, p=0.34 respectively). As expected, patients with DM 
had higher fasting glucose concentrations compared to both other groups and 
had a higher Hba1c than controls (p<0.001) and IGH patients (p<0.05), 
illustrated in figure 2.1. Patients with IGH did not have higher fasting glucose 
levels compared to controls. Post oral glucose levels were higher both at 1 
hours and 2 hour intervals in patients with IGH compared to controls (both 
p<0.001). Total cholesterol, LDL-C and triglyceride concentrations were not 
different across groups. HDL-C concentrations were lower in DM patients 
compared to controls (p=0.001). Proportionally more patients were receiving 
treatments for hypertension acting on the Renin-angiotensin-aldosterone axis 
compared to healthy men (21% versus 7%).  More patients received inhaled 
medication for asthma compared to controls (13% versus 7%). 
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Figure 2.1  
Hba1c according to glycaemic group in 63 individuals; DM vs Con p<0.001, DM vs IGH p<0.05. 
(Con=Control, IGH=Impaired glucose homeostasis, DM=Type 2 diabetes). 
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Table 2.0  
Demographic and biochemical parameters of participants. Normally distributed variables are 
represented as mean and standard deviation. Skewed data are displayed as median and 
interquartile range. * indicates significant differences compared to control subjects. # indicates 
significant differences compared to impaired glucose homeostasis (IGH) and control groups. 
 
 
 Control 
(n=30) 
IGH 
(n=19) 
Diabetes Mellitus 
(n=19) 
Age /yrs 51.8 (15.9) 56.8 (8.2) 56.7 (10.8) 
Weight /kg 77.7 (72.1,84.7) 77.9 (71.5,95.0) 90.1 (72.9,94.7) 
BMI 24.8 (22.1,25.8) 26.9 (24.2,30.1)* 28.8 (26.6,30.5)* 
Waist /cm 92 (85-96) 96 (87-106) 101 (97-104)* 
Smoking (Active) 4 (13%) 4 (21%) 3 (16%) 
Systolic Pressure 
/mmHg 
133 (13.3) 136 (15) 130 (16) 
Diastolic pressure 
/mmHg 
82 (10.6) 82 (10.8) 83 (6.1) 
Pulse pressure 
/mmHg 
51 (9.3) 55 (11.8) 50 (10.3) 
Fasting glucose 
mmol/l 
5.1 (4.7-5.5) 5.7 (4.9-6.2) 6.7 (6.3-8.5)# 
1 hour glucose 
mmol/l 
6.0 (4.5-8.0) 9.5 (7.2-11.2)* - 
2 hour glucose 
mmol/l  
5.0 (3.9-6.0) 6.8 (5.1-9.7)* - 
Mean glucose 
mmol/l 
5.3 (4.4-6.3) 7.4 (5.9-8.6) - 
Hba1C (%) 5.55  
(5.15,5.70) 
5.90 
(5.40-6.30) 
6.80# 
(5.90-7.90) 
 
Cholesterol mmol/l 
 
5.36 (0.86) 
 
5.21 (0.97) 
 
4.93 (1.1) 
HDL-C mmol/l 1.54 (0.31) 1.34 (0.36) 1.19 (0.269)* 
LDL-C mmol/l 3.27 (0.63) 3.30 (0.66) 3.05 (0.88) 
Triglyceride mmol/l 1.17(0.75-1.58) 0.97 (0.77-1.47) 1.38 (0.99-2.1) 
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2.1 LABORATORY METHODS 
2.11 Chemical pathology laboratory methods 
Fasting blood samples were taken from all participants for measurement of 
glucose, total cholesterol, HDL-C, triglyceride. LDL-C was calculated using the 
Friedewald formula (327). Electrolytes, renal function, liver enzymes and thyroid 
function were measured using these samples. Participants who had clinically 
significant aberrations in these parameters were excluded from the study. 
Cholesterol, lipoprotein and triglyceride measurements were performed using 
an Olympus AU 2700 autoanalyser (Olympus Life & Material Science, Ireland). 
Thyroid stimulating hormone was measured using an Immulite 2500 
autoanalyser (Siemens, Siemens Medical solutions & diagnostics LTD, 
Gwynedd, UK). Plasma free fatty acid concentrations were measured using an 
in-vitro colorimetric method (Wako Chemicals, Neuss, Germany) using a Cobas 
Mira (Hoffman-Laroche and company, Basel, Switzerland). Fasting glucose, 
creatinine and liver enzymes were measured using standardised laboratory 
techniques. HbA1c was measured by cation-exchange high performance liquid 
chromatography using a Tosoh Automated Glycohaemoglobin Analyser G7 
(Tosoh Bioscience Inc., Tokyo, Japan).  
 
 
2.2 Leukocyte isolation and RNA extraction 
Peripheral blood leukocytes were used for gene expression studies in keeping 
with our original study and lymphocytes as well as skin fibroblasts were used for 
the additional functional studies. 
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12ml of blood was collected into tubes containing EDTA and placed on ice. Red 
cells were lysed from whole blood by the use of erythrocyte lysis buffer (Qiagen, 
Crawley, UK). The leukocyte pellet was washed in buffer and stored at -80 oC in 
2ml of lysis (RLT) buffer (Qiagen), this contained 10% β-mercaptoethanol 
(Sigma-Aldrich Co, Poole, UK). Samples were homogenised using Qiashredder 
columns (Qiagen) by centrifugation at 16000 x g (Eppendorf, Cambridge, UK) 
for 2 minutes. RNA was extracted using RNeasy Midi kit (Qiagen) according to 
manufacturing instructions and mRNA absorbance was measured using a 
spectrophotometer (Ultrospec 2000, Amersham Biosciences, Buckinghamshire, 
UK). Samples were immediately stored at -80 oC. 
2.21 Monocyte isolation 
 
Monocytes can be identified by expression of the lipopolysaccaride receptor; 
CD14. This was used to isolate this particular subset from other peripheral 
blood mononuclear cells. After isolating leukocytes from whole blood, a cell 
count was determined using a haemocytometer. The pellet was resuspended in 
MACS buffer (Miltenyi Biotec Ltd, Surrey, UK) and centrifuged at 300 x g for 10 
minutes. After removal of supernatant, the pellet was resuspended in 80μl of 
MACS buffer mixed with 20μl CD14 microbeads per 10 cells. (Miltenyi Biotec 
Ltd.). The CD14+ cells were magnetically labelled with microbeads during a 15 
minute incubation at 4 oC. The cells were washed with 1-2ml MACS buffer and 
centrifuged at 300 x g for a further 10 minutes. After resuspending in 0.5ml of 
MACS buffer, the sample was applied to a LC column (Miltenyi Biotec Ltd.) 
which was prior magnetised (MidiMACS, Miltenyi Biotec Ltd.) and rinsed with 
3ml MACS buffer. The CD14+ cells were subsequently retained in the column. 
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After four washes in 3ml MACS buffer, the column was removed, placed in a 
collecting tube and eluted with 5ml of MACS buffer. To detach the beads from 
the monocytes, cells were incubated on ice for 2 hours and washed with MACS 
buffer at 400x g for 10 minutes at 4oC and supernatant removed. RNA was 
extracted from moncytes as outlined in section 2.2. 
2.22 Leukocyte protein extraction 
The leukocyte pellet was isolated and washed as above. This was suspended in 
1ml of Lysis buffer (Appendix I) containing a dissolved pellet of Protease 
inhibitor mixture (Complete protease inhibitor cocktail, Roche diagnostics, 
Mannheim, Germany). The lysates were stored at -80oC. Initial attempts in 
performing Western immunoblotting techniques using a monoclonal ABCA1-
antibody (Abcam, Cambridge UK) were unsuccessful due to frequent formation 
of double protein bands. Western blot development work was undertaken by Dr 
Christiane Albrecht and colleagues with the aim of producing a reliable assay to 
accurately detect ABCA1 protein. A novel enzyme linked immunosorbent assay 
(ELISA) was subsequently developed by our group which has the advantage of 
being more sensitive and quantitative than immunoblotting techniques. This 
methodology was validated in a variety of human tissues including arterial 
tissue, placenta and skin fibroblasts (328). Total cell lysates were prepared by 
incubating the leukocyte cell pellets with 1 ml ice-cold lysis buffer (50 mM 
mannitol, 2 mM EDTA, 50 mM, pH 7.6) containing complete protease inhibitor 
(Roche, Germany) and 0.1% w/v Triton X-100 for 60 minutes on ice. This was 
followed by five homogenization cycles (20 s each and 10 minutes resting time 
on ice after each homogenization step) in a Fastprep homogenizer. The 
leukocyte homogenates were centrifuged at 15,000 g for 15 minutes at 4oC and 
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the supernatants containing clear cell lysates were collected. Protein 
concentrations were determined by a bicinchoninic acid assay (329).  The clear 
leukocyte cell lysates were stored at -80oC until ABCA1 protein measurement 
was performed. Frozen leukocyte lysates were thawed and ABCA1 protein 
concentration was measured using an ELISA method as previously described 
(330). Briefly, either 50 µl ABCA1 peptide (ab14148, Abcam, UK) calibrators 
(range 8-1000ng) or 50 µl of unknown leukocyte lysates  were incubated in a 
ABCA1 peptide pre-coated and BSA blocked micro titre plate along with 100 µl 
(2 µg/l diluted in PBST) anti-ABCA1 rabbit antibody (ab7360, Abcam, UK). The 
incubation was carried out for 5 hours at room temperature while shaking on an 
ELISA plate shaker. The plate was washed with PBST and further processed by 
using biotin labelled anti-rabbit IgG goat antibody, streptavidin-HRP conjugate 
and tetramethylbenzidine enzyme substrate system. The enzymatic reaction 
was stopped by addition of sulphuric acid and absorbance measured at 450 nm 
on an ELISA plate reader (Sunrise, Tecan, Austria). ABCA1 protein 
concentrations of unknown samples were calculated from a calibration curve 
(Appendix I) and results were expressed as ABCA1 protein ng/ µg total protein. 
The inter-assay and intra-assay CV were <15%. 
2.23 Isolation of primary fibroblasts 
There was initial difficulty experienced in establishing fibroblast populations 
from biopsy material. This delayed the attainment of cholesterol efflux results 
from participants. Initial attempts using divided biopsy material resulted in lack 
of cellular proliferation and subsequent fungal contamination. Expertise was 
sought and fibroblast liberation was provided by Dr C. Poureyron and Ms. R 
Hannen, Tissue engineering group, Institute of Cutaneous Research, London. 
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An additional step of filtering of biopsy material through a cell strainer helped 
achieve quicker cellular proliferation. The protocol used was as follows: 
Primary fibroblast cell lines were obtained from human dermal biopsy using 
enzymatic digestion. The biopsy specimen was incubated in Dulbecco's 
Modified Eagle Medium (DMEM) (Invitrogen Ltd, Paisley, UK) containing 1% 
antibiotic-antimycotic solution (Sigma-Aldrich). This was stored at 4°C for up to 
24 hr before processing. Tissue was subsequently transferred into a 60 x 15 
mm Tissue Culture Disk (Falcon, Marathon Lab supplies, London, UK). 
The epidermis was removed using forceps and the sample cut into small pieces 
and placed in 4 ml of DMEM with 1% antibiotic-antimycotic solution containing 
0.5mg/ml (0.1265 U/ml) Collagenase D (Roche Diagnostics). The sample was 
incubated with Collagenase D overnight at 37°C to release fibroblasts from the 
collagen scaffold. On day two, the cell suspension was filtered through a 70 µm 
Cell Strainer (Becton Dickinson (BD) Oxfordshire, UK) and centrifuged at 220 x 
g for 5 min. The supernatant was carefully removed and the cells resuspended 
in 4 ml DMEM supplemented with 10% fetal bovine serum (FBS) (Sigma-
Aldrich) with 1% antibiotic-antimycotic solution. Cultivation was initially 
performed in 60 x 15 mm tissue culture disks. To maximise yield of fibroblasts, 
the cells that remained in the filter were also cultivated in the original culture 
disk. 
After two days, cells were washed with warmed phosphate buffered saline 
(PBS) and culture medium changed. When sufficient cells were visible, these 
were transferred into T-25 Culture Flasks (NUNC, Fisher Scientific Ltd, 
Loughborough, UK). The application of trypsin-EDTA solution (Sigma-Aldrich) 
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for less than 2 minutes allowed early detachment of fibroblasts and avoided 
contamination by keratinocytes which remained adherent.  
2.24 Subculture of normal human fibroblasts 
The culture media was changed twice weekly until cells were 80-100% 
confluent. In order to passage, the fibroblasts were detached with 20 µl Trypsin-
EDTA solution per cm2 culture dish for a period of 3- 5 min. They were 
subsequently transferred with DMEM to inactivate trypsin and centrifuged for 5 
min at 1000rpm in a Multifuge 3S-R (Heraeus). The cellular pellet was then 
finally resuspended in fresh, culture medium. 
Cells at high density (106 -107 cells/ml) were frozen by resuspending the 
fibroblast pellet in 1.5 ml freezing medium, comprising of FBS and sterile filtered 
10% Dimethylsulfoxide (DMSO) (Sigma-Aldrich). The suspension was 
transferred to a cryopreservation vial (Corning Incorporated, New York, USA) 
and cooled at a rate of 1°C/min, to -80°C. These vials were subsequently stored 
in liquid nitrogen or at -80 oC. Imaging of cell morphology was attained using a 
Kodak DC120 digital camera with Olympus CK2 microscope (Olympus UK Ltd, 
Middlesex, UK) and processed with Adobe Photoshop 5.0 LE (Appendix II). 
2.25 Fibroblast lysis and RNA extraction 
Fibroblasts from a fully confluent T75 culture flask were washed with PBS, lysed 
and removed using 1.5ml of RLT buffer (Qiagen) containing 10% β-
mercaptoethanol (Sigma-Aldrich). This was stored at -80 oC. The RNA 
extraction process was identical to that used for leukocyte cells as outlined 
above. 
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 2.26 Fibroblast protein extraction 
 Fibroblasts from a fully confluent T75 culture flask were washed with PBS and 
removed using a 23 cm cell scraper (NUNC, Fisher Scientific Ltd). Cells were 
stored in 1ml of lysis buffer (Appendix I) at -80 oC. 
2.3 ABCA1 FUNCTION 
 
2.31 Fibroblast ABCA1 function-cholesterol efflux  
 
The initial cholesterol efflux assay did not lead to reliable results and resulted in 
low radioactive counts with high variability (see Appendix II). Assay modification 
and development was required using a protocol which was provided by our 
collaborating group Dr C Albrecht (Physiology department, Munich Technical 
University, Germany) (331), this work is shown in section 3.2. Assay 
optimisation was attempted and was conducted in normal dermal human 
fibroblasts (Promocell, Germany) in cells of passage number under passage 5. 
Modifications to the protocol did not improve the variability seen in the assay. It 
was noted the protocol included prolonged labelling and equilibration steps 
which resulted in reduced radioactive counts. After helpful discussions with Dr 
Albert Groen, (Academic Medical Centre, University of Amsterdam) an 
alternative published methodology was selected (outlined below) which 
employed shorter incubation times (191). This resulted in more reproducible 
results as shown in section 3.2. 
 
Day 1 (Cultivation): 
Fibroblasts were counted using a Neubauer chamber and seeded at a density 
of 1- 2 x 104 per well in a 6-well plate. They were grown until 60-80% 
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confluency at 37oC in 5% CO2, in media containing 10% FBS and 1% 
antimicrobial solution. 
 
Day 2 (Cholesterol loading): 
Cells were washed and incubated with DMEM containing 0.5 µCi/ml 1,2-[3H] 
cholesterol (Perkin Elmer, UK) in the presence of 30mg/l cholesterol (Sigma-
Aldrich) and 0.2% bovine serum albumin (BSA) (Sigma-Aldrich) at 37oC for 
24hours. 
 
Day 3 (Equilibration and Efflux): 
Cells were washed 3 times with PBS-0.2% BSA solution to remove residual 
extracellular cholesterol. 10μg/ml ApoA-I (supplied frozen in 10nM in 
ammonium chloride, pH 7.4) from Sigma (LOT 084k16791/025K1442, Cat 
A0722) was added to half the wells in triplicate and DMEM with 1% antibiotic-
antimycotic was added to the remaining control wells. 
 
Day 4 (Efflux discontinuation and counting): 
After 20 hours, the medium was removed, centrifuged at 4oC to remove any 
cellular debris. Radioactivity was assayed liquid scintillation counting (LSC). 
Cells were washed with PBS, dissolved using 500µl-1ml 1M NaOH and 
assayed by LSC. (β-counter -LSC 6000SC, Beckman, USA). 
Further efflux experiments were performed using 1ml hexane-isopropanol (3:2 
v/v) to extract cellular cholesterol without disrupting cell membranes.  Hexane-
isopropanol was incubated for 30minutes prior to LSC. Counts per minute (cpm) 
were measured in triplicate samples. Cholesterol efflux was calculated with the 
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equation below. In initial experiments, efflux was compared using a number of 
cholesterol acceptors including commercial preparations of ApoA-I and serum 
samples taken from subjects. ApoB containing lipoproteins were removed from 
serum through precipitation. This was achieved by mixing and centrifuging 
serum samples with 10% Magnesium-dexran sulphate (3000rpm, 30min at 4 
degrees oC). 
 
Cholesterol efflux % = cpm in supernatant / [cpm (cells + supernatant)] 
 
2.4 Lymphocyte phosphatidylserine translocation  
 
2.41 Isolation of lymphocytes from human blood 
 
ABCA1 is thought to contribute to phospholipid transport as well as cholesterol 
transport as explained in section 1.81 (332). PS is usually confined to the inner 
leaflet of cellular membranes, transfer to the outer leaflet is an early signal of 
apoptosis and transport can be stimulated by calcium ionophore (333;334). 
Reduced PS transport in lymphocytes has been reported by our group in a 
patient known to have a ABCA1 mutation (210). We therefore elected to 
investigate the effect of glycaemia on function of ABCA1, as measured by PS 
translocation in CD4 positive T-lymphocytes.  
 The protocol for assessing PS transport in T-lymphocytes was obtained from 
Dr James Elliott who was a member of the Membrane transport group (MRC 
Clinical Sciences Centre, London). Ms Julia Feldmeyer contributed to the 
validation of this technique.  
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Density gradient centrifugation with FicollTM -sodium diatrizoate solution (Ficoll-
Paque) (Amersham Biosciences, Buckinghamshire, UK) was used for 
separation of lymphocytes and peripheral mononuclear cells (PBMC)  in human 
whole blood. 4 ml of the diluted blood was layered on 4 ml of Ficoll-Paque 
solution and centrifuged for 15 min at 400 x g with brakes and low acceleration. 
Differential migration during centrifugation resulted in the formation of layers 
which contained the different cell types. Lymphocytes were found at the 
interface between the plasma and the Ficoll-Paque solution because of their 
lower density. Lymphocytes were removed using a pipette and washed twice 
with PBS to remove platelets, Ficoll-Paque and plasma. 
2.42 Phosphatidylserine translocation analysis 
Lymphocytes were transferred into a polystyrene fluorescence activated cell 
sorting (FACS) tube (BD Falcon, UK) and were washed and suspended in 
phenol-red-free Dulbecco’s modified Eagle medium (DMEM/F12) (Invitrogen, 
UK). 100 µl of this solution was transferred and stained with 15 µl mouse anti-
human monoclonal IgG1 antibody specific for the CD4 T-lymphocyte marker. 
This antibody was conjugated to a fluorochrome and was incubated with the cell 
suspension for 10 min. Labelled T-lymphocytes were then washed with 
DMEM/F12 to remove excess antibody. To measure PS translocation, 25-50 µl 
cell suspension was equilibrated with 15 µl AnnexinVFITC (AV) (Becton 
Dickinson) and diluted in 1 ml DMEM/F12.  Baseline fluorescence was 
measured for 1 min prior to addition of 1 µM calcium ionophore; calcimycin 
(Sigma-Aldrich). Cells were analysed in real-time for PS externalisation using 
flow cytometry, measurements were acquired using FACS LSR machine 
(Becton Dickinson) and data analysis was performed using FACSCalibur 
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(Becton Dickinson). Identical instrument calibration settings were used for each 
experiment and Cell Quest software (Becton Dickinson) was used for data 
acquisition and analysis. Cumulative PS translocation was measured for a total 
of 8min after the addition of calcimycin. Using multicolour gating, external PS 
exposed cell events (PS+) were expressed as a percentage of all CD4+ cell 
events. Non-CD4+ cells were excluded from the analysis (Figure 2.2). Figure 
2.2(a) shows distribution of all cellular events according to size and granularity. 
Figure 2.2(b) demonstrates differential staining of different lymphocyte 
populations. Figure 2.2(c) shows an example of back gating of cellular events, 
only events in lymphocytes are seen. Figure 2.2(d) demonstrates analyisis of 
cumulative PS+ cells (FL1-H positive) before and after calcimycin 
administration. The sensitivity and throughput rate of this methodology allows 
detection of PS externalisation in CD4+ T-lymphocytes, but can also be applied 
to detect rarer cellular events.  
2.43 Fluorochromes 
The fluorochromes used and corresponding wavelengths of cytometer lasers 
are listed in Table 2.1. 
A mouse anti-human monoclonal IgG1 antibody specific for the T-cell marker 
CD4 was used. These clones were conjugated with R-Phycoerythrin (PE), 
Allophycocyanin (APC) or Phycoerythrin-Cychrom5 (PE-Cy5). 
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Table 2.1 
Fluorescent activated cell sorting (FACS) fluorochromes and laser wavelengths.  
 
Fluorochrome Excitation 
Peak [nm] 
Emission 
Peak (nm) 
Laser Wavelengths 
(nm) 
Laser 
FITC 495 520 488 Argon 
Phycoerythrin (PE) 565 575 488, 514, 568 Argon 
Phycoerythrin-
Cychrom5 (PE-Cy5) 
565 670 488, 514 Argon 
Allophycocyanin 
(APC) 
650 660 633, 635, 647 Helium-
Neon 
 
Fluorochromes APC and PE were selected for use after demonstrating 
differential binding properties of PE-Cy5 compared to PE which caused up to a 
12% difference in AV positive events (figure 2.3). This change resulted in 
improved resolution between CD4+ cell populations. Two labelled CD4+ 
populations were analysed in a single FACS tube (Becton Dickinson) to 
minimise inter-assay variability. Control subjects and patients who had IGH 
underwent an OGGT with PS flop measurements at time points 0, 1 and 2 hrs. 
Samples were incubated at 37 oC and analysed simultaneously. Incubation of 
CD4+ cells at 37 oC for 2hrs had no significant difference in PS flop compared 
to freshly isolated cells (figure 2.4).  
CD4+ PS externalisation rates from patients with DM were compared to control 
CD4+ cells by using fasting samples from patients with DM compared to a 
sample taken from a single heathy subject. Rates of PS exposure were 
- 91 - 
 
 
R2
 
analysed using Cell Quest with measurements taken at 40 second intervals for 
8 min. 
 
 
a)     b) 
c)      d)  
 
Figure 2.2 Flow cytometry results and gating.  
(a) All cellular events are shown according to cell size (FSC-H) and granularity (SSC-H).  
(b) Differential lymphocyte staining is illustrated; APC staining cell population (red) is plotted 
against PE staining cells (arrow). (c) Using back gating only CD4+ cells are shown. (d) The rate 
of PS translocation (AV positive events) is measured at baseline over 1 min and after calcium 
ionophore administration (blue arrow) for 8 mins. Measurement of AV positive cell events were 
taken for analysis at 40 s intervals (bar). 
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Figure 2.3 Comparison of conjugated fluorochrome pairs 
Analysis of AV-positive events from single populations of lymphocytes from a control subject 
according to separate pairs of antibody-fluorochromes conjugates (PE-Cy 5 and PE versus APC 
and PE). Mean values taken from at least quadruplicate experiments. 
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Figure 2.4 Timing of lymphocyte isolation and effect on PS flop  
Shows A-V positive cells according to lymphocyte isolation timing.  
0h.2 represents a control sample incubated at 37deg for 2 hours prior to lymphocyte isolation 
(blue). 0h.1 represents the control sample with immediate isolation of lymphocytes (pink). Mean 
values are shown from a duplicate experiment. 
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2.5 GENE EXPRESSION  
2.51 cDNA synthesis 
1 μg of RNA from each sample was diluted in 25 μL of PCR grade water. 
Reverse transcription to synthesise complementary DNA (cDNA) was 
performed using the ABI high capacity reverse transcription (RT) kit (Applied 
Biosciences, Warrington, UK). The composition of master mix (MM) is listed 
(Appendix I). A thermal cycler (Genius, Techne) was used to perform the RT 
reaction. Aerosol free filtered pipette tips were used and experiments performed 
in an ultraviolet light hood to help eliminate genomic DNA contamination. 25 μL 
sample was mixed with 20 μL 2xMM. Up to 40 samples were placed into the 
thermal cycler with pre-optimised settings according to RT kit instructions 
(Applied Biosystems) (Appendix I). cDNA samples were subsequently stored at 
-20 oC. 
2.52 Quantitative Polymerase chain reaction  
An adapted methodology was performed using SYBR green fluorescence. 
Primers were designed to be exon spanning to minimise non-specific 
amplification. PCR temperature settings are shown in table 2.2.  Due to 
methodological difficulties which are outlined in section 3.0, a Taqman based 
method was also performed to measure gene expression using primer-probe 
sets (table 2.3).  
A prior optimised laboratory protocol was used for PCR experiments using 
manufactured primer-probe sets (Applied Biosystems) (Appendix I for protocol). 
The sample was determined in duplicates each with a total reaction volume of 
10μl. Amplification was performed using a Rotorgene 2000 real-time cycler 
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(Corbett Research, Cambridgeshire, UK). β-Actin was used as the housekeeper 
comparator gene. 
Table 2.2  
SYBR green Rotor Gene temperature settings used for PCR gene amplification 
 
 
PCR Step Temperature Duration 
Hold 50 oC 2 min 
Initial denaturation 95 oC 10 min 
Denaturation 
Amplification 
Annealing 
95 oC 
60 oC 
72 oC 
15 sec 
10 sec 
25 sec 
 
Table 2.3  
Applied Biosystems primer and probe set identification details.  
 
FAM channel 
(470-510nm) 
Applied Biosystems 
Set identification 
Exon 
site 
Amplicon length 
(base pairs) 
ABCA1 (Hs01059122_m1) 34-35 103 
ABCG1 (Hs00245154_m1) 5-6 58 
PPARγ  (Hs00234592_m1) 7-8 107 
LXRα (Hs00172885_m1) 6-7 78 
VIC channel 
(530-555nm) 
   
β-Actin (4310881E) 2-3 90 
GAPDH (4310884E) 3 118 
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All experiments were performed in duplicate with amplification of both gene of 
interest (GOI) and housekeeper in a single tube (multiplex) to minimise variation 
between experiments. A single PCR protocol was used for all gene 
measurements (Appendix I). The primer-probe set were premixed and 
consisted of 18mM primer and 5mM probe (Applied Biosystems). The GOI 
probe was conjugated to a reporter fluochrome (FAM) which is detectable once 
the probe is displaced by GOI primer amplification and cleaved by polymerase. 
The housekeeper probe had a VIC reporter flurochrome (Table 2.3). Primers 
were aliquoted to minimise disruption from repeated freeze-thaw cycles. 
Experiments with leukocyte ABCA1 and β-actin in subjects who underwent 
detailed functional analysis were repeated to yield mean gene expression data 
for analysis. Additional experiments in leukocytes were performed to validate 
findings using a separate housekeeper; glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Table 2.3). Target gene quantity was calculated from 
a standard curve with four samples 1:1, 1:2, 1:4 and 1:8. To allow 
standardisation of cDNA quantity, gene expression was normalised to the 
housekeeper gene and expressed as a ratio. Analysis was conducted using the 
Rotorgene 6 comparative quantitation algorithm using the Rotorgene Software 
version 6 (Corbett Research, Cambridgeshire UK). To compare gene 
expression results from separate experiments the delta threshold cycle (dCt) 
measurements were compared. 
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2.53 DNA gel (Southern blot) 
A 1% agarose gel was made to identify gene product by size using a standard 
protocol. DNA was stained using Ethidium Bromide (Sigma) Samples were 
mixed with 1μl of loading buffer (10x blue juice, Invitrogen) and applied to 
separate lanes within the gel. This was transferred to a tank (Bio-Rad 
laboratories LTD, Hertfordshire, UK) with application of 60 volt direct current. A 
DNA size marker (1kb-plus DNA ladder, Invitrogen) was added to the first lane 
to compare sizes of the resulting DNA products. The gel was inspected under 
ultraviolet light after 20 minutes using a Kodak DC290 digital camera and 
processed with Adobe Photoshop 5.0 LE. 
 
Statistics 
 
Baseline demographic data was analysed by one-way ANOVA and Kruskal 
Wallis tests with Holm Sidak and Dunn’s methods for multiple pairwise 
comparison. A 2-tail t-test and Mann Whitney test were utilised to compare 
normally distributed and skewed data, respectively. Continuous variables were 
assessed by Spearman and Pearson correlation. In analyses of small sample 
number, Spearman correlation was the preferred test for correlation. A 
Kolmogorov-Smirnov test was used to assess normal distribution of variables. 
Variables which passed this test were also assessed using D'Agostino and 
Shapiro-Wilk criteria. Multiple OGTT time point gene measurements were 
analysed using a repeated measures one-way ANOVA. Multiple linear 
regression was used to assess independence.  Sigmastat version 3.5 (Systat 
software, Inc. Germany) and GraphPad Prism, version 4.03 (GraphPad 
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software, San Diego, CA USA) software packages were used for analysis and 
generation of figures respectively. The threshold of significance in each test was 
set at p<0.05. 
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3.0 VALIDATION OF METHODS 
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3.1 Validation of gene expression assay 
 
Leukocytes were used for gene expression studies and there were initial 
problems with the assay. Amplification signals were seen in samples that 
contained only PCR grade water and primers (no template control). As these 
signals were detectable within a few amplification cycles (Ct) of DNA samples 
(figure 3.1) melt curve analyses were undertaken to identify these amplification 
products. An example of a melt curve is seen in figure 3.2. This demonstrates 
signal peaks at temperatures between 55-60oC and at 65oC in the no template 
control samples.  
This occurred presumably due to either contamination or primer-dimer 
formation. Attempts to overcome these interfering signals were initially 
undertaken by cleaning the dedicated PCR hood and equipment and 
experiments were repeated using new primers to exclude DNA contaimination. 
As this non-specific amplification persisted, I elected to alter the PCR settings 
initially by increasing the annealing temperature, followed by reducing primer 
concentrations to reduce the chance of dimerisation between primer pairs. 
These measures were not successful (figure 3.3) therefore alternative primer 
design was undertaken with the help of Dr Gaby deSilva (Imperial College, 
South Kensington Campus) to further reduce the probability of dimerisation. The 
basic local alignment search tool (BLAST), (National centre for biotechnology 
information, Bethesda, USA) was used to aid primer design to avoid 
complimentary and palindromic sequences. My standard curve DNA samples 
were amplified using a separate machine (ABI 7500 machine -Applied 
Biosystems) in Dr deSilva’s laboratory. Results using this machine did not show 
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any evidence of non-specific amplification in the water samples.  As non-
specific amplification was observed only when amplifying certain genes, the 
most likely cause for this was therefore likely to be dimer formation between 
primers. I therefore elected to change to a more specific hydrolysis probe 
(Taqman) methodology to overcome this issue. This technique used pre-
optimised primer-probe sets (Applied Biosystems) (Table 2.3). This change in 
methodology resolved non-specific amplification. 
Figure 3.1 PCR amplification curves 
DNA amplification curves from an ABCA1 PCR experiment using SYBR green fluorescence 
methodology. Amplification of multiple DNA samples are shown and a fluorescence signal can 
be seen in a no-template control sample (arrow, blue curve).   
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Figure 3.2 Non-specific amplification-Melt curve 
A melt curve fluorescence analysis showing non-specific amplification in no-template control 
samples (blue) and DNA samples (green, pink). The Melting peak for the ABCA1 gene product 
is 82-83 oC seen in DNA containing samples. Earlier signal peaks between 55 and 70 oC are 
seen in samples including no-template control samples.  
 
 
 
Figure 3.3 Melt Curve 
Melt curve fluorescence analysis from a PCR experiment using reduced primer concentrations. 
ABCA1 gene expression was measured using SYBR green methodology. The gene product 
signal peak is seen at approximately 83oC. Additional fluorescence signal peaks are seen 
between 55 and 65oC in no template control samples (blue) and DNA samples (green and pink). 
 
There was little difference in gene expression results whether the house keeper 
gene amplification was measured in a separate tube or in a single tube with the 
gene of interest (GOI). To minimise variability between multiple experiments, 
both GOI and housekeeper genes were amplified together in a single multiplex 
reaction. Gene expression of two common house keeper genes was compared 
in leukocytes from 23 subjects who also underwent a skin biopsy for functional 
ABCA1 assessment, which consisted of healthy men and patients. Gene 
expression of GAPDH and β-actin housekeeper genes were comparable in 
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these subjects, as seen in figure 3.4. Based on these results, β-actin was used 
as a single housekeeper comparator gene for future experiments.  
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Figure 3.4 Gene expression of two housekeeper genes 
Comparison of gene expression of two housekeeper genes in leukocytes using a hydrolysis 
probe (Taqman) PCR methodology. Sample measurements represent mean values of duplicate 
samples. (n=23) (arbitrary units). 
 
The specificity of PCR amplification reaction was verified by gel electrophoresis 
(figure 3.5). 
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Figure 3.5 1% agarose gel 
1% agarose gel, identifying ABCA1 DNA PCR amplification products in 7 fibroblast samples  
(ABCA1 gene amplicon length=103 basepairs). 
 
The reproducibility of leukocyte ABCA1 gene expression (inter-assay CV) was 
assessed in a calibrator sample in each experiment. The mean CV of duplicate 
samples, measured in 7 different PCR experiments performed on different days, 
was 10% (Figure 3.6). 
 
Figure 3.6 Reproducibility of ABCA1 gene expression 
Mean ABCA1 Delta Ct PCR measurements and normalised ABCA1 gene expression 
measurements are plotted from duplicate samples taken from 7 separate PCR experiments 
performed on different days. The Mean CV for normailised gene expression was 10%.  
 
 
Statistics 
 
In participants who underwent detailed gene expression in leukocytes and 
functional studies using fibroblasts (n=25) cholesterol, HDL-C and LDL-C 
variables passed tests for normality. Despite this, in view of the relative small 
number of observations in this cohort, correlation was undertaken using a 
Spearman test. 
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3.2 Development and validation of the cholesterol efflux (ABCA1 
function) assay 
Skin fibroblasts were used to assess ABCA1 function (cholesterol efflux) but 
initial results using a provided laboratory methodology yielded low supernatant 
radioactive measurements, resulting in low efflux results with substantial count 
variability. A relatively high background efflux was also evident. This occurred 
despite repeating experiments using cells of differing passages. To examine 
this more closely, assay parameters from the original protocol provided by Dr 
Albrecht were altered (outlined below). 
 
Original cholesterol efflux (ABCA1 function) methodology: 
 
 
Day 1:  Cultivate < 20,000 cells/well in wells with 1ml cultivation medium 
for 24h, 37°C, 5% CO2 (until 40% -70% confluence). 
 
Day 2: Remove cultivation medium, wash cells 1 x with 1ml /well medium 
A and incubate cells with 1ml/well labelling medium for 48 h, 37°C, 
5% CO2. 
 
Day 4: Wash cells twice with 1ml/well medium A. Add 1ml/well 
equilibration medium and incubate for 24 h, 37°C, 5% CO2.  
 
Day 5: Wash cells 2 x with medium A 
add 300 µl efflux medium and incubate for 2h, 37°C, 5% CO2. 
Collect the supernatant for LCS. Wash cells with PBS, dissolve in 
300µl 1 M NaOH for LCS,  
 
LSC  Fill vial with 3ml scintillant 
add 200µl sample and shake to mix, β-counter 3H for 2 min 
(calculate cpm) 
  
 
Medium A: DMEM + 1% Antibiotic-Antimycotic Solution 
 
Labelling Medium: Medium A + 5% FBS + 1 µCi/ml 1, 2-[3H] Cholesterol  
 
Equilibration Medium: Medium A + 1% BSA (7.5% solution) 
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Efflux Medium: Medium A + 20 µg/ml ApoA-I (2.15 µg/µl solution) 
 
 
It was initially noted that radioactivity counts significantly diminished during the 
labelling and equilibration steps as shown in figure 3.7. Figure 3.8 illustrates the 
fundamental steps involved in a cholesterol efflux assay.  
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Figure 3.7 Supernatant 3H counts during the efflux assay 
Supernatant radioactivity counts (3H) during the cholesterol efflux assay in primary dermal 
human fibroblasts (passage <5) (Promocell). Mean value of duplicate samples are shown. 
  
 
The following parameters were altered to improve efflux supernatant counts and 
reduce variability: 
• Labelling time 
• Equilibration time 
• Efflux duration 
• Cholesterol acceptor (ApoA-I) concentration 
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Figure 3.8 Cholesterol efflux assay 
Fundamental steps involved in measuring cholesterol efflux from skin fibroblasts. 
 
3.21 Labelling time 
Labelling time of 48 hours was compared to 24 and 72 hours (figure 3.9). 
Shortening the labelling time reduced cholesterol efflux measurements primarily 
due to low supernatant counts, typically<500 cpm. Labelling for 48 and 72 hours 
resulted in high background efflux. Net ApoA-I-mediated efflux was less than 
5% in all experiments except when labelling for 72 hours. Variability of efflux 
was higher in cells that were labelled for 72 hours (mean 12.9%, standard 
deviation 4.5%, 3 hours after ApoA-I exposure) figure 3.9. In these experiments, 
specific ApoA-I-related efflux was not improved by increasing incubation time 
with ApoA-I. 
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3.22 Equilibration time 
 
The next step was to examine whether altering equilibration times improved net 
efflux. Equilibration was undertaken for 24 and 48 hours and efflux was 
measured at 3 and 6 hours. Labelling time was kept constant at 48 hours as per 
protocol. High basal efflux was again observed in all experiments (figure 3.10) 
with little added specific efflux induced by ApoA-I (after 6 hours exposure with 
ApoA-I, cells equilibrated for 24 hours yielded a net efflux of 3.3%). Similarly, 
ApoA-I mediated efflux was 1.6% after equilibration for 48 hours. 
 
 
 
Figure 3.9 Effect of labelling time on cholesterol efflux 
Effect of altering labelling times on cholesterol efflux in fibroblasts. Equilibration was for 18 
hours, mean efflux and standard deviation from triplicate wells are shown. Efflux was measured 
after 3 and 6 hours of exposure to 10μg/ml ApoA-I (Sigma). 
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Figure 3.10 Effect of equilibration time on cholesterol efflux 
Effect of equilibration times using Bovine serum albumin (BSA) on cholesterol efflux in 
fibroblasts (Promocell). Labelling time was 48 hours, mean efflux and standard deviation from 
triplicate wells are shown after 3 and 6 hours induction using 10μg/ml ApoA-I (Sigma). 
 
3.23 Efflux duration 
 
As changes in labelling and equilibration times did not substantially improve net 
efflux or variability, duration of exposure of fibroblasts and concentration of 
ApoA-I was investigated. Labelling and equilibration times were used as per 
protocol.  Results are seen in figure 3.11. Background efflux was relatively 
constant up to 4 hours but appeared much higher after 6 hours of ApoA-I 
exposure.  Non-specific efflux was comparable to that induced by ApoA-I after 1 
hour.  There was little difference in ApoA-I- mediated efflux at 4hours compared 
to 2 hours. The higher concentration of ApoA-I was not consistently associated 
with a higher efflux apart from at the 2 hour time point where it was 2-fold higher 
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than the background rate. A second source of commercially available ApoA-I 
(Calbiochem) did not increase net efflux results. 
 
 
Figure 3.11. Effect of ApoA-I concentration and exposure on 
cholesterol efflux 
Effect of ApoA-I concentration and duration of incubation on cholesterol efflux in fibroblasts. 
Labelling time 48 hours, equilibration time 24 hours. Mean and standard deviation are shown 
from quadruplicate wells. 
 
The original assay was next run using freshly isolated primary fibroblasts taken 
from a study participant to see whether this affected net efflux. These results 
were compared to a second protocol which was established in the Academic 
Medical Centre, Amsterdam under the guidance of Dr Albert Groen. The main 
difference between protocols was that the second assay used shorter 
equilibration and labelling times (191). Furthermore, labelling was in the 
presence of unlabelled cholesterol instead of 5% FBS which was designed to 
induce cellular ABCA1 expression. Exposure to ApoA-I was continued for 20 
hours which is considerably longer than the original protocol. Overall net efflux 
achieved was higher using the newer assay (4.2% versus 1.6%) but ApoA-I 
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produced a similar factor difference compared to background efflux (1.8 versus 
1.9). However, the main advantage of the second protocol was it produced 
consistent results with lower count variability (figure 3.12). This second protocol 
was therefore adopted (see protocol below) for use for all further efflux 
experiments in this study (see results in section 5.0).  
a)  
 
 
 b)   
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Figure 3.12 Comparison of results from two cholesterol efflux 
assays 
Cholesterol efflux in cultured primary fibroblasts (passage number 4) comparing the original 
efflux protocol see sction 3.2 (a) to a second adopted protocol (b) see section 2.31. 
 
 
In summary problems with gene expression measurements were overcome by 
changing to a more specific methodology. Variability in results for the functional 
cholesterol efflux assay in skin fibroblasts was only improved by adopting a 
different published methodology. This assay was demonstrated to be specific to 
ABCA1 action by pharmacological inhibition. 
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3.3 Materials  
 
Agarose     Sigma 
 
Apolipoprotein-AI    Sigma 
 
Annexin V     Becton Dickinson 
 
Antibiotic-Antimycotic solution  Sigma 
 
Bovine Serum Albumin   Sigma 
 
Calcimycin     Sigma 
 
Cell scraper     NUNC 
 
Cell strainer 70μm    Becton Dickinson 
 
Cholesterol     Sigma 
 
1,2-[3H] Cholesterol    Perkin Elmer 
 
Collagenase D    Roche 
 
Complete protease inhibitor cocktail Roche 
 
Cryopreservation vial   Corning 
 
DMEM, DMEM/F12    Invitrogen 
 
DMSO     Sigma  
 
DNA ladder 1kb-plus   Invitrogen 
 
Erythrocyte Lysis Buffer   Qiagen 
 
Ethidium Bromide    Sigma 
 
Fetal Bovine Serum    Sigma 
 
Ficoll-Paque plus    Amersham 
 
LC Column     Miltenyi Biotech 
 
Loading Buffer (10xblue juice)  Invitrogen 
 
MACS buffer     Miltenyi Biotech 
 
β-Mercaptoethanol    Sigma 
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Microbeads CD14    Miltenyi Biotech 
 
NaOH      Sigma 
 
Normal human dermal fibroblasts  Promocell 
 
PBS tablets     Sigma 
 
Probucol     Sigma 
 
Qiashredder columns   Qiagen 
 
Scintillation fluid    Sigma 
 
Suture pack     Rochialle inHealth 
 
Tris-EDTA Borate    Sigma 
 
Trypsin-EDTA solution    Sigma 
 
Conjugated FACS Antibodies  Becton Dickinson 
 
R-Phycoerythrin 
 
Phycoerythrin-Cychrom5 
 
Allophycocyanin & FITC 
 
Other Antibodies 
 
ABCA1 peptide ab14148    Abcam, Cambridge 
 
Anti-ABCA1 rabbit antibody ab7360  Abcam, Cambridge 
 
Primer-Probe sets (see Table 2.3) Applied Biosciences 
 
Primers (SYBR green method)  MWG Biotech, Munich 
 
KITS 
 
cDNA high capacity RT kit   Applied Biosciences 
 
First strand cDNA kit   Amersham Biosciences 
 
NEFA kit     Wako chemicals 
 
PCR light cycler fast start kit  Roche 
 
RNeasy midi kit    Qiagen 
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Results 
 
4.0 ABCA1 gene and protein 
expression 
- 115 - 
 
The effect of glucose on ABCA1 gene expression and related genes was 
investigated in both leukocytes and skin fibroblasts. Subjects varied according 
to glucose homeostasis. The immediate and short term effects of glucose were 
assessed in blood leukocytes during an OGTT. 
  
4.0 The chronic effect of glucose on leukocyte ABCA1 gene 
expression 
 
The chronic effect of glucose on ABCA1 gene expression was assessed in 
leukocytes. Gene expression data were available in 63 individuals; leukocyte 
extraction from 4 subjects did not yield RNA of adequate quality for PCR 
experiments. One healthy control (C12) was excluded as we discovered 
significant abnormalities in liver enzyme biochemistry which required further 
clinical investigation. Gene expression results were compared from multiple 
PCR experiments due to the sample capacity of the thermal rotor. Therefore, 
analysis was performed compared to a fixed sample. This calibrating sample 
was present in each PCR experiment. Variability in the measurement of the 
calibrator sample is shown in figure 3.6. Each experiment included samples 
taken from both patients as well as healthy men.  
There was a significant negative relationship with glycaemia in 63 individuals, 
ABCA1 expression versus HbA1c (rho=-0.43, P=<0.001) figure 4.1; and versus 
glucose (rho=-0.31, p=0.01). Verification was sought using comparative 
quantitation and delta-delta Ct methods of PCR analysis which yielded 
concordant results; Hba1c (both methods p<0.01) and fasting glucose (p<0.01 
and p=0.016 respectively). 
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Figure 4.1  
ABCA1 gene expression as measured by PCR. The relationship of HbA1c to ABCA1 gene 
expression (normalised to β-actin –arbitrary units and relative to a calibrating sample) in 63 
participants (27 control, 18 IGH and 18 diabetes, n=63, rho=-0.41, p<0.001).  
 
 
A smaller cohort of 25 subjects (9 control, 6 IGH and 10 DM) were studied in 
more detail with measurements taken from circulating leukocytes and functional 
measurements in skin fibroblasts. Gene expression data for leukocyte ABCA1 
in this cohort were analysed (using mean values from two experiments). Results 
confirmed a negative relationship with Hba1c (rho=-0.5, p=0.01) and borderline 
significant relationship with fasting glucose (rho=-0.35, p=0.09). These 
relationships persisted when ABCA1 expression was compared to GAPDH. 
In DM patients, ABCA1 gene expression was lower than in healthy men (n=63 
p=0.03) (figure 4.2). Gene expression in patients with impaired glucose 
homeostasis appeared lower than in healthy men but this did not reach 
statistical significance (n=63, p=0.27). There was no difference in gene 
expression between patients with IGH and diabetes (p=0.33).  Analysis of the 
cohort who underwent more detailed measurements, also revealed significant 
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differences between groups with lower ABCA1 expression in patients with 
diabetes (p=0.03) and IGH (p=0.05) compared to that in healthy men. 
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Figure 4.2  
Leukocyte ABCA1 gene expression, expressed as normalised values (arbitrary units) from PCR 
experiments. Mean and standard error are shown according to subject glycaemic status in 63 
participants Con=Controls (n=27), IGH=Impaired glucose homeostasis (n=18), DM=Type 2 
Diabetes (n=18). Con vs. DM; p=0.03, Con vs. IGH; p=0.27, IGH vs. DM p=0.33. 
 
4.1 The acute effect of glucose on leukocyte ABCA1 gene 
expression 
 
The acute effect of glucose on ABCA1 gene expression was assessed during 
an OGTT where leukocyte samples were taken at baseline, 1 hour and 2 hours 
after 75g oral glucose administration. Gene expression in healthy subjects at 1 
hour and 2 hour-post glucose time points was significantly higher than at 
baseline (repeated measures one-way ANOVA, n= 24, p<0.001, p<0.05 
respectively) (figure 4.3). Differences in gene expression during an OGTT were 
not seen in patients with IGH (figure 4.5). 
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There was a positive relationship between change in glucose (baseline versus 2 
hours) and change in gene expression (baseline versus 2 hours) in samples 
taken from controls (n=25, rho =0.45, p=0.023) but this correlation between 
change in glucose and gene expression was not observed at 1 hour time points 
(rho=0.27 p=0.22). Mean glucose concentration during the OGTT (a measure of 
glucose exposure) did not relate to the mean level of gene expression in healthy 
men (p=0.82). In patients with IGH, gene expression did not change during the 
OGTT (n=16, p=0.12) and did not associate with changes in glucose 
concentration. Taking both control and IGH subject groups together, one and 
two hour gene expression values were higher than baseline; p<0.001 baseline 
versus 1 hour, p<0.05 baseline versus 2 hour, but this did not relate directly to 
changes in glucose levels. 
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Figure 4.3 
Leukocyte ABCA1 gene expression during an OGTT in healthy men. Results are at 3 timepoints 
during an oral glucose tolerance test (OGTT) (normalised relative units). (n=24 t=0 versus 1hr 
p<0.01; t=0 versus 2hr p<0.05).   
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Figure 4.4  
The relationship between change in glucose concentration (delta glucose mmol/l) and leukocyte 
ABCA1 gene expression in healthy subjects. Samples were taken before and after a oral 
glucose tolerance test (OGTT)-baseline versus 2 hours post-glucose administration (normalised 
relative units); n=25, rho=0.45, p=0.023.  
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Figure 4.5 
Leukocyte ABCA1 gene expression measurements during an oral glucose tolerance test 
(OGTT) in patients with impaired glucose homeostasis (IGH) (normalised relative units). (n=19 
p=0.09, t=0 versus 1hr p=0.35; t=0 versus 2hr p=0.94 ).   
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4.2 Comparison of leukocyte and monocyte ABCA1 gene expression 
 
Leukocyte and monocyte ABCA1 gene expression was measured in 7 healthy 
subjects to investigate whether gene expression was equivalent. This was 
conducted whilst establishing the SYBR green PCR methodology. Gene 
expression was measured before and in response to oral glucose (OGTT). 
There was a positive relationship between leukocyte and monocyte gene 
expression at baseline (rho=0.79, p=0.048). The positive relationship between 
gene expression was not significant at 2 hours after oral glucose administration 
(rho=0.66, p=0.11). Due to time limitations this work could not be validated 
using the Taqman hydrolysis probe method. 
 
4.3 Relationship of LXRα, PPARγ mRNA to ABCA1 and glycaemia 
 
LXRα and PPARγ are nuclear transcription factors known to positively regulate 
ABCA1 gene expression.  Gene expression of these transcription factors were 
measured to confirm this in our study cohort and to investigate whether 
glycaemia-mediated alterations in ABCA1 gene expression occurred through 
alteration of gene expression of these transcription factors. The inter-assay CV 
for LXRα gene expression using 11 leukocyte samples analysed in two PCR 
experiments varied from 0.25% to 3% (mean 1.1%). LXRα and PPARγ gene 
expression was measured in 25 participants (9 Control, 6 IGH and 10 DM). 
These subjects underwent more detailed gene expression studies in blood 
leukocytes. Results were obtained for 23 participants. There was no significant 
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relationship between either fasting plasma glucose or HbA1c levels and either 
leukocyte PPARγ (versus HbA1c p=0.13) or LXRα (versus HbA1c p=0.13) 
expression. In this cohort leukocyte LXRα expression correlated significantly 
and positively with leukocyte ABCA1 (rho=0.52, p=0.01) but there was no such 
relationship with PPARγ expression. LXRα expression data was available in a 
total of 61 participants (26 control, 17 IGH, 18 DM), and a positive relationship 
with ABCA1 was confirmed (n=61, r=0.41, p=0.001), see figure 4.6 There was 
no difference in LXR gene expression between glycaemic groups (p=0.89) and 
gene expression did not vary significantly with age (p=0.78). Furthermore, there 
was no evidence of a continuous relationship between LXRα and glycaemia or 
other biochemical parameters (p=0.56 versus fasting glucose).  Using bivariate 
linear regression, both fasting plasma glucose concentrations and leukocyte 
LXRα expression remained independent predictors of leukocyte ABCA1 
expression (both p<0.001). 
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Figure 4.6  
Positive relationship between leukocyte liver X receptor alpha (LXRα) gene expression and 
ABCA1 gene expression taken from subjects with varying glucose homeostasis, dCt=delta cycle 
number (arbitrary units); n=61, r=0.41, p=0.001. 
 
 
4.4 The relationship of leukocyte ABCG1 gene expression to 
glycaemia 
 
Expression of ABCG1 was not reduced in patients with IGH or DM compared to 
healthy men (n=25, p=0.24). Unlike with ABCA1, ABCG1 expression did not 
relate significantly to glycaemic indices (p=0.54, versus fasting glucose and 
p=0.94 versus Hba1c). However in a larger sample of 47 subjects there did 
appear to be a negative relationship to both mean glucose concentration during 
an OGTT (rho= -0.33, p=0.024) and HbA1c (rho= -0.31, p=0.033). Gene 
expression was not lower in all patients with hyperglycaemia (combined IGH 
and DM groups) compared to healthy men (p=0.16).  ABCG1 strongly 
associated with ABCA1 expression (n=25, rho=0.53, p=0.008) and this was 
confirmed in the larger sample (19 control, 12 IGH, 16 DM rho=0.40, p=0.005). 
LXRα gene expression correlated positively with ABCG1 levels (n=25, 
rho=0.73, p<0.001).  
Bivariate regression analysis, using LXRα and mean glucose as predictors of 
ABCG1 expression revealed neither to be significant independent contributors. 
When gene expression of ABCA1 and glycaemia (mean glucose or HbA1c) 
were analysed as independent predictors, only ABCA1 remained a significant 
predictor of ABCG1 RNA (mean glucose p=0.32; Hba1c p=0.65; ABCA1 
p<0.05) confirming the relationship between glycaemia and ABCG1 was 
dependent on ABCA1 expression. There was no significant relationship 
between ABCG1 and PPARγ expression (p=0.12). 
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 4.50 The effect of glucose on ABCA1 protein  
 
It has been suggested that diabetes has a direct effect on ABCA1 protein levels. 
The effect of glycaemia on ABCA1 protein concentrations was assessed in both 
leukocytes and fibroblasts. This was performed with the assistance of Dr Vijay 
Paul using a newly established methodology (335). Due to problems with 
leukocyte sample storage and transportation, protein data in leukocytes was 
only available in 50 participants (17 control, 17 IGH and 16 DM). Fibroblast 
protein measurements were obtained from all 25 subjects. ABCA1 protein 
measurements were expressed as concentration per total protein concentration. 
4.51 Leukocyte ABCA1 protein concentration in subjects according 
to glycaemia 
 
ABCA1 protein concentration was different between groups with borderline 
significance (p=0.059) see figure 4.7. Patients with diabetes had lower ABCA1 
protein concentration compared to healthy men (n=33, p=0.029) and compared 
to IGH with borderline significance (n=33, p=0.059). There was no difference in 
protein levels between healthy and IGH groups (n=34 p=1).  
- 124 - 
 
Con IGH DM
0
1
2
3
p=0.03
Glucose status
A
B
C
A
1 
pr
ot
ei
n 
co
nc
en
tr
at
io
n
(n
g/
μg
 to
ta
l p
ro
te
in
)
 
Figure 4.7  
ABCA1 protein concentration according to glucose homeostasis (n=50, p=0.059).Protein 
concentration was measured using an enzyme immunoassay methodology(336). Con=control 
subjects, IGH=Impaired glucose regulation and DM=Type 2 diabetes. Con versus DM p=0.029, 
IGH versus DM p=0.059, Con versus IGH p=1. 
 
There was no significant relationship between baseline protein concentration 
and fasting glucose (rho=-0.21, p=0.13) and Hba1c (rho=-0.08, p=0.56). Protein 
levels in leukocytes did not vary significantly during an OGTT (p=0.67). A 
negative relationship was evident between baseline ABCA1 protein and 
adiposity (rho =-0.39, p=0.005 versus BMI and rho=-0.29, p=0.04 versus waist 
circumference) see figure 4.8. When fasting glucose was entered into a 
bivariate model with BMI or waist circumference, glucose did not appear to be 
an independent determinant of protein levels (p=0.6) whereas markers of 
adiposity did independently predict protein concentrations (BMI p=0.02, Waist 
circumference p=0.02). Protein concentrations correlated positively with plasma 
HDL-C levels (n=50, rho=0.34, p=0.02), see figure 4.9, but there was no 
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significant relationship observed between protein concentrations and gene 
expression in blood leukocytes (p=0.68). 
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Figure 4.8 
The relationship between subject waist circumference and ABCA1 protein concentration in 
leukocytes measured by an enzyme immunoassay (n=50, rho =-0.29, p=0.041). 
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Figure 4.9 
Positive relationship between leukocyte ABCA1 protein concentration (measured by an enzyme 
immunoassay) and plasma HDL-C concentration at the time of sampling in subjects with varying 
glucose homeostasis (n=50, rho=0.34, p=0.02). 
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4.6 The relationship of fibroblast ABCA1 measurements with ABCG1 
and glycaemia 
 
Since undertaking this work it was discovered that a related transporter, ABCG1 
contributes to cholesterol efflux in skin fibroblasts. Therefore, ABCG1 gene 
expression was measured in fibroblasts as well as leukocytes to compare to 
ABCA1 gene expression and indices of glycaemia. 
Results of gene expression in fibroblasts were obtained for 21 of the 25 
samples. (7 control, 6 IGH and 8 DM). Samples taken from 5 subjects (C6, C28, 
D3, D15 and D18) yielded very low expression of β-Actin. This skewed results 
of normalised ABCA1 expression. Similar low β-Actin gene expression levels 
were observed in these 5 fibroblast samples in PCR experiments involving 
LXRα and ABCG1 genes. There were no observed demographic nor cellular 
differences that could explain these results and cell passage number were 
equivalent in all fibroblast samples. Experiments were subsequently repeated 
with GAPDH and data are shown in figure 4.10. Based on these observations 
gene expression results normalised to GAPDH were used for analyses. 
Fibroblast ABCA1 mRNA level did not differ between glycaemic groups 
(p=0.67) and did not correlate with HbA1c nor fasting plasma glucose 
concentrations (p=0.77 versus fasting glucose).  
Similar to observed measurements in blood leukocytes, ABCA1 mRNA level 
positively related to both ABCG1 gene expression (n=21, rho=0.8, p<0.001) and 
LXRα gene expression (n=21, rho=0.78, p<0.001).  
There appeared to be a trend towards a difference in ABCA1 protein 
concentration between subject groups (p=0.08). Patients with diabetes had a 
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marginally higher protein concentrations than healthy controls (median 
concentration 0.38ng/μg versus 0.3ng/μg protein; p=0.04). There were no 
differences in protein content between other subject groups and no observed 
continuous relationship between fibroblast protein and glycaemia (p=0.53 
versus fasting glucose, p=0.73 versus HbA1c). Protein expression in fibroblasts 
did not vary with adiposity. 
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Figure 4.10 
Comparison of gene expression of ABCA1 in skin fibroblasts using two house keeper genes, 
arbitrary units (n=21, rho=0.55, p=0.01). 5 subjects (C6, C28, D3, D15 and D18) had 
disproportionately lower β-Actin gene expression measurements, yielding a higher ABCA1 
normalised ratio relative to β-Actin (arc). 
 
In summary, leukocyte ABCA1 gene expression was lower in patients with DM 
and associated negatively with glycated haemoglobin and fasting glucose in 63 
subjects. This relationship was confirmed in a subset of 25 subjects whose 
samples were measured in a single PCR experiment which was performed 
twice. These experiments compared ABCA1 gene expression to two separate 
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housekeeper genes. The acute effect of glucose on leukocyte ABCA1 gene 
expression was assessed during an OGTT. ABCA1 gene expression increased 
at 1 hour and 2 hour time points compared to basal gene expression in healthy 
men. There was a positive correlation between ABCA1 and LXRα but not 
PPARγ gene expression in leukocytes. Both LXRα and PPARγ gene expression 
did not vary with glycaemia and did not confound the relationship observed 
between glycaemia and ABCA1 gene expression. ABCG1 gene expression in 
leukocytes did not vary with glucose homeostasis but did strongly associate 
with ABCA1 gene expression. 
Leukocyte ABCA1 protein levels were lower in subjects with DM and this was 
assessed in 50 subjects. There was no significant continuous relationship 
between glycaemia and protein levels, but leukocyte protein concentrations did 
positively relate to plasma HDL-C and independently with markers of adiposity.     
 
In fibroblasts, ABCA1 gene expression did not alter between groups of differing 
glucose homeostasis nor did gene expression correlate significantly with 
glycaemia in 21 subjects. Fibroblast ABCA1 gene expression positively related 
to both ABCG1 and LXRα gene expression. Fibroblast ABCA1 protein 
concentrations were slightly higher in patients with DM but did not vary with 
adiposity. 
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5.0 ABCA1 Function :  
5A Cholesterol Efflux 
5B   PS translocation  
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ABCA1 function was measured in skin fibroblasts as cellular cholesterol export 
(cholesterol efflux) and in CD4-positive lymphocytes as trans-membrane 
phospholipid transport. 
 
5.0 Cellular cholesterol efflux in skin fibroblasts 
25 participants underwent a skin biopsy and adequate cell proliferation was 
achieved from all biopsies. At the time of undertaking these experiments, it was 
unknown whether human fibroblasts expressed ABCG1 and therefore a number 
of acceptor particles were initially investigated to eastablish the range and 
variability of efflux in fibroblasts taken from healthy subjects. This is illustrated in 
figure 5.1. (HDL particles were isolated using ultracentrifugation from a healthy 
man, sample kindly provided by Dr M. Yee). The isolated HDL-3 particle 
(density range 1.20-1.21g/ml) produced the highest cholesterol efflux which is 
presumed to be the combined action of ABCG1 and ABCA1. ApoB depleted 
serum produced equivalent cellular efflux compared to pooled Apo-AI. As serum 
without ApoB produced reduced levels of efflux compared HDL separated by 
ultracentrigugation, it is possible the reagents or process in which ApoB is 
removed may have had a negative effect on HDL particle function. Alternatively 
it is also plausible that HDL particles taken from two separate subjects had 
markedly differing HDL function. It was not possible to isolate HDL using both 
methods in a single subject. 
To investigate whether observed efflux to ApoA-I was specific to ABCA1 action, 
cellular cholesterol efflux was inhibited using a pharmacological inhibitor of 
ABCA1 which interferes with ABCA1 intracellular protein shuttling (explained in 
section 1.812). Probucol was applied to wells (20μM) for 2 hours prior to 
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commencing efflux with ApoA-I. This resulted in a 78% decrease in efflux to 
ApoA-I, illustrated in figure 5.2.  
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Figure 5.1  
Cholesterol efflux in primary fibroblasts taken from a healthy subject. This compares various 
acceptors of cholesterol in equivalent concentration using an adopted methodology. Mean 
values and standard deviation taken from measurements in triplicate wells are shown. Cells 
were loaded with tritiated cholesterol containing 30mg/l unlabelled cholesterol for 24 hours. 
Cells were subsequently washed with PBS/BSA (0.2% v/v) and efflux was commeneced using a 
particle acceptor for 20 hours at 37oC and 5% CO2. ApoA-I (10μg/ml, Sigma), HDL-UC=HDL-3 
particle (density 1.20-1.21g/ml), isolated by ultracentrifugation from a healthy donor. No 
ApoB=ApoB depleted serum taken from a healthy donor, con=control (background) efflux for 
each experiment in wells that contain only culture medium. 
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Figure 5.2 
Pharmacological inhibition of cholesterol efflux to ApoA-I in human fibroblasts.  
Probucol 20μM (Sigma) was added two hours prior to commencing efflux with ApoA1 (10μg/ml, 
Sigma). Cells were loaded with tritiated cholesterol containing 30mg/l unlabelled cholesterol for 
24 hours. Cells were subsequently washed with PBS/BSA (0.2% v/v) and efflux was conducted 
for 20 hours at 37oC and 5% CO2. Mean and standard deviation of triplicate wells. +P=with 
Probucol, -P=without Probucol. 
 
 
The efflux assay was repeated in a number of experiments using primary cells 
to compare results using a cellular cholesterol extraction method (2,3 propanol) 
with results attained by cellular digestion (1M NaOH). This yielded comparable 
results (rho=0.70) and is shown in figure 5.3. 
The mean CV for efflux experiments in 25 subjects was 12%, see table 5.1. 
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Figure 5.3 Measurement of labelled cellular cholesterol  
Cellular efflux results comparing methods of cellular cholesterol extraction;cellular digestion 
using 1M NaOH for 1 minute versus cellular cholesterol extraction using 2,3 hexane-propanol 
for 30mins. Radioactivity was assayed by liquid scintillation couting (LSC 60000SC, Beckman, 
USA) for 2 minutes. n=20, rho=0.70,p<0.001.  
 
Table 5.1 
 
Cholesterol efflux data in participants (ABCA1 function). Experiments were performed in 
cultured skin fibroblasts taken from subjects.Total efflux refers to culture medium containing 
10mg/ml ApoA-I compared to culture media without ApoA-I (control efflux). Delta efflux (Total 
minus control efflux) represents ApoA-I-mediated cholesterol efflux. Experiments were 
conducted in triplicate wells. Mean efflux CV in wells containing ApoA-I overall was 12.0%. 
 
 
Subject 
Code  
Total 
efflux 
(%) 
Control 
efflux 
(%) 
Delta 
efflux 
(%) 
Factor 
efflux 
(Total/Control)
ApoAI 
 efflux 
CV (%) 
Mean 
Group 
CV (%) 
C1  6.19 3.00 3.19 2.06 7.75  
C4  6.48 1.66 4.82 3.90 13.29  
C6  5.75 2.50 3.25 2.30 22.35  
C7  5.99 2.82 3.17 2.12 12.80  
C8  5.32 1.47 3.85 3.62 13.16  
C9  3.07 1.52 1.55 2.02 10.40  
C21  2.50 1.45 1.05 1.72 8.78  
C28  5.70 3.50 2.20 1.63 23.12  
C29  4.98 2.93 2.05 1.70 6.91 13.2 
I1  3.70 1.22 2.48 3.03 4.67  
I6  3.94 1.75 2.19 2.25 16.72  
I10  5.02 2.36 2.66 2.13 5.11  
I12  6.03 1.15 4.88 5.24 18.43  
I15  3.11 0.7 2.41 4.44 4.88  
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I16  4.55 3.5 1.05 1.30 22.04 12.0 
D3  3.67 1.90 1.77 1.93 7.07  
D4  3.59 1.87 1.72 1.92 10.69  
D5  2.78 1.13 1.65 2.46 7.40  
D7  6.06 3.86 2.20 1.57 3.72  
D9  2.28 1.12 1.16 2.04 14.18  
D11  3.84 2.19 1.65 1.75 2.96  
D15  5.18 3.62 1.56 1.43 6.80  
D16  5.38 2.65 2.73 2.03 23.79  
D18  5.90 3.20 2.70 1.84 16.55  
D20  3.75 2.47 1.28 1.52 17.73 11.1 
 
 
5.1 The effect of hyperglycaemia on cholesterol efflux  
 
All efflux experiments were performed in cells of less than passage number 6. 
There were no differences in efflux according to passage number. When 
analysing individual groups, ApoA-I-mediated cholesterol efflux from fibroblasts 
was reduced in patients with diabetes compared to control subjects (1.8% 
versus 2.8%, p=0.04; figure 5.4) and correlated inversely with fasting plasma 
glucose levels (rho = -0.50, p=0.01; figure 5.5) but not significantly with HbA1c 
(rho = -0.30, p=0.07). After adjusting for protein concentration, efflux remained 
significantly lower in patients with diabetes compared to healthy subjects (4.5% 
versus 11.2%). There was no significant relationship between ApoA-I-mediated 
cholesterol efflux and age or body weight. ApoA-I-mediated cholesterol efflux 
from fibroblasts was negatively associated with waist circumference (r= -0.53, 
p<0.01) but this relationship was dependent on fasting plasma glucose level 
(bivariate analysis; waist circumference p=0.3, fasting plasma glucose 
concentration p=0.06).  
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5.2 Relationships between fibroblast ABCA1 and plasma HDL 
cholesterol 
 
Overall there was no significant relationship between fibroblast ABCA1 
expression and protein concentrations (p=0.26). ABCA1 gene expression did 
relate to plasma HDL-C concentrations with borderline significance (n=21, 
rho=0.41, p=0.06). In fibroblasts taken from healthy individuals, there was a 
close correlation between ABCA1 expression and plasma HDL-C 
concentrations (n=7, rho=0.93, p<0.007). ABCA1 expression was closely 
related to ABCG1 expression in fibroblasts (n=21, rho=0.80, p<0.001) and 
which correlated with LXRα RNA (rho=0.78, p<0.001). Multiple linear regression 
confirmed that LXRα predicted ABCA1 levels independent of ABCG1 (LXRα 
p=0.004, ABCG1 p=0.21).  
Fibroblast ABCA1 expression positively related to total cholesterol efflux (n=21, 
rho=0.50, p=0.02) but not significantly with ApoA-I-specific efflux (n=21, 
rho=0.38, p=0.09). ABCG1 gene expression in skin fibroblasts did not correlate 
with cholesterol efflux (rho=-0.02, p=0.92). ABCA1 protein concentration did not 
relate significantly to function (rho= -0.36, p=0.08 versus ApoA-I specific efflux). 
Despite this, there was a significant and positive relationship between 
cholesterol efflux and plasma HDL-C concentrations (rho=0.41, p=0.02; figure 
5.6). 
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Table 5.2  
Summary of Spearman correlation of ABCA1 parameters in fibroblasts. (FPG=Fasting plasma 
glucose). 
 
 FPG Hba1c HDL-C Protein Efflux 
Gene 
expression 
0.07 
P=0.77 
- 0.24 
P=0.30 
0.41 
P=0.06 
-0.26 
P=0.26 
0.38 
P=0.09 
Protein 
Concentration 
0.13 
P=0.53 
0.29 
P=0.16 
- 0.02 
P=0.93 
 - 0.36 
P=0.08 
Cellular Efflux - 0.5 
P=0.01 
- 0.30 
P=0.07 
0.41 
P=0.02 
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Figure 5.4 
Cholesterol efflux in skin fibroblasts according to glycaemic status (mean and standard error). 
IGH=Impaired glucose homeostasis, Cells were loaded with tritiated cholesterol containing 
30mg/l unlabelled cholesterol for 24 hours. Cells were subsequently washed with PBS/BSA 
(0.2% v/v) and efflux was commeneced using 10μg/ml Apo-AI (Sigma) for 20 hours at 37oC and 
5% CO2.  DM=Type 2 Diabetes. n=25, Control versus DM; p=0.04. Control vs. IGH; p=0.39.  
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Figure 5.5 
The relationship between fasting glucose and fibroblast ApoA-I-mediated cholesterol efflux Cells 
were loaded with tritiated cholesterol containing 30mg/l unlabelled cholesterol for 24 hours. 
Cells were subsequently washed with PBS/BSA (0.2% v/v) and efflux was commeneced using 
10μg/ml Apo-AI (Sigma) for 20 hours at 37oC and 5% CO2. (n=25, rho= -0.50, p=0.01). 
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Figure 5.6 
Positive relationship between ApoA-I mediated efflux in fibroblasts and plasma HDL-cholesterol 
concentration at the time of sampling. Cells were loaded with tritiated cholesterol containing 
30mg/l unlabelled cholesterol for 24 hours. Cells were subsequently washed with PBS/BSA 
(0.2% v/v) and efflux was commeneced using 10μg/ml Apo-AI (Sigma) for 20 hours at 37oC and 
5% CO2. n=25, rho=0.41, p=0.02. 
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5B Phospholipid translocation function in lymphocytes 
 
5.3 The effect of chronic glycaemia on PS translocation in diabetic 
subjects 
 
There was substantial inter-assay variability in this method. Fresh control 
samples assayed separately on 5 occasions yielded a CV of 31% (figure 5.7). 
Apart from a marked difference in a single subject, there was no difference in 
calcimycin-induced PS translocation (flop) in 4 diabetic subjects versus a single 
healthy subject (p=0.52), see figure 5.7. It was not possible to repeat 
experiments with participant D5.  
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Figure 5.7 
Comparison of phosphatidylserine (PS) membrane translocation in blood CD4 lymphocytes in 
response to calcimycin. Cumulative PS translocation was measured by flow cytometry for 9 
minutes after addition of calcimycin. Measurements are shown in 5 patients with Type 2 
diabetes (D3,4,5,7,9) and are compared to simultaneous measurements in a healthy male 
subject (control) (p=0.52). 
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5.4 The acute effect of glucose on phosphatidylserine translocation 
 
This was assessed in CD4+ cells at 3 time points during an OGTT. Baseline PS 
flop and response to calcimycin was compared to 1hr and 2hr time points 
respectively. There were no consistent differences observed compared with 
baseline, illustrated in figure 5.8. Change in PS flop did not relate to changes in 
glucose concentrations at corresponding time points (n=9, p=0.71 at 1hr and 
p=0.11 at 2hr). A single control subject (C8) did exhibit a large reduction in PS 
flop from baseline at both time points.  
 
Figure 5.8  
Phosphatidylserine (PS) translocation in blood CD4 lymphocytes during an oral glucose 
tolerance test. Cumulative PS translocation was measured by flow cytometry for 9 minutes after 
addition of calcimycin. This is compared to PS translocation performed 1 hour and 2 hours after 
oral glucose administration. (Participants who exhibited marked differences in response to 
glucose are labelled, C=Control participants, I=patients with impaired glucose homeostasis). 
 
 
There were no significant relationships between phospholipid membrane 
translocation, as measured by PS flop, and cholesterol efflux, leukocyte gene 
expression or plasma HDL-C in participants (p=0.61, p=0.78, p=0.27 
respectively). Based on these provisional results, together with practical 
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difficulties in simultaneously isolating leukocyte and lymphocyte populations for 
analysis, no further samples were taken for PS translocation measurements.  
 
In summary, Apo-AI induced cholesterol efflux was reduced in skin fibroblasts 
taken from patients with DM. Furthermore, there appeared to be a negative 
association between cholesterol efflux and blood glucose levels at the time of 
initial skin sampling. Efflux did not independently vary with age nor adiposity but 
did positively correlate with plasma HDL-C concentrations in 25 subjects. 
In skin fibroblasts, ABCA1 gene expression did not significantly relate to protein 
concentrations or function. ABCA1 gene expression did positively and 
significantly relate to total efflux (Apo-AI mediated and non-specific). There was 
a relationship between fibroblast ABCA1 gene expression and plasma HDL-C 
concentration of borderline significance. This relationship was significant in the 
subset of healthy men. These relationships are summarised in table 5.2.  
 
In lymphocytes, variability in PS transport was observed between experiments 
and PS translocation did not vary with glucose homeostasis during an OGTT. 
PS transport did not significantly relate to other ABCA1 measurements in 
fibroblasts or leukocytes. 
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6.0 Carotid intima-media 
thickness 
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CIMT measurements were performed by B-mode ultrasound and were used as 
a quantitative measure of atherosclerosis. People with ABCA1 mutation have 
been demonstrated to have increased CIMT. ABCA1 gene expression was 
hypothesised to be inversely related to CIMT. 
6.0 CIMT measurements  
 
The reproducibility of measurements of IMT was assessed in the Irvine vascular 
laboratory, the CV for the measurement of IMT was 5.8%. 
Measurements taken with current equipment were compared to that taken by 
the same radiographer using a previous scanner. The intra-observer variability 
in 67 measurements was 9.0% with a mean standard deviation of 0.08cm. 
Measurement methods are stated in an earlier section (2.04) and all 
measurements were performed by a single senior radiographer. Results are 
displayed in Table 6.1. Figure 6.1 illustrates ultrasound CIMT. The ultrasound 
image was taken from a diabetic participant (D12) and demonstrates a lipid rich 
plaque at the carotid bulb. 
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Figure 6.1 
Longitudinal ultrasonographic view of the left common carotid artery taken from a participant 
with diabetes. A lipid rich atherosclerotic plaque can be seen at the bifurcation of the carotid 
artery (arrow). CIMT measurement was 0.072cm at the posterior wall as shown (double headed 
arrow). 
Common Carotid 
Internal 
External  
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Table 6.1 
Carotid intima media thickness (CIMT) measurements (cm) in participants (n=68). Qualitative 
comments for images and measurements are included. (ICA=internal carotid artery, 
CC=common carotid artery). 
 
  
Participant  LEFT RIGHT MEAN Notes 
  
C1 0.038 0.05 0.044   
C2 0.042 0.045 0.044     
C3 0.058 0.044 0.051     
C4 0.044 0.054 0.049     
C5 0.042 0.048 0.045     
C6 0.071 0.07 0.071     
C7 0.074 0.067 0.071     
C8 0.054 0.062 0.058     
C9 0.050 0.050 0.050     
C10 0.074 0.067 0.071     
C11 0.059 0.060 0.060     
C12 0.052 0.049 0.051     
C13 0.050 0.057 0.054     
C14 0.074 0.066 0.070 small R.bulb plaque   
C15 0.100 0.074 0.087 bilateral ICA plaque <50%  
C16 0.043 0.048 0.046 small calcified spec in R.CC  
C17 0.048 0.046 0.047 Lean subject, checked  
C18 0.058 0.052 0.055 L.IC -29% diameter reduction   
C19 0.051 0.048 0.050     
C20 0.068 0.072 0.070     
C21 0.069 0.082 0.076 Generalised thickening  
C22 0.083 0.077 0.080     
C23 0.089 0.079 0.084     
C24 0.051 0.064 0.058  
C26 0.070 0.070 0.070     
C27 0.089 0.073 0.081 L.bulbar plaque 42% reduction 
C28 0.053 0.069 0.061     
C29 0.080 0.073 0.077 Ext. Carotid plaques only R>L  
C31 0.053 0.063 0.058     
I-1 0.070 0.070 0.070     
I2 0.053 0.05 0.052     
I3 0.057 0.059 0.058 30-40% ICA stenosis   
I4 0.068 0.063 0.066 L. Carotid bulb plaque 
I5 0.08 0.079 0.080    
I6 0.072 0.07 0.071 minor plaque R.bulb   
I7 0.094 0.088 0.091     
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I8 0.072 0.065 0.069  
I9 0.071 0.067 0.069     
I10 0.077 0.058 0.068 R.ICA anomaly (kink)  
I11 0.081 0.070 0.076 Bilateral bulb plaques<50%  
I12 0.077 0.071 0.074 L.ICA plaque<50%   
I13 0.058 0.061 0.060 R.ICA small plaque   
I14 0.053 0.057 0.055     
I15 0.073 0.073 0.073 R.ICA small plaque   
I16 0.052 0.078 0.065     
I19 0.071 0.053 0.062     
C25 0.080 0.058 0.069 L.small plaque at L.ICA  
I20  0.058 0.042 0.050     
D13 0.072 0.08 0.076 R.bulb plaque of 0.135cm  
D2 0.068 0.047 0.058 R.ant  wall thicker   
D3 0.069 0.069 0.069 Small calcium fleck L&R ICA  
D4 0.073 0.064 0.069 L.small plaque    
D5 0.081 0.081 0.081     
D6 0.055 0.058 0.057     
D7 0.103 0.075 0.089     
D9 0.068 0.074 0.071     
D10 0.062 0.078 0.070  L.distal CC small plaque  
D11 0.086 0.065 0.076     
D12 0.072 0.058 0.065  L.large bulbar plaque (photo)  
D14 0.094 0.067 0.081 Left diffuse thickened  
D15 0.062 0.063 0.063 R.small ca fleck    
D16 0.104 0.049 0.077 L.plaque, R.bulbar thickening   
I17/D 0.066 0.052 0.059  
D17 0.072 0.063 0.068 R.ICA small ca fleck    
D18 0.205 0.091 0.148  
D19 0.048 0.058 0.053     
I21 0.054 0.045 0.050     
D20  0.097 0.096 0.097 L double IMT, R.small plaque 
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6.01 Demographic and biochemical determinants of CIMT 
 
There was a trend to increased CIMT measurements, with increasing glycaemia 
across the three glycaemic categories, see figure 6.2 (p=0.09). Patients with 
DM had higher CIMT than healthy men (p=0.049). There were no significant 
differences between other groups. 
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Figure 6.2 
Ultrasound measurement of carotid intima-media thickness (CIMT) according to glycaemic 
status of subjects (n=68, p=0.09;Con vs DM p=0.049) (Con=control, IGH=impaired glucose 
homeostasis, DM=type 2 diabetes). 
 
 
Spearman correlation demonstrated that several variables associated with 
CIMT. Age and measures of glycaemia and adiposity positively related to CIMT. 
Lipid and blood pressure parameters did not relate to CIMT (table 6.2). 
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Table 6.2  
 
Correlations comparing demographic and biochemical characteristics to carotid intima-media 
thickness (CIMT) measurements (cm) (n=68). P-values are shown (* indicates Mann Whitney 
test).  
 
 
PARAMETER P VALUE 
Age 0.003 
BMI 0.005 
Waist Circumference 0.003 
Fasting glucose 0.005 
Mean glucose (during OGTT) 0.0001 
HbA1c 0.04 
Mean Systolic BP 0.44 
HDL-C 0.18 
LDL-C 0.78 
Triglyceride 0.11 
Smoking Status 0.11* 
 
 
When BMI, fasting glucose and age were entered in a multiple regression 
model, only age remained a significant independent predictor of CIMT 
(p<0.001). Statistically, fasting glucose and BMI were inter-related and did not 
independently predict changes in CIMT (p=0.08, p=0.16 respectively). In 
contrast, mean glucose concentration (during an OGTT) did predict changes in 
CIMT independent of age and BMI (p=0.01). 
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6.1 The relationship of ABCA1 to CIMT 
 
CIMT associated significantly and negatively with ABCA1 gene expression 
(p=0.046 versus delta Ct). However, this relationship was confounded by the 
relationship of CIMT to glycaemia. Bivariate regression analysis demonstrates 
fasting glucose, but not ABCA1 expression independently predicted CIMT 
(p=0.04 and p=0.69 respectively). ABCG1 gene expression did not show a 
significant relationship with CIMT (n=49, p=0.22). 
ABCA1 protein in blood leukocytes did not relate significantly with CIMT (n=49, 
p=0.33). Cellular cholesterol removal in skin fibroblasts, a measure of ABCA1 
function, did not appear to associate with CIMT (n=25, p=0.47). However, a 
single patient had a cholesterol plaque at the site of CIMT measurement, which 
produced a skewed measurement, seen in figure 6.3. Excluding this skewed 
measurement, yielded results suggesting a trend between efflux and CIMT (r= -
0.35, p=0.095), but this was not independent of fasting glucose on multivariate 
analysis (p=0.29).  In the more detailed characterised cohort of twenty five 
participants, CIMT significantly associated with plasma triglyceride (rho= 0.63, 
p=0.009) and negatively with HDL-C (r= -0.50, p=0.012). It is unclear why 
similar correlation was not seen with triglyceride and HDL-C in the entire study 
group. 
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Figure 6.3 
The relationship of Apo-AI mediated cholesterol efflux in skin fibroblasts to carotid intima-media 
thickness (CIMT), skewed data point (arrow) represents a patient who exhibited a carotid 
plaque at the site of measurement, n=24, r=-0.35, p=0.095. 
 
 
In summary 68 subjects underwent CIMT measurements, patients with DM had 
higher CIMT measurements and CIMT positively associated with age, adiposity 
and glycaemia. The observed relationship between leukocyte ABCA1 gene 
expression and CIMT was confounded by the relationship between glycaemia 
and ABCA1 gene expression. Leukocyte ABCA1 protein levels did not 
significantly relate to CIMT. In fibroblasts, there was a trend towards a negative 
relationship between efflux and CIMT. 
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7.0 The effect of adiposity, age 
and glucose lowering treatment 
on ABCA1 
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It has been proposed that unsaturated fatty acids negatively regulate ABCA1 
gene expression. Excess adiposity is associated with insulin resistance which is 
the cause for subsequent impaired glucose homeostasis. Therefore, 
measurements for both clinical and biochemical markers of adiposity were 
taken to investigate if these confounded the proposed relationship between 
glycaemia and ABCA1 gene expression and function. Our original findings 
suggested that ABCA1 gene expression may be related with age and this  
analysis in the present cohort is presented below. The effect of a glucose 
lowering treatment on leukocyte ABCA1 gene expression and protein 
concentrations was additionally undertaken.  
 
7.0 The relationship of plasma fatty acids with ABCA1 
 
Plasma NEFA concentrations were measured in fasting plasma samples taken 
from participants who underwent detailed gene expression and functional 
studies. Fasting plasma sample was unavailable in one subject. Fasting NEFA 
levels, positively related to both waist circumference (n=24, rho=0.42, p=0.043) 
and HbA1c (rho=0.46, p=0.023) and negatively with HDL-C (rho= -0.40, 
p=0.023). Bivariate analysis (log transformed data) demonstrated waist 
circumference but not HbA1c independently predicted NEFA concentration 
(p=0.03 and p=0.43 respectively).  
There was no significant relationship between ABCA1 mRNA and fasting NEFA 
concentration (rho= -0.17, p=0.42). No significant relationships were observed 
between NEFA and either LXRα (p=0.98) or PPARγ gene expression (p=0.50). 
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Cholesterol efflux nor CIMT significantly related to NEFA concentration (p=0.53 
and p=0.51 respectively).  
 
7.1 The relationship of age to ABCA1 expression and function 
 
Leukocyte ABCA1 gene expression or ABCA1 protein concentrations did not 
alter with increasing age (n=63, p=0.18 and n=49, p=0.22 respectively). These 
findings contrast with results of gene expression our earlier study in younger 
men (324). Cholesterol efflux measured in skin fibroblasts (ABCA1 function) did 
not change with age (n=25, p=0.37). 
  
7.2 The effect of glucose lowering on ABCA1 gene expression and 
protein content 
 
Patients with DM were treated for six weeks with an AMP kinase activator, 
Metformin. Fasting samples were taken to measure ABCA1 expression and 
protein concentration before and after treatment. Twelve patients with DM 
agreed to participate with the treatment over a six week period. Over the period 
there was a mean reduction in Hba1c was 0.59% (range -1 to 2.7%) p=0.003 
and non-significant reduction in fasting glucose was 0.55mmol/l (-1 to 
2.4mmol/l) (p=0.23). Patients with the highest baseline Hba1c achieved the 
greatest reduction in glucose. There was a non-significant mean weight loss of 
0.98 kg weight (-4.3 to 5.5 kg) observed (p=0.15). As expected, there was 
correlation between change in glucose and change in HbA1c (r=0.72, p=0.009). 
There was no significant relationship between change in weight and change in 
Hba1c (rho =0.42, p=0.18).  
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Gene and protein data were available in 11 of the 12 subjects. Change in 
normalised gene expression in blood leukocytes did not significantly relate to 
change in Hba1c (r=0.14, p=0.69) or change in glucose (r=0.36, p=0.27), figure 
7.1. Change in protein content did not appear to alter in accordance to change 
in glycaemia (p=0.25 versus delta Hba1c and p=0.25 versus delta glucose). 
Fasting NEFA concentrations did not vary significantly with change in glycaemia 
(r=-0.19, p=0.59) or change in weight (p=0.15). There was no relationship seen 
between delta NEFA and change in gene expression or protein expression 
(p=0.95 and p=0.65 respectively). There did appear to be a negative trend 
between change in weight and change in gene expression but this did not reach 
significance (r=-0.48, p=0.14) figure 7.2. Change in gene expression of ABCA1 
and change in protein concentrations were positively related with borderline 
significance (rho=0.79, p=0.07). 
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Figure 7.1 
Relationship between change in Hba1c induced by glucose lowering treatment and change in 
leukocyte ABCA1 gene expression (measured by PCR and normalised to β-Actin) in patients 
with type 2 diabetes treated for six weeks with Metformin; n=11, r=0.14, p=0.69. 
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Figure 7.2 
Relationship between change in weight and change in leukocyte ABCA1 gene expression 
(measured by PCR and normalised to β-Actin) in response to glucose lowering treatment with 
Metformin for six weeks in patients with type 2 diabetes; n=11, r=-0.48, p=0.14. 
 
In summary, waist circumference independently predicted plasma NEFA 
concentrations. There were no significant relationships between measures of 
ABCA1 with plasma NEFA concentrations. Furthermore, measurements of 
ABCA1 gene expression, protein level or function did not vary significantly with 
age. The effect of glucose lowering treatment was assessed over six weeks in 
12 subjects and reductions in glucose were not associated with significant 
changes in leukocyte ABCA1 gene expression or protein concentrations. Some 
subjects experienced weight loss during the treatment and a tentative inverse 
relationship between weight loss and leukocyte ABCA1 gene expression was 
observed. Changes in ABCA1 gene expression in leukocytes during treatment 
were concordant with changes in protein concentrations. 
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8.0 GENERAL DISCUSSION 
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8.1 ABCA1 and effects of glycaemia  
 
Our pilot study demonstrated an association between fasting glucose and 
ABCA1 expression in blood leukocytes in normoglycaemic men (324). The 
basis of the current hypotheses and study was to investigate the effect of 
glycaemia on ABCA1 expression and function in humans, by studying patients 
with impaired glucose homeostasis. These were age-matched, drug naive men 
with no differences in blood pressure or total cholesterol.   
In blood leukocytes, patients with DM had lower ABCA1 expression in keeping 
with our original results and hypothesis. Moreover, a continuous negative 
relationship was observed between gene expression and glycaemia (both 
Hba1c and fasting glucose) in this larger group of individuals compatible with 
results from our original study. To my best knowledge, this is the first study to 
report this finding. A continuous relationship between ABCA1 expression and 
Hba1c was not seen in the original pilot study, this can possibly be explained by 
the narrow range of Hba1c values seen in healthy individuals. 
Most of the decline in gene expression occurred up to an HbA1c level of 7.5%, 
with little further fall above this level. These results contrast with results in 
leukocytes from Hoang and colleagues (322) as that study did not find a 
difference in gene expression in patients with DM but did find a positive 
association with physical activity. One third of patients in this study were 
receiving oral hypoglycaemic medications for diabetes and patients had lower 
LDL-C levels than healthy subjects this may have influenced these findings. 
My results appear also to conflict with that of Zhou and Mauldin et al., where 
monocytes and macrophages were studied. These studies showed that 
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expression and function of ABCG1 (but not ABCA1) was decreased in diabetic 
patients (185;323). Mauldin discussed a major draw-back of their study; patients 
were not well characterised, with little information available on demographics, 
clinical disease and medications (185). Disease related factors and medications 
could have influenced these fingings as discussed below.  Significant numbers 
of the patients studied by Zhou and colleagues, had evidence of microvascular 
complications; 40% with retinopathy and 43% had some evidence of 
nephropathy (323). Data from animal experiments indicate that complications 
such as nephropathy can reduce macrophage ABCA1 and increases cellular 
cholesterol content. Moreover, agents used in the treatment of diabetic 
nephropathy can restore macrophage ABCA1-mediated cholesterol efflux (337).  
More patients in my study were receiving these classes of medication for 
hypertension (either Angiotensin converting ezyme inhibitor or Angiotensin II 
receptor antagonist). However ABCA1 mRNA, protein and function remained 
lower in patients compared to healthy men with no difference in blood pressure 
across groups. It is therefore unlikely that these treatments had significant 
positive effects on ABCA1 expression and function in this study.   
Concomitant medications used for these conditions are likely to have had 
bearing on results obtained by Zhou and colleagues. Patients were treated with 
hypoglycaemic medications and one-third were receiving insulin treatment 
(323). My study has the distinct advantage of investigating drug naive patients, 
who were not receiving either lipid lowering or glucose lowering medications 
and were clinically free of diabetes-related complications. It is feasible that 
hypoglycaemic treatments used by diabetic patients in the previous studies may 
have contributed to the discrepancies compared to our findings. For example, 
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insulin decreases human macrophage ABCA1 and ABCG1 expression in-vitro 
and the oral hypoglycaemic agent, glyburide has been shown to inhibit ABCA1 
mediated cholesterol efflux (338;339). My results are compatible with 
observations made by Forcheron et al., in monocytes taken from patients with 
DM and dyslipidaemia (301). There was also a trend to reduced monocyte 
LXRα expression in that study, this was not observed in my experiments.  
ABCA1, ABCG1 and LXR gene expression were positively related in leukocytes 
as well as in fibroblasts, confirming a common regulatory pathway in-vivo in 
humans, similar to that in-vitro. 
In the present study, skin fibroblasts were used to assess ABCA1 function, as a 
surrogate for arterial macrophages. Skin fibroblasts, have been employed for 
this purpose in previous studies where the functional consequences of genetic 
variation in ABCA1 have been studied (246;247). My tritiated cholesterol-based 
technique for assessment of ApoA-I-mediated cholesterol efflux was derived 
from a validated methodology (192). Cellular cholesterol export was 
successfully inhibited by a pharmacological agent known to block the action of 
ABCA1 which confirmed specificity of the assay. I have demonstrated in healthy 
men, gene expression in fibroblasts was closely related to plasma HDL-C 
concentrations and there was a tentative relationship observed in patients with 
hyperglycaemia. Fibroblast ApoA-I-mediated cholesterol efflux was reduced in 
patients with DM and a continuous negative relationship was seen with 
glycaemia.  To my knowledge, this is the first such observation in humans 
without a known ABCA1 mutation. Fibroblasts have been used previously to 
investigate the effects of genetic abnormalities on ABCA1 function, subjects in 
the present study were from a diverse ethnic background and, therefore, 
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ethnicity related variants in ABCA1 are unlikely to have contributed to observed 
differences in ABCA1 gene expression and function. I have further 
demonstrated that ABCA1-mediated cholesterol efflux is positively related to 
plasma HDL cholesterol concentration, confirming its key role in HDL particle 
formation.  These conclusions contrast with those from studies in patients with 
the metabolic syndrome (with and without hyperglycaemia) where cholesterol 
efflux was unrelated to HDL concentration (184).  ABCG1-mediated cholesterol 
export is not thought to be a major contributor to maintaining plasma HDL 
cholesterol concentration but seems to be important in preventing 
atherosclerosis in animals (72).  A positive relationship between ABCA1 and 
circulating HDL-C in patients with diabetes has only been previously 
demonstrated in patients with common gene variants, who had evidence of 
proteinuria and renal dysfunction (340).  
Reduced ABCG1-mediated cholesterol efflux in monocytes has been reported 
in diabetic patients by Zhou and colleagues and results for ABCA1-mediated 
efflux were not reported in this study (323). Mauldin and co-workers showed a 
30% reduction in ABCG1-mediated efflux in macrophages taken from patients 
with DM with no difference in ABCA1-induced export. Macrophages, in this 
study, were cultured in autologous (diabetic) serum which appears 
physiological, but serum from diabetic patients is likely to contain altered 
concentrations of pre-β HDL compared to healthy people which could influence 
cellular efflux results (341). It is noteworthy that, unlike ABCA1, ABCG1 
transporter dysfunction has not been reported to be associated with a human 
clinical disease.  Due to the synergistic relationship between ABCA1 and 
ABCG1, an element of redundancy may exist for ABCG1 as suggested from 
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results in animal knockout studies (74).  However, ABCA1 seems to be crucial 
as it initiates cholesterol export and provides a lipidated ApoA-I substrate for 
subsequent ABCG1 action.  
It should be noted that my gene expression measurements in leukocytes and 
cholesterol efflux and gene measurements in fibroblasts were made against 
very different backgrounds. Leukocyte gene expression likely relates to the 
conditions under which the leukocytes were taken at the time of sampling, 
whereas fibroblasts had undergone prolonged in-vitro culture before 
measurements were made. Consistent with this, I demonstrated both ABCA1 
gene expression and protein concentrations were reduced in leukocytes taken 
from diabetic patients. 
Prolonged in-vitro conditions may account for the lack of association between  
fibroblast RNA level and ApoA-I-mediated cholesterol efflux. Acidic environment 
can negatively influence efflux this finding may have relevance in advanced 
atherosclerotic plaques (342). Hoang and colleagues, similar to our findings in 
fibroblasts and leukocytes, did not find a relationship between human leukocyte 
and skeletal muscle ABCA1 gene expression (322). Alternatively, there could 
be discrepancies between ABCA1 gene expression, translation and protein 
activity and such discrepancies have been reported in animals (343). The 
observed lack of relationship between gene expression, protein concentrations 
and function in human skin fibroblasts should be further investigated. 
Importantly, however, despite prolonged in-vitro culture at constant 
hyperglycaemia (25mmol/l), a relationship was still apparent between fibroblast 
cholesterol efflux and the in-vivo glucose concentrations the fibroblasts had 
been exposed to in the subjects from whom they were taken. These findings 
- 162 - 
 
were in spite of DM patients having higher protein concentration in fibroblasts 
which indicates either altered protein localisation or protein modification due to 
a “diabetic milieu” leading to accumulation of dysfunctional protein. Future 
experiments should aim to explore whether DM patients have altered 
subcellular and plasma membrane localisation by interrupted shuttling of 
ABCA1. This could be assessed using biotinylation methods and would help 
explain the current findings in skin fibroblasts. Alternatively, DM patients may 
have physicochemical differences in cellular membranes that prevent Apo-AI 
interacting with ABCA1. Tang and Oram have reviewed the possible 
mechanisms by which diabetes could adversely affect ABCA1; AGEs have 
been shown to impair ABCA1 function in cultured cells and fatty acids enhances 
degradation of the protein (344). The effect of AGE could help explain our 
findings of reduced ABCA1 function in cultured fibroblasts but is not consistent 
with the observed increase in ABCA1 protein. Some of the proposed 
mechanisms by which diabetes negatively influences ABCA1 protein seem to 
be independent of effects on RNA. Comparing the effects of different 
concentrations of cholesterol on ABCA1 gene expression in fibroblasts could 
help establish if there are altered set points for gene expression in patients with 
diabetes.  
The relationship of transporter function in fibroblasts to plasma glucose levels at 
the time of sampling implies the possible existence of mechanisms that can 
sustain a prolonged metabolic memory on the part of the cells. This is 
compatible with observations made by Senanayake and colleagues, where 
there was no difference in gene expression in monocytes, whether cultured in 
physiological or high glucose concentrations in either DM patients or healthy 
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individuals (313). In complete contrast, a study which investigated several ABC 
transporters in monocyte-derived macrophages from healthy individuals, 
demonstrated high glucose (25mmol/l) incubated for 72 hours specifically 
decreased gene expression of both ABCA1 and ABCG1. Protein levels were 
also decreased in response to high glucose incubation (345). If this is confirmed 
to occur in-vivo, as suggested by Mauldin et al.,(185) one can cautiously 
conclude glucose may compromise synergistic mechanisms involved in cellular 
cholesterol removal. 
 An alternative functional measure of ABCA1 was conducted in blood 
lymphocytes. This did not yield sufficient results due to practical limitations. 
There was no difference in phospholipid transport observed in hyperglycaemic 
patients compared to healthy men and no obvious differences in gene 
expression were seen during an OGTT. There was substantial inter-assay 
variability in this method and it is likely this was due to assay variability rather 
than for biological variation as samples from patients with DM yielded similar 
results to measurements taken from a single control subject (figure 5.3).   
PS transport was considered to be a valid functional measure of ABCA1 and 
abnormalities in PS transport have been reported in a patient with a rare 
ABCA1 mutation (210). However, in my study, the measure of exofacial PS 
membrane transport did not quantitatively relate to cholesterol efflux in 
fibroblasts, the latter was demonstrated to be specific to ABCA1. The 
measurement of PS flop, therefore, may not represent a reliable measure of 
ABCA1 activity.  The effect of probucol on PS flop has not been studied and this 
could help clarify whether ABCA1 is required for this function as a number of 
mechanisms promoting phospholipid flop have been identified (346). PS flop 
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has been shown to occur independent of ABCA1 and may be more dependent 
on changes in membrane organisation (334). 
 
The acute effect of glucose on leukocyte ABCA1 gene expression was 
investigated in my study using an OGTT in healthy men and patients with IGH. 
There appeared to be an increase in gene expression at 1 hour and 2 hour time 
points compared to baseline, with a concordant relationship between the 
change in glucose and change in gene expression at 2 hours. This may be 
related to an acute effect of insulin release, but the physiological relevance of 
this is unclear and would require further investigation, ideally employing a 
physiological method such as a euglycaemic-insulin clamp. This observation 
does indicate that gene expression of ABCA1 in circulating blood leukocytes is 
dynamic and changes may occur in response to blood glucose concentrations. 
Whether these changes are due to acute hyperglycaemia or other related 
factors is unknown and could be further investigated by the administration of 
intravenous glucose. These results would be compatible with the view that 
ABCA1 RNA is a rapidly turned over with an estimated half-life of 1-2hrs (276). 
Both leukocyte protein and efflux (ABCA1 function) in skin fibroblasts positively 
related to plasma HDL-C concentration. This proposes leukocyte and fibroblast 
ABCA1 activity may either reflect hepatic activity or alternatively peripheral cell 
ABCA1 function could directly contribute to formation of HDL particles. Data 
from animal studies imply hepatic ABCA1 is predominantly responsible for HDL 
formation with a minor contribution from intestinal and haemopoetic cells 
(69;70;197). The contribution of peripheral cell ABCA1 to HDL formation in 
humans is unknown. 
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A specific atheroprotective effect of leukocyte specific ABCA1 activity has been 
previously seen in mice. Animals lacking leukocyte ABCA1 activity had more 
advanced atherosclerotic lesions due to increased recruitment of inflammatory 
cells (198). This suggests that leukocyte ABCA1 may have an important 
immune function contributing to its athero-protective effect, which may be 
distinct from its transporter function. This area of work warrants further 
investigation. The idea of dual ligand function has been explored in the related 
nuclear receptor, LXR. Joseph and colleagues report an anti-inflammatory 
effect of LXR activation in macrophages in response to pathogens both in-vitro 
and in mice (347). The reciprocal modulation of inflammation and lipid 
metabolism highlights a potential interaction of lipid metabolism and 
inflammation at a cellular (macrophage) level. This group further showed that 
LXR modulates innate immunity by inhibiting induction of key inflammatory 
genes (348). A report by Tang and Oram has suggested similar anti-
inflammatory properties of ABCA1 in cultured macrophages (349). This area of 
work provides some evidence of cross-talk between lipid metabolism and 
inflammation in process of atherogenesis.  
 
 
8.2 Independent effects of glucose, age and adiposity  
 
The relationship of glucose to ABCA1 gene expression in leukocytes appeared 
to be independent of the amount of LXRα RNA. There was no direct 
relationship between LXR expression and glycaemia which contrasts with 
conclusions made by Mitro and colleagues (296). There was no observed 
association between PPARγ and ABCA1 expression in my study but results 
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from animal studies implicate that PPARγ agonist therapy reduces blood 
glucose levels through the action of ABCA1 (350). This pivotal study 
demonstrated mice devoid of pancreatic-specific ABCA1 developed glucose 
intolerance in early life. This proposes the idea that pancreatic ABCA1 activity 
may influence insulin secretion and subsequent glucose lowering. Whether a 
similar mechanisms exist in humans is unknown, but studies investigating 
insulin secretion in Tangier patients carrying loss of function mutations, indicate 
mild hyperglycaemia (351). Reports have showed that Rosiglitazone may have 
variable effects on glycaemia and lipids in DM patients with certain ABCA1 
gene variants (352;353). It is unknown whether the amount of baseline ABCA1 
RNA alters efficacy of PPARγ agonist therapy or has any bearing on pancreatic 
secretory reserve. This area merits further investigation and implies ABCA1 
may have some utility as a pharmacogenetic marker in the future. Both ABCA1 
and ABCG1 have now been implicated in islet cell function in mice (350;354). 
Contemporary animal studies have demonstrated decreased ABCA1 protein 
with cellular cholesterol accumulation in macrophages in different mouse 
models of type I diabetes (355). These observations, along with our findings in 
humans, indicate a common glycaemia-mediated suppression of ABCA1.  In 
support of this, in-vitro work indicates that hyperglycaemia specifically down 
regulates ABCA1 and ABCG1 mRNA and protein content in human 
macrophages (345). Supplementary work in vascular smooth muscle cells 
proposes hyperglycaemia leads to reductions in ABCA1 mRNA and protein 
content with concordant changes in ABCA1 promoter activity (356). Further 
work is required to explore the mechanisms involved. 
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Dysglycaemia and atherosclerosis are known to be more prevalent with age, 
raising the question whether abnormalities in RCT are an age-related process. 
Our previous study showed age did not independently influence leukocyte 
ABCA1 expression levels in healthy men (324). In my study, subjects were age-
match to help evaluate this. ABCA1 expression or activity did not decline with 
age. Berroughi and colleagues have demonstrated an age related reduction in 
function of HDL particles to remove cholesterol from macrophages and 
extrapolated that this may be principally mediated by differences in the ABCA1 
pathway (357). These findings are not supported by my results in young and 
middle aged men. Pre-β-1 HDL concentrations seem to be important in 
determining efflux by ABCA1 in people with similar total plasma HDL-C 
concentrations (341).  
Apart from glycaemic variables, markers of adiposity appeared to independently 
relate to measurements of ABCA1. Leukocyte ABCA1 protein was negatively 
related to BMI and waist circumference. It is unclear whether this effect is 
mediated by inflammation, as inflammatory markers were not measured, or due 
to excess fatty acids associated with metabolic syndrome. Total NEFA levels in 
my study were not different between subject groups but NEFA concentrations 
did correlate independently with waist circumference. Unsaturated fatty acids 
have been shown to destabilise ABCA1 and promote protein catabolism 
(276;358;359). Plasma NEFA levels may not represent an accurate measure of 
cellular unsaturated fatty acid burden. Consistent with this concept, work by 
Senanayake and others implicated monocyte-derived macrophages in patients 
with DM have higher unsaturated fatty acid levels, despite similar plasma levels 
compared to control subjects (313). Excess cellular fatty acids may lead to 
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lower availability of ABCA1. Moreover, there is now evidence to show fatty 
acids may differentially regulate ABCA1. Palmitic acid, a saturated fatty acid, 
was shown in- vitro to increase in both gene and protein expression in cultured 
monocyte-derived macrophages taken from healthy subjects (345). It is thought 
transporter activity is modified by altering protein localisation at the plasma 
membrane (360) In direct contrast, linoleic acid, an unsaturated fatty acid, 
showed a negative effect on ABCA1 expression (345).  
Cholesterol efflux in skin fibroblasts negatively related to adiposity and efflux 
was lower in diabetic men despite an increased level of protein compared to 
healthy men. Possible underlying mechanisms may involve intracellular 
transporter trapping, altered protein turnover or transporter dysfunction and 
further work is required to clarify a mechanism. Elevated concentrations of AGE 
and inflammatory mediators have been shown to inhibit cholesterol efflux in 
similar models which may have contributed to my findings (320;361). 
Medications which reduce glycation of HDL, such as Metformin, have been 
shown to improve cholesterol efflux via the ABCG1 pathway (362). The 
extracellular domains of the ABCA1 transporter are usually glycosylated (205) 
and it is currently unknown whether excess glycation occurs or can have any 
direct effect on transporter function. In the present study results from eleven 
patients treated with metformin over a six week period are reported. Although 
there was no direct relationship between change in glycaemic indices and 
changes in gene expression, metformin and lifestyle mediated weight loss 
appeared to have a positive effect on gene expression. As weight loss is 
generally associated with improvements in glycaemia through decreased insulin 
resistance, insulin concentrations are likely to be a confounding factor in these 
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observations. Increased gene expression in response to Metformin therapy was 
associated with concordant changes in protein expression and this indicates 
modulation gene expression results in a similar variation in protein translation. It 
is assumed an increase in protein levels would lead to increased function but 
this requires confirmation in people with DM. 
Future approaches to measure the effect of hypoglycaemic therapy on gene 
expression, must account for changes in adiposity and should be adequately 
powered to differentiate between these inter-related factors. A physiological 
study; Pioglitazone on cardiac function and large arteries (PICCOLA) has a sub-
study designed to assess the effect of PPARγ agonist therapy on leukocyte 
ABCA1 gene expression in patients with diabetes at Imperial College.  
 
 
8.3 Dysfunctional HDL and HDL kinetics 
 
ApoA-I modification has been reported in DM and CHD and this may play a role 
in modifying cellular cholesterol export. Oxidation of HDL-C particles by 
myeloperoxidase, an enzyme released from phagocytes, has been shown to be 
more common in patients with established coronary artery disease. These 
modified proteins were shown to be less effective in inducing cholesterol efflux 
in cultured cells (363).  
Dysfunctional HDL-C molecules have been reported in a number of 
inflammatory conditions which may contribute to the observed elevated risk of 
CHD in such patients. Navab et al., showed defective anti-inflammatory action 
of HDL on LDL-C particles in coronary disease patients compared to healthy 
participants (124). Animal models of atherosclerosis have further shown 
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correlation between pro-inflammatory HDL function and lesion size (125). Short 
term treatment with simvastatin has been demonstrated to improve the anti-
inflammatory function of HDL particles in CHD or at risk patients (364). These 
studies highlight the importance of the antioxidant and anti-inflammatory 
function of HDL which may help prevent the CHD.  De Souza and colleagues 
have demonstrated defective function in smaller HDL particles taken from 
patients with MS (128). Dodani further proposes HDL dysfunction may 
contribute to the increased CHD commonly risk seen in South Asian people 
(365). 
Since the landmark Apo-AI “Milano” study (240), recombinant HDL and ApoA-I 
mimetic molecules have been developed with the to aim to increase whole body 
cholesterol removal. This therapeutic approach would involve direct infusion of 
ApoA-I or a structurally similar molecule. The amphipathic α-helix is the major 
structural determinant of ApoA-I required for interaction with ABCA1 and 
synthetic analogues containing this structure have been shown to remove 
cellular cholesterol and phospholipid .(366-368)  
Mukhamedova reports that up regulation of ApoA-I and ABCA1-mediated efflux 
in mice, leads to increased whole body RCT in-vivo (369).  A blinded, cross 
over study in humans has since investigated the effects of injecting 
reconstituted HDL into male patients with DM. This resulted in an improvement 
in the cholesterol removal capacity of plasma as early as 1 hour after injection, 
with up to a 60% increase in efflux by 72 hours. Improvements in inflammatory 
parameters were also noted (370). 
Most interestingly, ApoA-I therapy has been associated with improvements in 
glucose metabolism (371). Recombinant HDL infusion in patients with DM has 
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reported to reduce plasma glucose through activation of skeletal muscle 
AMPkinase (372).  It is noteworthy that an increase in insulin concentrations 
was also observed in this study. Apo-AI-mimetic therapy is biologically likely to 
overcome adversely modified ApoA-I particles in DM or CHD, but may not 
redress diminished transporter function.  It is not known whether this type of 
treatment will have beneficial effects on atherosclerosis in humans, but this line 
of therapy remains a viable option for future drug development. It is entirely 
possible ApoA-I-based therapy may result in beneficial metabolic effects 
beyond lipid metabolism and raises questions whether low HDL-C is a cause or 
consequence of glucose intolerance.  
A further explanation for the discordant results in different tissues is that 
mechanisms involved in regulation of ABCA1 in fibroblasts may be distinct from 
that in blood leukocytes. In addition the environment in which these cells 
function may affect cellular responses.   
The decreased HDL-C seen in patients with DM and insulin resistance has 
been recognised, to date, to be due to increased particle catabolism secondarily 
to increased hydrolysis of triglyceride enriched particles via the action of HL and 
CETP (165;166). ApoA-I or HDL synthesis has not been reported to be 
compromised although others have postulated a decrease in RCT in patients 
with DM (309).  
Our results, which show a positive relationship between fibroblast transporter 
function and plasma HDL concentration at the time of sampling, suggest a 
possible alternative view; decreased ABCA1 function may in-part contribute to 
the lower HDL-C levels observed in patients with impaired glucose regulation 
and insulin resistance. It has been recently discovered that common variants of 
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ABCA1 in diabetic patients had a moderate influence on HDL-C levels (373). 
This concept has obvious therapeutic implications. ABCA1 is a potential 
pharmacological target which could increase plasma HDL-C levels which may 
lead to improvements in cholesterol excretion. Ultimately, this approach may 
achieve superior regression of atherosclerosis compared to currently available 
therapies. However, enhancing this initial step of HDL biosynthesis, may cause 
counter-regulatory changes in more distal steps of RCT, which may serve to 
preserve cholesterol homeostasis. An example of this is seen in LCAT knockout 
mice. These animals were shown to have relatively preserved macrophage 
RCT, despite LCAT being traditionally thought of as a critical component of RCT 
(86). In humans, Calabresi and colleagues have shown that LCAT is not 
required for cholesterol efflux in macrophages, mainly due to a secondary 
increase ABCA1-mediated efflux capacity (374).   
A kinetic approach to investigation, is more likely to yield useful information 
about whole body cholesterol flux. Rader and colleagues have developed a 
RCT model in mice and have demonstrated that macrophage-mediated RCT 
better predicts atherosclerosis than steady state blood HDL-C levels (375).  The 
effect of pharmacological agents was studied using this model and both LXRα 
and PPARα agonist therapy were associated with increased RCT in-vivo, with 
decreased atherosclerosis (375). Although this is not reproducible in humans, 
patients with MS and low HDL-C have been studied using a kinetic approach. 
PPARα agonist therapy in these individuals was associated with increased 
ApoA-I and ApoA-II production rate and increased catabolism with no net 
change in plasma HDL-C concentration (376). These results imply steady state 
HDL-C concentrations in blood yield only limited information about whole body 
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cholesterol transport and indicate that measurement of cholesterol flux is more 
likely to reliably predict changes in atherosclerosis. Other work has confirmed 
this impression in patients with MS and DM; Rosuvastatin increased HDL-C 
levels by decreasing catabolism of ApoA-I thereby increasing HDL particle 
transit time in the circulation (153;377). Current clinical practice is limited to the 
widespread use of measuring plasma lipoprotein concentrations to help stratify 
CV risk. The future development of standardised measures of HDL function and 
whole body RCT is likely to reflect whole body cholesterol removal more 
accurately but this will require verification in humans.  This strategy may help 
development of more targeted therapies to help prevent atherosclerosis more 
effectively in the future.  
 
8.4 Increasing ABCA1 availability and mechanisms by which 
glucose may affect ABCA1 
 
A wealth of evidence currently proposes ABCA1 to be an atheroprotective 
protein. The effect of drugs that selectively induce ABCA1 expression merit 
further investigation. Both animal models and humans should be investigated 
despite differences in the RCT cycle between these species.  Measuring RCT 
reliably in humans remains a practical challenge as measurement of hepatic 
cholesterol flux requires invasive hepato-biliary sampling which is not clinically 
appropriate.  
Forcheron et al., have shown that PPARα agonist therapy lead to an increase in 
monocyte ABCA1 RNA in patients with DM. However, the observed, 
concomitant lowering of glucose and free fatty acids could partially explain this 
effect (301).  Several PPARα and PPARγ drugs have now been shown to 
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increase ABCA1 expression and HDL biosynthesis in the presence of LXRα  in 
cultured macrophage and fibroblasts (378). Attempts to augment cellular 
cholesterol removal using LXR agonist therapy have been associated with liver 
steatosis and hypertriglyceridaemia. This occurs through fatty acid synthase 
and SREBP1c activation which induce enzymes involved in fatty acid synthesis 
(295;379). RXR-receptor activation, which increases ABCA1 expression, has 
not been as extensively explored because it has potential to form non-specific 
heterodimers with many other nuclear receptors.  
Understanding the mechanism of how glucose may affect ABCA1 gene 
expression will be crucial to the development of any future therapeutic 
intervention. Until recently, it was thought insulin was a major signal to regulate 
gene expression, and conveyed information of glucose variation. However, it is 
now appreciated that glucose is directly able to modulate gene expression. This 
effect may be mediated by carbohydrate or fatty acid cellular sensors such as 
ChEBP or SREBP which can affect gene expression or through a direct effect of 
glucose. Glucose activates ChREBP by dephosphorylation, thereby allowing 
nuclear entry and DNA binding (380;381). ChREBP is highly abundant in 
lipogenic tissues such as liver and adipose tissue but is expressed ubiquitously 
(382). Target genes of ChREBP affect glycolysis, lipogenesis and 
gluconeogenesis (382). Inhibition of ChREBP in mouse models of obesity has 
been shown to produce metabolic improvements and therefore may be utilised 
to prevent MS, but its physiological role needs to be elucidated. In contrast, 
Mitro et al., demonstrated that glucose could directly bind and activate 
transcriptional activity of LXR, which subsequently controls various genes 
involved in cholesterol homeostasis including SREBP (296;296;383). In rat 
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pancreatic β-cells, incubation of glucose for 24 hours led to altered gene 
expression in two hundred genes suggesting direct effects (384). Investigation 
of gene promoter activity in cultured human cells could help identify underlying 
mechanisms to these observations. Present-day work in vascular smooth 
muscle cells proposes hyperglycaemia leads to reductions in ABCA1 mRNA 
through changes in ABCA1 promoter activity with evidence this involves the 
p38-mitogen-activated protein kinase pathway (356). 
The proposition that glucose lowering will lead to decreased CVD in DM has 
been subject to a lengthy debate and remains uncertain. Recent large studies 
investigating this have shown tight glycaemic control to be hazardous in older 
patients with long standing DM; An increase in cardiovascular mortality was 
shown despite a decrease in risk of MI (385;386). These deleterious results 
have not been replicated in other large studies but no cardiovascular benefits 
were seen (387). It is postulated that autonomic nervous system dysfunction 
may occur as a result of recurrent hypoglycaemia and this may help explain the 
excess mortality, but currently there is little evidence to substantiate this. In 
contrast, intensive treatment of glycaemia in both type I and DM in the early 
stages of disease has been associated with cardiovascular benefits many years 
later, even when glucose levels subsequently rise to that seen with less 
intensive treatments (19;19;23). The mechanisms underlying this early 
metabolic programming or glycaemia-mediated ‘legacy effect’ are yet to be 
unravelled and may involve early epigenetic changes. The preserved effect of 
glycaemia, at the time of sampling, on ABCA1 function in fibroblasts in my study 
may represent an example of such a phenomenon. Possible mechanisms 
underlying this include differences in cellular proliferation and cholesterol 
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trafficking which have been reported to modify efflux in fibroblasts (388). 
Alternatively, membrane modification, possibly through protein glycation, could 
result in adverse cell surface interaction leading to diminished efflux. This 
suggests altered physical properties may lead to transporter dysfunction.  
Finally, ER stress is associated with insulin resistance (389) and may result in 
reduced transporter function due to altered intracellular cholesterol trafficking. 
 
8.5 The effect of ABCA1 on atherosclerosis  
 
To investigate whether ABCA1 provides significant protection against CVD in 
patients with dysglycaemia, the relationship between ABCA1 and a marker of 
atherosclerosis was explored.  A previous study suggested ABCA1 function 
negatively associated with CIMT in patients heterozygote for ABCA1 mutations 
(255). For this reason, we measured CIMT in all study participants. DM patients 
had higher CIMT measurement compared to healthy men with borderline 
significance. There appeared to be a positive association of CIMT with age, 
glycaemia and adiposity. Using multiple regression, age and mean glucose 
independently predicted CIMT, this is consistent with other studies. However, 
there was no significant relationship observed with lipid parameters, blood 
pressure or smoking status and this is not consistent with previous findings from 
large studies. This inconsistency may be due the relatively small number of 
participants in the study. An independent relationship with ABCA1 expression 
was not observed and no significant relationships were observed with protein 
concentrations in leukocytes. ABCA1 function in fibroblasts negatively related to 
CIMT with borderline significance. ABCA1, therefore, did not show a strong 
influence on CIMT in our participants compared with the study which 
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investigated patients with a ABCA1 mutation (255).  A greater variation in 
cholesterol efflux was evident in individuals with mutated forms of ABCA1 
compared to individuals in my study and this may help explain why there was a 
lack of clear correlation between ABCA1 function and CIMT in the present 
study. Consistent with my findings, Soro-Paavonen and colleagues did not find 
a significant relationship between efflux and CIMT in families with low HDL-C 
without a known ABCA1 mutation (258). In this study, efflux was reduced in 
macrophages from affected individuals only when compared to protein and 
gene expression levels. The positive relationship between cholesterol efflux and 
HDL-C observed in my study is similar to that reported in fibroblasts in subjects 
with ABCA1 mutation (255). This confirms the positive relationship between 
ABCA1 activity and HDL-C concentration in humans with functional ABCA1.  
Cellular cholesterol efflux was reduced by an average of 46% in patients with 
DM compared to healthy men. When correcting for ABCA1 protein levels, efflux 
was reduced by 60% in the DM group, accentuating the difference. These 
results are comparable to the reduction in efflux seen in Tangier heterozygotes 
(390) and as such is likely to represent reduced protection against 
atherosclerosis.  
Measurement of gene expression in fibroblast samples, in response to 
cholesterol loading, could investigate whether there is an underlying 
LXRα− mediated signalling defect in patients with DM which could account for 
diminished ABCA1 expression. Although LXRα gene expression was not lower 
in fibroblasts taken from diabetic subjects, this would not account for differences 
in ligand activity. Work in macrophages has shown that LXR agonists can 
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overcome reduced cellular cholesterol export leading to reduced foam cell 
formation in patients with DM (185).  
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8.6 Limitations and future work 
 
There are a number of limitations to this study; my data implies a novel 
glycaemia-mediated negative effect on gene expression and function of this 
transporter; this is based on observational association, with little evidence of 
causality. In-vitro investigation, as outlined above, could address this by 
measuring the maximum effect of cholesterol and glucose on gene expression 
and function by loading cultured cells with increasing concentrations. This work 
should also attempt to explore possible underlying mechanisms to help 
understand my findings. For example, the possibility of subcellular trapping of 
ABCA1 in fibroblasts could be investigated using membrane biotinylation 
techniques.  However, the reported acute effect of oral glucose in-vivo indicates 
gene expression is dynamic and there is a suggestion that glucose may affect 
gene expression over a 2 hour period. Confirmation that mRNA levels from 
pooled leukocytes reflect gene expression in monocytes is required. The 
relationship between glucose lowering, AMP kinase activation and ABCA1 
expression requires confirmation both in-vitro and in humans. Potential 
confounding variables, such as insulin concentration and physical activity were 
not accurately measured in my study. There was no difference in smoking 
status and no differences in alcohol consumption seemed apparent but the 
latter was not adequately quantified. Further analyses showed there was no 
difference in alcohol consumption between groups. Measurements of insulin 
secretion would be helpful to clarify any causal relationship with ABCA1. 
Indeed, the challenge of disentangling the effects of glycaemia from that of 
adiposity and associated low grade inflammation, should be considered in 
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future work. Ideally, patients and healthy participants should be matched for 
BMI to help control for changes due to adiposity. The study cohort should have 
been genetically characterised for common polymorphisms which may influence 
gene expression. Nonetheless, participants in my study were heterogeneous 
and recruited from a genetically diverse area, making it less likely that gene 
polymorphisms could account for the findings. The importance of the non-
transport related function of HDL has been highlighted by various studies and 
should be incorporated in future investigation. A current population based study 
investigating HDL particle heterogeneity endorses the view that functional 
information remains vital to help characterise the effect of genetic variants of 
ABCA1 on CVD (391). This warrants exploration to help understand these 
epidemiological findings with an approach to develop therapies designed to 
enhance cellular cholesterol removal. Future work in humans should be 
targeted to study monocytes and macrophages cultured for a short duration, as 
this is a more relevant cell type for atherosclerosis. There is also a possibility 
that glycaemic status may affect sub-populations of leukocytes (ie. 
granulocytes, lymphocytes, monocytes) differently. A greater number of 
participants would help clarify the numerous relationships of borderline 
significance observed in my work as this study was not powered to detect a 
modest effect. The potential relationship of transporter expression or function 
with surrogate markers of atherosclerosis could be further examined with use of 
specific imaging of regional circulation employing techniques such as coronary 
artery calcification. Developing molecular imaging techniques to target 
cholesterol would directly aid the measurement of cholesterol movement at a 
cellular and sub-cellular level.  
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Accomplishing such work in drug naive, dysglycaemic patients will be 
challenging due to clinical trends for early intervention with statin and 
hypoglycaemic therapies in such patients. Cholesterol export studies using 
participants own ApoA-I and HDL particles could further assess if there is a net 
pathophysiological defect in cellular efflux in these patients. This is under the 
assumption that frozen HDL lipoproteins isolated from plasma retain their full in- 
vivo functional properties. A comparison of different methods of separation 
would be required to validate this. Leukocyte ABCA1 may develop to be a 
useful biomarker for macrophage gene expression if a close relationship is 
confirmed by subsequent studies. This further assumes modulation of gene 
expression will be concordant in leukocytes and macrophages. 
Other proteins are involved in HDL remodelling such as endothelial lipase may 
influence HDL-C levels in humans (392). These aspects should be considered 
in future studies investigating diabetes related CVD. There is some evidence 
that serum levels of this enzyme may be elevated in patients with DM (393).  
Reverse cholesterol transport and excretion is slowly becoming unravelled and 
ABCA1 is still considered to be a critical component in this process. The present 
study concludes diabetes may adversely affect transporter availability and 
function. ABCA1 has the potential to be a therapeutic target for future drug 
development, the effect of enhancing transporter activity may have beneficial 
effects in patients prone to premature vascular disease. 
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APPENDICES 
APPENDIX I  
Buffers, solutions, protocols and results  
 
Leukocyte lysis buffer for RNA extraction 
RLT Buffer (guanidine thiocynate 25-50%, Ph 7.0) (Qiagen)  
10% β-mercaptoethanol (Sigma) 
 
Leukocyte lysis buffer for protein extraction 
50 mM mannitol (Sigma) 
2 mM EDTA, 50 mM (Sigma) pH 7.6  
Complete mini protease inhibitor cocktail (Roche) 
 
Reverse transcription reaction mix (Applied Biosystems) 
2 μl 10xRT Buffer 
0.8μl 25xdNTP (100nM)     
2μl 10xRT RND primer  
4.2μl PCR grade water  
1μl Multiscribe RT-enzyme 
 
MACS Buffer 
PBS, 0.5% BSA, 1mM EDTA 
 
Fibroblast Freezing medium 
1.5 ml freezing medium comprising of FBS and sterile filtered 10% DMSO 
 
Optimised thermal cycler settings for cDNA synthesis (Applied Biosystems) 
Step 1  25oC for 10min 
Step 2  37oC  120min 
Step 3  85oC  5seconds 
Step 4  4oC  until samples removed and stored. 
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Optimised PCR  reaction mix  
1.25μl Primer 1 (Gene of interest) 
1.25μl Primer 2 (Housekeeper gene) 
12.5μl 2x PCR Master Mix (Applied Biosciences) 
1μl (30ng) cDNA, 9μl PCR grade water 
 
 
Taqman Hydrolysis probe PCR temperature program 
 
PCR Step Temperature Duration 
Hold 50 oC 2 min 
Initial denaturation 95 oC 10 min 
Denaturation 
Amplification 
95 oC 
60 oC 
 
15 sec 
60 sec 
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Leukocyte ABCA1 Gene Expression Results : 
 
(Mean values of duplicate measurements, normalised to housekeeper gene, 
arbitrary units. n=63). C=Control, healthy men, I=IGH, D=DM  
 
    gene                     log delta Ct 
   expression                               
        gene                  log delta Ct 
         expression  
C1. 0.286   1.692 
C2. 0.334  1.651  
I16. 0.254  1.898 
I17. 1.628  1.522 
C3. 0.276  1.807 I19. 0.393  1.772 
C4. 0.708  1.482 I20. 0.533  1.061 
C5. 0.340  1.633 D2. 0.079  2.016 
C6. 0.296  1.673 D3. 0.072  2.061 
C7. 0.172  1.812 D4. 0.408  1.633 
C8. 1.666  1.194 D5. 0.095  1.996 
C9. 1.692  1.256 D6. 0.226  1.807 
C10. 1.229  1.022 D9. 0.287  1.761 
C11. 0.553  1.562 D10. 1.590  1.543 
C13. 1.224  1.356 D11. 0.177  1.845 
C14. 1.079  1.635 D12. 0.385  1.782 
C15. 0.192  1.829 D13. 1.063  1.466 
C16. 0.834  1.611 D14. 0.143  1.910 
C17. 1.322  1.541 D15. 0.209  1.820 
C18. 0.720  1.550 D16. 0.248  1.746 
C19. 0.323  1.812 D17. 0.125  1.974 
C20. 0.475  1.660 D18. 0.466  1.641 
C21. 0.580  1.513 D19. 0.656  1.493 
C22. 0.575  1.654 D20. 0.892  1.366 
C23. 0.528  1.683 I21/D. 0.596  1.607 
C24. 0.392  1.753  
C25. 0.465  1.733  
C26. 0.090  1.959  
C27. 0.318  1.714  
C28. 0.490  1.543  
C29. 0.571  1.613  
C31. 1.233  1.233  
I1. 0.121  1.884  
I2. 0.183  1.800  
I3. 0.538  1.564  
I4. 0.525  1.528  
I5. 0.151  1.837  
I6. 0.370  1.627  
I7.         0.133                 1.992  
I9. 0.175  1.915  
I10. 0.627  1.522  
I11. 1.298  1.297  
I12. 0.367  1.746  
I13. 0.702  1.530  
I15. 0.777  1.537   
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Leukocyte  LXRα Gene Expression Results : 
 
(Mean values of duplicate measurements, normalised to housekeeper gene) 
C=Control, healthy men, I=IGH, D=DM  
Gene Expression (arbitrary units) n=61 
 
 gene 
expression 
 delta 
Ct 
 gene 
expression
 delta 
Ct 
 
C1 0.410    7.77 I13 2.253  3.61    
C2 0.627    5.54 I15 1.972  5.34    
C3 0.284    6.82 I16 0.294  7.94    
C5 0.419    6.32 I17 0.343  6.73    
C6 2.271    5.26 I19 0.735  6.21    
C7 0.278    8.27 I20 1.290  3.04    
C8 1.125    6.35 D2 0.474  6.03    
C9 0.973    6.88 D3 0.721  7.09    
C10 2.998    3.29 D4 0.886  6.30    
C11 1.037    4.76 D5 1.360  6.07    
C13 0.627    5.5 D6 0.738  5.25    
C14 0.411    6.22 D9 0.702  7.07    
C15 1.239    4.51 D10 0.740  5.19    
C16 0.539    5.77 D11 1.029  6.12    
C17 0.951    4.82 D12 0.733  5.25    
C18 0.895    5.09 D13 1.044  4.71    
C19 0.481    6.71 D14 0.797  5.06    
C20 1.232    5.43 D15 0.890  6.58    
C21 1.296    6.61 D16 0.597  5.93    
C22 0.702    6.09 D17 0.475  6.52    
C23 0.529    6.45 D18 2.245  5.39    
C24 0.630    6.24 D19 0.897  5.00    
C25 0.515    6.51 I21/D 0.543  6.16    
C26 0.907    5.41 D20 0.667  6.24    
C27 0.755    5.73      
C28 0.525    5.81      
C29 1.292    5.33      
I1 0.238    8.43      
I2 0.606    5.5      
I4 0.512    5.85      
I5 1.052    4.66      
I6 0.428    7.65      
I7 0.318    6.62      
I9 0.466    6.00      
I10 0.763    6.84      
I11 1.000    4.72      
I12 0.893    6.83      
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Leukocyte  PPARγ Gene Expression Results : 
 
(Mean values of duplicate measurements, normalised to housekeeper gene) 
C=Control, healthy men, I=IGH, D=DM  
 
Normalised Gene Expression (arbitrary units) n=23 
 
  
 gene expression 
 
C1 0.60 
C6 1.05 
C7 0.18 
C8 1.32 
C9 0.68 
C21 0.60 
C28 0.64 
C29 0.47 
I1 0.68 
I6 0.52 
I10 1.04 
I12 1.63 
I15 1.22 
I16 0.58 
D3 0.79 
D4 0.63 
D5 1.01 
D7 1.13 
D9 1.58 
D11 1.28 
D15 1.01 
D16 2.45 
D18 0.50  
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Leukocyte  ABCG1 Gene Expression Results : 
 
(Mean values of duplicate measurements, normalised to housekeeper gene, arbitrary 
units. n=47) 
C=Control, healthy men, I=IGH, D=DM  
 
  gene expression  gene expression 
 
C1  0.657 D18 0.913  
C2  0.566 D19 1.000  
C3  0.643 D20 0.686  
C4  1.048   
C5  0.682   
C6  1.166   
C7  0.375   
C8  1.056   
C9  1.257   
C10  0.695   
C11  0.836   
C13  0.947   
C14  0.988   
C15  0.411   
C16  1.067   
C17  1.417   
C18  0.990   
C21  0.707   
C28  0.987   
C29  1.158   
I1  0.444   
I2  0.535   
I4  1.061   
I6  0.570   
I9  0.847   
I10  0.922   
I11  0.800   
I12  0.679   
I13  0.528   
I15  0.725   
I16  0.411   
I17  0.575   
D13  1.317   
D2  0.466   
D3  0.369   
D4  1.276   
D5  0.460   
D6  0.638   
D7  0.620   
D9  0.511   
D10  1.153   
D11  0.655   
D12  1.001   
D14  0.642   
D15  0.586   
D16  0.803   
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ELISA Calibration Curve 
Calibration curve for ABCA1 quantification in human tissues. Taken from Paul V 
et al (394). A typical calibration curve from serial dilutions (8 to 1000ng/well) of 
ABCA1 peptide in assay buffer. The working range of (9 to 1000ng/well) of the 
calibration curve was derived on the basis of CV<20% between the replicates of 
ABCA1 calibrators. 
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APPENDIX II -Functional methodology in fibroblasts 
 
Image of fibroblast cell morphology (high magnification): 
 
Primary fibroblasts in culture, during cholesterol loading, a spindle shaped fibroblast is seen in 
the centre as well as surrounding cells undergoing mitosis. Cholesterol crystals are visible. 
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APPENDIX III Demographic data: Clinical examination measurements 
wt=weight (kg), ht=height (m), WC=waist circumference (cm), sys=systolic blood pressure, dia=diastolic blood pressure, PP=pulse pressure.  
 
 
  Ethnicity Smoker age wt ht BMI WC 
Mean 
sys 
Mean 
dia Mean PP
Healthy 
Men                     
C1 Chin Y 32 66.0 1.72 22.3 74 112.0 76.0 36 
C2 Chin/As N 21 60.2 1.76 19.4 81 136.5 74.5 62 
C3 As N 49 60.2 1.66 21.8 81 137.5 89.0 49 
C4  Cau N 23 73.1 1.82 22.1 83 119.5 75.0 45 
C5 Cau N 22 75.8 1.79 23.7 88 143.5 103.0 41 
C6  Cau N 57 78.0 1.82 23.5 85 147.5 84.0 64 
C7 Cau Ex  49 73.0 1.80 22.5 85 118.5 74.0 45 
C8 Cau N 58 78.5 1.79 24.5 88 137.0 77.0 60 
C9 Cau N 38 81.5 1.85 23.8 87 117.5 70.0 48 
C10 Cau N 43 86.8 1.82 26.2 95 130.5 85.5 45 
C11 Cau Ex  35 72.5 1.75 23.7 85 124.0 68.0 56 
C12 Afro N 30 95.1 1.93 25.5 96 147.0 92.0 55 
C13 As N 51 83.0 1.82 25.1 100 120.0 89.0 31 
C14 Cau Y 55 77.3 1.74 25.5 94 136.0 90.0 46 
C15 Cau N 63 80.0 1.77 25.7 96 133.0 83.0 50 
C16 Cau N 44 80.4 1.77 25.7 91 133.5 81.0 53 
C17 Cau N 61 74.2 1.79 23.2 93 147.5 92.5 55 
C18 Cau N 60 87.7 1.79 27.4 97 165.0 111.0 54 
C19 As N 41 90.9 1.80 28.1 101 133.5 84.5 49 
C20 As N 52 95.7 1.84 28.3 107 123.0 80.0 43 
C21 Cau N 63 87.7 1.79 27.4 103 144.5 95.5 49 
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C22 Cau Y 54 68.5 1.75 22.5 85 146.5 87.0 60 
C23 Cau N 70 86.1 1.78 27.2 107 123.3 77.3 46 
C24 Cau N 59 71.7 1.77 22.9 86 113.0 76.8 36 
C26 Cau N 75 72.8 1.70 25.3 95 134.3 74.0 60 
C27 Cau N 74 73.4 1.73 24.5 93 147.8 77.5 70 
C28 Cau N 66 67.3 1.78 21.4 79 124.8 72.5 52 
C29 Cau N 70 80.6 1.79 25.2 96 112.8 57.5 55 
C31 Cau N 74 68.1 1.62 25.9 91 146.5 83.5 63 
Patients Ethnicity Smoker age 
 
 
wt 
 
 
ht 
 
 
BMI 
 
 
WC 
 
Mean 
sys 
 
Mean 
Dia 
 
 
Mean PP
I-1 Afro Y 70 77.9 1.72 26.3 91 151.5 93.0 59 
I-2 Afro Ex  54 111.3 1.76 35.9 113 132.5 72.5 60 
I-3 As N 48 91.1 1.74 30.1 99 153.5 105.0 49 
I-4 Cau Y 58 71.5 1.68 25.3 91 140.5 86.0 55 
I-5 Cau Y 57 66.9 1.84 19.8 84 120.5 77.5 43 
I-6 Cau Ex  61 84.5 1.78 26.7 96 135.5 76.0 60 
I-7 As N 50 95.0 1.72 32.1 115 165.5 97.0 69 
I-8 Cau Ex  60 165.0 1.72 55.8 165 120.0 76.0 44 
I-9 Cau N 59 62.6 1.66 22.7 87 142.0 67.0 75 
I-10  As Y  59 71.4 1.63 26.9 95 145.0 88.5 57 
I-11 Cau Y  62 72.0 1.75 23.5 84 111.5 71.5 40 
I-12 Cau Ex  68 69.9 1.70 24.2 87 146.5 65.0 82 
I-13 Cau N 60 75.4 1.67 27.0 87 144.0 88.0 56 
I-14 Cau N 43 79.3 1.77 25.3 85 112.0 75.5 37 
I-15 As N 52 76.8 1.67 27.5 100 148.0 95.0 53 
I-16 Cau N 71 76.0 1.79 23.7 96 138.5 83.0 56 
I19 Cau Ex  49 100.1 1.91 27.4 104 128.0 73.5 55 
C25/I Cau Y 65 83.3 1.80 25.7 94 148.3 83.3 65 
I20  Cau Ex  42 111.7 1.88 31.6 106 138.8 84.5 54 
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D13/I Cau N 53 102.8 1.74 34.0 112 146.3 93.5 53 
D2  As N 61 55.7 1.61 21.5 81 120.0 73.5 47 
D3  Cau N 71 88.8 1.80 27.4 103 154.0 86.0 68 
D4  Cau Ex  72 106.7 1.87 30.5 113 149.0 93.0 56 
D5  Cau N 42 87.3 1.74 28.8 100 126.0 88.5 38 
D6 As Y 34 71.9 1.74 23.9 91 106.5 74.5 32 
D7 As Y  54 89.4 1.74 29.5 102 131.0 76.5 55 
D9 Cau Y  41 96.5 1.81 29.5 98 130.0 88.5 42 
D10  Cau Ex  59 94.7 1.83 28.3 101 129.0 81.0 48 
D11  Cau Ex  49 90.4 1.68 32.0 104 125.5 77.5 48 
D12  Cau Ex  64 82.4 1.71 28.3 97 130.0 88.0 42 
D14  Cau N 61 92.5 1.87 26.6 99 147.8 85.8 62 
D15  Cau Ex  66 72.7 1.76 23.5 88 146.5 86.0 61 
D16  As Ex  53 91.7 1.79 28.8 104 127.8 81.8 46 
I17/D Arabic Ex  57 90.5 1.80 27.9 108 115.0 77.3 38 
D17  Cau N 67 72.9 1.58 29.2 101 125.3 80.8 45 
D18  As Ex  67 90.1 1.72 30.5 106 157.3 88.0 69 
D19  Cau Ex  57 91.4 1.83 27.3 100 133.0 78.3 55 
I21/D As N 44 64.3 1.64 23.9 91 120.0 76.8 43 
D20  Cau Ex  63 107.8 1.78 34.0 122 116.5 78.0 39 
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Fasting 
Glucose  
 
1hr 
Glucose
 
 
2hr 
Glucose
 
Chol HDL-C LDL-C Trig HbA1c (%) 
Healthy 
Men                 
C1 4.7  3.1 4.87 1.51 2.89 1.04 5.7 
C2 4.3 4.6 2.3 4.23 1.34 2.58 0.69 5.7 
C3 5.6  5 3.58 1.42 1.81 0.77 5.8 
C4 4.6 3.4 4.1 5.34 1.86 3.08 0.87 5.1 
C5 4.7 3.2 3.5 5.55 1.35 3.49 1.56 4.8 
C6 5.2 6.3 4.1 5.59 2.07 3.21 0.69 4.8 
C7 4.4 4.7 3.9 6.72 1.44 4.26 2.23 5.6 
C8 4.2 5.3 6.3 4.86 1.7 2.66 1.09 5.4 
C9 5 3.7 4.7 3.85 1.3 2.21 0.74 5.4 
C10 4.5 7.5 3.9 4.96 1.7 2.97 0.63 4.9 
C11 5.1 4.2 4.5 5.33 1.64 3.35 0.75 5.5 
C12 5.7 5.9 5.3 5.94 2.06 3.47 0.89 4.8 
C13 4.8 4.4 6.1 4.35 1.1 2.72 1.17 5.1 
C14 5.8 7 5.4 6.12 1.15 4.04 2.05 5.3 
C15 5.5 6.6 6.9 7.48 1.72 4.73 2.26 5.6 
C16 5 6 6.2 6.36 2.07 3.44 1.86 5.5 
C17 5.1 3.7 3.9 6.03 1.57 3.54 2.01 5.7 
C18 5 4.9 5.1 5.55 1.54 3.78 0.51 5.7 
C19 4.2 4.2 3 4.61 1.28 2.80 1.16 4.7 
C20 5.5 10.1 7.4 4.83 1.05 3.24 1.19 5.9 
C21 5.5 9.7 4.6 5.18 1.69 2.97 1.15 5.2 
C22 5.1 5.2 5.2 5.61 1.65 3.69 0.59 5.4 
C23 5.6 7.1 5.8 6.15 1.42 4.08 1.42 5.9 
C24 5.3 5.6 5.7 5.1 1.1 3.27 1.59 5.7 
C26 5.6 9.3 6.7 6.37 1.56 4.08 1.6 6.2 
C27 5.1 10 5.7 4.83 1.64 2.64 1.2 6.2 
C28 5.2 10.5 3.6 5.65 2.09 3.23 0.72 5.6 
C29 5.4 8.2 4.9 5.25 1.34 3.30 1.34 5.7 
C31 5.1 7.8 4.3 6.11 1.79 3.72 1.32 5.4 
Patients         
I-1 4.7 12 10.6 6.15 1.97 3.89 0.64 5.7 
I-2 5.4 11.2 7.9 4.5 1.11 3.06 0.73 6.4 
I-3 5.7 9.4 6.4 3.73 0.95 2.43 0.77 5.4 
I-4 6.3 8.7 3.8 5.59 1.72 3.60 0.6 6.3 
I-5 5.9 7.2 10.8 4.3 1.6 2.35 0.77 6.9 
I-6 4.7 10.7 8.3 6.03 1.44 4.15 0.97 5.4 
         
       
       
       
       
       
       
APPENDIX IV  Participant biochemical measurements     
Data in mmol/l unless otherwise stated. Serial glucose measurements were during an OGTT, Chol=total 
cholesterol, Trig=fasting triglycerides. Duration of diabetes stated (years), median 0.7 years. 
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Most subjects known to have DM did not undergo OGTT (grey box).  
I-7 5.9 11.1 7.2 5.03 0.92 2.92 2.61 6.0 
I-8 8.5 11.3 10.1 4.56 0.98 3.01 1.24 6.8 
I-9 6.3 10.2 9.7 5.32 1.57 3.40 0.77 5.6 
I-10 5.1 12.2 8.5 5.61 1.13 3.18 2.85 5.4 
I-11 4.5 5 5.1 4.17 0.97 2.76 0.96 5.9 
I-12 5.1 6.5 4.8 6.07 1.84 3.84 0.85 5.4 
I-13 4.9 9.8 6.8 4.1 1.12 2.48 1.09 4.9 
I-14 4.8 7.1 3.4 4.88 1.09 3.06 1.59 5.5 
I-15 6.2 11.8 10.4 4.8 1.35 2.95 1.09 6.1 
I-16 6 9.5 6.3 7.68 2.02 4.99 1.47 5.9 
I19 5 6.4 6.4 5 0.93 3.48 1.29 6.0 
C25/I 5.3 8.5 8.1 4.48 1 2.91 1.26 5.9 
I20 5.9 7.5 4.2 6.4 1.29 3.81 2.84 6.2 
D13/I 5.9 9.1 6.3 3.62 0.85 1.51 2.77 5.8 
D2 (2) 8.5     6.73 1.29 4.85 1.29 7.9 
D3 (3.1) 9.1     4.16 1.11 2.65 0.87 7.6 
D4 (0.7) 6.4     3.91 1.22 2.24 0.99 6.4 
D5 (0.1) 11     5.4 1.06 2.82 3.32 11.2 
D6 (3.75) 6.3     5.18 1.74 2.99 0.99 8.7 
D7 (0.3) 5.6     4.61 1.04 2.94 1.38 5.8 
D9 (0.6) 10.7     5.94 1.11 3.84 2.17 10.0 
D10 (0.2) 6.7     3.85 0.89 2.59 0.89 5.9 
D11 (0.2) 7.5     4.01 0.71 2.56 1.62 7.4 
D12 (6) 5.2     4.47 1.51 2.60 0.78 5.3 
D14 (3) 11     5.23 1.29 3.23 1.56 8.0 
D15 (0) 6.8     5.66 1.34 3.87 0.99 6.5 
D16 (3.5) 6.8     4.53 1.15 2.60 1.72 7.2 
I17/D (0) 6.3 9.4 6.5 5.09 1.38 3.34 0.82 6.4 
D17 (3.75) 5.3     4.14 1.24 2.41 1.07 6.3 
D18 (0.1) 6.9 14.3 11.4 7.44 1.56 4.90 2.16 6.8 
D19 (3) 6.7 12.5 10.9 6.68 1.47 4.28 2.05 6.5 
I21/D (0) 6.7 18.8 15.1 3.88 1.17 2.05 1.45 7.3 
D20 (1) 6.3 12 13.4 4.26 0.81 2.16 2.82 5.7 
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APPENDIX V Participant medication list 
Healthy Men 
 
    
C1-5 ,C7-16,  
C19, C22,  
C24, C27,  
C29, C31 
 
No medications    
C6 Irbesartan    
C17 Fexofenadine    
C18 Loratidine, Budesonide nasal spray    
C20 Irbesartan/hydrochlorothiazide    
C21 Timolol eye drops    
C23 Aspririn, Lansoprazole, Diclofenac    
C26 Timolol eye drops    
C28 Budesonide and Terbutaline inhalers    
Patients     
I-1 Nifedipine    
I-2 Nil    
I-3 Amlodipine    
I-4 Nil    
I-5 Nil    
I-6 Tamsulosin    
I-7 Ramipril, Doxazocin, Atenolol, Omeprazole     
I-8 Aspirin, Ramipril, Indapamide, Felodipine    
I-9 Bendroflumethazide, Ramipril, Alendronic acid, Symbicort* and Combivent# inhalers     
I-10 Paroxetine     
I-11 Desloratidine     
I-12 Ramipril, Bendroflumethazide, Amlodipine     
D13/I Nil     
I-13 Aspirin, Methotrexate     
I-14 Nil     
I-15 Becotide inhaler     
I-16 Glucosamine     
I19 Paroxetine      
C25/I Calcipotriol     
I20  Salbutamol, Seretide (Budesonide/Formoterol) inhalers     
D2  Nil     
D3  Salbutamol, Symbicort* inhalers 
D4  Allopurinol 
D5  Fluoxetine 
D6  Nil 
D7  Ramipril, Tamsulosin,  Omeprazole, Venlafaxine, Fluticasone, Diazepam and Naproxen PRN  
D9  Cocodymol, Diazepam 
D10 Nil 
D11 Nil 
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D12 Enalapril 
D14 Allopurinol 
D15 Aspirin, Cannesten/Hydrocortisone cream 
D16 Ramipril, Atenolol, Aspirin, Glucosamine 
I17/D Nil 
D17 Allopurinol, Irbesartan, Tamsulosin, Testosterone, Aspirin, Cephalexin 
D18 Allopurinol, Beclomethasone inhaler, Quinine Sulphate 
D19 Tamsulosin 
I21/D Nil 
D20 Allopurinol, Fish oil, Calcium +Vitamin D (AdCal), Vitamin C+E 
  
*Symbicort =Budesoinide/Formoterol  
#Combivent = Salbutamol+Ipratropium bromide
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